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Summary
Six passages of the mosquito borne flavivirus, yellow fever (YF) wild- 
type strain Asibi in HeLa cells attenuates the virus for monkeys and newborn 
mice. Attenuation following passage in HeLa cells was not unique to YF virus 
strain Asibi as demonstrated by the attenuation of another wild-type YF virus 
strain, the French viscerotropic virus, and three strains of the mosquito borne 
West Nile (WN) virus. In comparison, two tick-borne flaviviruses (louping-ill 
and Langat) and a member of the dengue virus subgroup (dengue-2 virus) 
remained virulent for mice following six passages in HeLa cells.
Attenuation of YF and WN viruses was accompanied by alterations in the 
antigenic and biological properties of the viruses including changes to surface 
epitopes, appearence of temperature sensitivity and loss of haemagglutination 
(HA) ability following six passages in HeLa cells. Some of the antigenic 
changes have been proposed to have a bearing on the attenuation observed, 
however, it is believed that loss of HA ability has no function in the 
attenuation of flavivirus virulence. Moreover, attenuation of YF viruses 
coincided with the loss of binding of virus with monkey liver cell receptors. 
The lack of binding of virus to the receptors of the liver may explain the loss 
of viscerotropism that is observed for attenuated YF virus strains.
It is proposed that attenuation of flaviviruses following passage in HeLa 
cells is dependant on the tropism of the virus. Viruses of low neurotropic 
potential/invasiveness (YF and WN viruses) are attenuated to significant degrees 
after very few passages in HeLa cells, whereas viruses of enhanced
neurotropism/invasiveness (louping-ill, Langat, and neuroadapted dengue-2 virus) 
are refractive to attenuation after very few passages in HeLa cells.
Therefore, it is suggested that the attenuation of flaviviruses following 
passage in HeLa cells provides a model system to examine the molecular basis 
of attenuation of non-neurotropic flaviviruses.
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Chapter 1. Literature review
1.1 Taxonomy
a) Arboviruses
Earlier this century Walter Reed and his co-workers demonstrated that 
yellow fever virus was transmitted to man by mosquitoes (Reed and Carroll, 
1902). This represented a major breakthrough both for medicine and in the 
potential control of disease. More importantly though it provided the first 
example of an arthropod-borne virus.
The term arbovirus (derived from arthropod-borne) was not introduced 
until 1942 to describe animal viruses that are maintained in a transmission cycle 
between haematophagous arthropod vectors and susceptible vertebrate hosts. A 
number of different arthropods have been implicated with the transmission of 
disease including mosquitoes, ticks, Culicoides species (midges) and Phlebotomus 
species (sandflies) (World Health Organization Technical Report, 1967).
The first viruses recognised as arboviruses were associated with the cause 
of large epidemics in both man and/or animals, these included yellow fever. 
Rift Valley fever, Japanese, St. Louis, and Murray Valley encephalitis viruses 
(World Health Organization Technical Report, 1967). The number of viruses 
classified as arboviruses has increased dramatically over the past years. By 1953 
there were thirty-five catalogued viruses yet in 1978 the figure had risen to 389 
viruses (Berge, 1975). The increase in numbers was largely the result of field 
investigations connected with major epidemics of diseases, like yellow fever, that 
occurred in various parts of the world (Theiler and Downs, 1973). The 1985
edition of The International Catalogue of Arboviruses refers to 504 registered 
viruses, 32 of which are designated as probably or not arthropod-borne viruses 
(Karabatsos, 1985).
Arboviruses were originally classified according to morphologic and 
serologic relationships based on tests employing complement fixation, 
haemagglutination inhibition and infectivity neutralisation. The first groups 
recognised as being antigenically distinct were designated groups A,B, and C 
(Casals and Brown, 1954; Casals, 1957). Most of the viruses studied by 1980 
were grouped into four major taxonomic groups (Schlesinger, 1980); (1) family 
Togaviridae, genera Alphavirus and Flavivirus (Casals group A and B 
respectively); (2) family Bunyaviridae (Casals group C); (3) family
Rhabdoviridae; and (4) family Reoviridae. The registered arboviruses are 
presently separated into 63 serogroups (Karabatsos, 1985).
Despite both alphaviruses and flaviviruses being in the same family, there 
were distinct differences between the two genera. It was first noted that 
alphaviruses possessed nucleocapsids of cubical symmetry (Horzinek and 
Mussgay, 1969) whereas the symmetry of the flaviviruses was less certain. 
More convincing evidence was provided by researchers studying the molecular 
biology of the viruses. The alphaviruses specified a subgenomic 26 S mRNA 
corresponding to the 3’ end of the genome that coded for the structural proteins 
(Kââriâinen and Soderlund, 1978). No subgenomic mRNA has been found in 
flavivirus infected cells (Westaway, 1973; Westaway and Shew, 1977). In 1984, 
the International Committee on Taxonomy of Viruses (ICTV) approved a 
recommendation of the ICTV Togavirus Study Group to transfer the flaviviruses 
from Togaviridae into a new taxon- Flaviviridae (Westaway et al., 1985a and
1985b).
b) Flaviviridae
The family Flaviviridae contains a single genus Flavivirus which contains 
the prototype species, yellow fever virus, and approximately 67 other members 
(Westaway et al., 1985a; Calisher et al., 1989). Of the registered members, 
48% are mosquito borne and responsible for epidemics such as yellow fever, 
Japanese encephalitis and dengue. The remainder of the group are tick-borne 
(27%) or have no proven arthropod vector (25%) (Calisher et al., 1989). Two 
other viruses which were putatively described as flaviviruses, the Aedes 
albopictus cell fiising agent (Igarashi et al., 1976) and simian haemorrhagic 
fever virus (Leon, 1982) are placed outside the genus.
1.2 Flaviviruses
a) Medical significance
There currently exists 68 registered flaviviruses of which approximately 
50% have been associated with human disease (Karabatsos, 1985). As many 
members have been isolated from humans in either sporadic or epidemic form, 
the flaviviruses represent the most important group of viruses from a medical 
standpoint. Three viruses , yellow fever (YF), dengue (Den) and Japanese 
encephalitis (JE) virus cause epidemics which engender global and pam-egional
concern (Monath, 1986).
Mosquito borne YF has been a threat to mankind for over two centuries 
and despite the introduction of the 17D YF vaccines, major epidemics still 
occur with the most recent occurring in Nigeria 1987-1988 (Nasidi et al., 
1989). Even though the 17D vaccine is probably the finest example of a live 
attenuated vaccine, its effectiveness in an epidemic depends on the early 
recognition of cases and availability of sufficient quantities of vaccine.
The four Den viruses (Den 1-4) each give rise to classical Den fever 
which is recognised as a self-limiting illness associated with a rash. The viruses 
are transmitted to man by the bite of an infected mosquito and of the known 
flaviviruses they cause the highest morbidity rate (Halstead, 1988). Each of 
the serotypes of Den virus can be responsible for a more severe form of 
disease, namely dengue haemorrhagic fever (DHF) and dengue shock syndrome 
(DSS) which are believed to have an immunopathological basis (Halstead, 1980,
1988). Infection by Den-1 virus followed by subsequent infection with Den-2 
virus carries a greater risk of DHF/DSS (Sangkawibha et al., 1984; Burke et 
al., 1988). Den viruses continue to cause severe epidemics with an outbreak 
being recorded at Rio de Janiero in 1986 (Schatzmayer et al., 1986). This 
particular outbreak was unusual because Den virus infection had not been 
reported in Brazil for over 50 years.
JE virus occurs in endemic and epidemic forms over much of Asia and 
causes the highest mortality rates of any flavivirus. In epidemic forms, mortality 
rates have ranged from 10-20% in most outbreaks upto figures in excess of 
30% (BuTock, 1986; Umenai et al., 1985). An unfortunate sequelae of JE 
infection is permanent neurological impairment which occurs in a significant
number of cases. Mosquito borne JE virus continues to threaten large 
populations even though massive vaccination campaigns have been undertaken. 
Vaccination, however, may be undermined by the high degree of antigenic 
variation exhibited by different subtypes of JE virus (Susilowati et al, 1981).
Other mosquito borne flaviviruses of medical significance include St. Louis 
encephalitis (SLE), Murray Valley encephalitis (MVE) and West Nile (WN) 
virus. SLE became a serious public health problem in the United States in the 
1960’s and continues to cause sporadic outbreaks which give cause for concern 
(Kokernot et al., 1969). MVE causes epidemics in Australia with disease 
occurring intermittently in areas that have experienced high rainfall periods 
(Forbes, 1975). Epidemics are usually recorded from January to March and 
coincide with high population levels of the mosquito vector (Shope, 1980). WN 
virus (unlike JE, SLE and MVE viruses) causes a generalised fever, rash and 
lymphadenopathy with encephalitis only associated with infection of elderly 
persons (Spigland et al., 1958). The virus is widely distributed in Africa, the 
Middle East, Europe and Asia. In hyperendemic areas, infection usually occurs 
during childhood as evidenced by high numbers of sero-positive adults and 
adolescents (McIntosh et al., 1976).
Tick-borne encephalitis (TBE) has long been recognised as a public health 
problem of Eastern Europe. In Russia, the virus caused high mortality in the 
1930’s and prompted great effort to isolate the causative agent and to produce 
a vaccine (Silber and Soloviev, 1946). TBE has been defined as a number of 
different sub-types depending on geographical location and include; Eastern sub- 
types such as Sofyn which is the causative agent of Russian Spring Summer 
Encephalitis (RSSE) (Silber and Soloviev, 1946); Western sub-types such as
Hypr (Blaskovic et al., 1967) and Neudôrfl (Ackerman et al., 1986). In India, 
Kyasanur Forest disease (KFD) virus occurs annually and is responsible for 
hundreds of infections in man, characterised by fever, mild meningoencephalitis 
and haemorrhagic fever with a mortality rate of between 1 and 10% (Work, 
1958; Sreenivasan et al., 1979).
b) Veterinary significance
Eight flaviviruses have been reported to cause disease in domesticated 
and/or wild animals and being of major economic importance to the former 
group. The most important is JE virus which causes epizootic encephalitis in 
horses and stillbirth/abortion in pigs in many areas of Asia (Umenai et al., 
1985). The virus has also been shown to cause infection in wild and 
domesticated boars (Habu et al., 1977). The principal viraemic amplifying hosts 
of JE virus have been established as pigs and birds with Culex species of 
mosquito responsible for transmission to man (Beuscher and Scherer, 1959).
Wesselsbron (WSL) virus is a pathogen found in South Africa where it 
causes abortion and death of newborn lambs and pregnant ewes (Henderson et 
al., 1970). WSL virus has also been isolated from a dead cow which died 
during an epizootic Rift Valley fever attack in Zimbabwe in 1978 (Blackburn 
and Swanpoel, 1980). Serological evidence suggests that WSL infection occurs 
on a much greater scale than the number of proven cases suggests and detailed 
epidemiological studies of livestock where virus infection is thought to cause 
problems is required (Swanpoel, 1988).
Louping-ill (LI) virus is a member of the TBE complex and causes 
neurological disease in sheep with infection being highest in Scotland (Monath,
1989). The virus is also responsible for important economic losses due to
infection of pigs, red grouse and deer (Reid et al., 1982; Bannatyne et al.,
1980).
One of the most dramatic veterinary diseases was caused by the flavivirus 
Israel Turkey Meningoencephalitis virus (ITME). The disease affected turkey 
populations in Israel between 1958 and 1959 with morbidity approaching 50% 
and a case fatality rate of 10-12% (Komarov and Kalmar, 1960). A reservoir 
for the virus has not been found and the only other occurrence of ITME to 
date was in South Africa (Barnard et al., 1980).
Other flaviviruses causing disease of veterinary importance to one degree
or another include; WN virus infections of horses (Guillon et al., 1968) and 
Kunjin virus (related to MVE virus) which was isolated from the spinal cord 
of a horse with severe encephalomyelitis in Australia (Badman et al., 1984).
c) Epidemiology
Transmission of flaviviruses to man is usually by arthropod vectors and 
human to human transmission does not occur, although virus may be present 
in the blood and various body secretions during acute infection. Paramount to 
initiation of epidemics is the availability of reservoirs of infectious virus and 
high levels of vector populations to maintain an infection cycle.
YF virus circulates in nature through transmission by forest mosquitoes
to wild primates but there is also evidence of transovarial transmission of YF 
through mosquitoes (Beaty et al., 1980). Forest primates are involved in the 
maintenance of the virus in nature, but the role of other vertebrate species is 
uncertain (Porterfield, 1989).
All Den viruses are or have been widely distributed throughout the world 
where Aedes aegypti mosquitoes are abundant. Jungle Den fever in Malaysia has 
been shown to involve monkeys in the transmission cycle (Rosen, 1982), this 
being the first isolation of Den virus from a jungle mosquito. Since the 
different serotypes of Den virus are poorly cross-protective, one Den serotype 
can infect a person who possesses circulating antibody to a different Den 
serotype. Therefore, the great significance of the various Den viruses lies in 
their constant potential to cause disease. Moreover, virtually any A. aegypti 
infested area in the world is subjected to the threat of an epidemic 
(Chamberlain, 1980).
Transovarial transmission of virus in mosquitoes is not only important for 
the maintaining of YF virus but has also been shown to be involved in the 
natural history of other flavivirus diseases (JE and SLE) (Rosen, 1986, 1987). 
Water birds are important amplifying hosts for JE and MVE viruses with pigs 
being implicated as amplifying host for JE in which infected foetuses are 
aborted (Takashima et al., 1988). SLE has been demonstrated to overwinter 
effectively in the gizzards of cowbirds (Chamberlain et al., 1957).
Infection by TBE viruses is mediated principally by two subtypes of tick, 
the particular subtype varying according to geographical origin. The main vector 
of Eastern TBE is Ixodes persulcatus ticks which utilise wild rodents and forest 
birds as primary vertebrate hosts (Cerney, 1976). The Western subtype of TBE
is transmitted by Ixodes ricims ticks. Large animals such as goats and sheep 
act as host for adult ticks whilst immature ticks are often found on ground 
birds (Nosek et al., 1967). Other tick species have been implicated in 
transmission of TBE where Ixodes ticks are absent.
Little data is available concerning the epidemiology of non-vector borne 
flaviviruses.
d) Antigenic classification
All flaviviruses are antigenically related as determined by serological 
assays. Flaviviruses possess surface antigens which are capable of reacting in 
haemagglutination (HA), haemagglutination inhibition (HAI), plaque reduction 
neutralisation tests (PRNT) and assays involving immunofluorescence (IF), 
enzymes and radio-isotopes (Monath, 1989). The Flaviviridae was originally 
grouped according to cross-reactivities in HI tests performed with polyclonal 
antisera (Casals and Brown, 1954). More recently, cross-neutralisation tests using 
polyclonal hyperimmune antisera has been used to separate flaviviruses into 
serogroups. DeMadrid and Porterfield (1974) classified 36 flaviviruses into 7 
complexes or serogroups with 6 distinct viruses which remained ungrouped. A 
serogroup is defined as a group of viruses which are closely related but distinct 
from each other thus constituting an antigenic complex (serogroup) (Calisher, 
1980). There now exists 68 or so flaviviruses which form 8 antigenic 
complexes which comprise 49 viruses and 17 unclassified viruses (see Table 
1.1) (Calisher et al., 1989). This antigenic classification conforms to major
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Table 1.1
Relationship between Flavivirus subgroup and mode of transmission
Tick-borne viruses 
Virus Subgroup
Non vector-borne 
Virus Subgroup
Mosquito-borne viruses 
Virus_______Subgroup
Karshi 1
Kyasanur Forest 1
Langat 
Louping-ill 
Negishi 
Omsk 
Powassan 
Royal Farm
Tick-borne enc. 1
Meaban lA
Saumarez Reef lA 
Tyuleniy lA
Gadgets Gulley U 
Kadam U
Total 14
Carey Island 1 
Phnom Penh bat 1
Apoi
Bukalasa bat 
Dakar bat 
Entebbe bat 
Rio Bravo 
Saboya
Cowbone Ridge 
Jutiapa 
Modoc 
Sal Vieja 
San Perlita
Aroa
Batu Cave 
Cacipacore 
Montana M.L. 
Sokuluk 
Tamana bat
2A
2A
2A
2A
2A
2A
2B
2B
2B
2B
2B
U
( u y
uuu
19
Alfuy
Japanese enc.
Kedougou
Kokobera
Koutango
Kunjin
Murray Valley 
St. Louis enc. 
Stratford 
Usutu 
West Nile 
Yaounde
^^w eni
Bagaza 
Israel Turkey 
Ntaya 
Tembusu 
Yokose
Banzi 
Bouboui 
Edge Hill 
Potiskum 
Uganda S
Dengue 1 
Dengue 2 
Dengue 3 
Dengue 4
Busuquara
Ilheus
Jugra .
Naranjal
Rocio
Sepik
Wesselsbron 
Yellow fever
(5?)
3 
3 
3 
3 
3 
3 
3 
3 
3 
3
3
(3)*
4 
4
5
5
5
5
5
6 
6 
6
(6)*o
7
7
7
7
U
U
U
U
U
U
U
U
36 = 69
From Andrewes’ Viruses of Vertebrates. Chapter 7- Flaviviridae by 
J. S. Porterfield.
Based on Madrid and Porterfield (1974) and Calisher et al. (1989).
U = unrelated to any other virus.
* Batu Cave, Potiskum and Yaounde viruses were not examined in either 
in either series but are included for completeness.
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biological and epidemiological characterisation of flaviviruses.
1.3 Molecular biology of the flaviviruses
a) Morphology
Flavivirus virions comprise an isometric RNA core of 30-35nm in 
diameter which is surrounded by a lipid bilayer to yield a total diameter of 
approximately 45nm. The outer surface is covered in projections that are 5- 
lOnm in length terminating in a 2nm diameter knob (Murphy, 1980). The 
flavivirus nucleocapsid core contains one copy of a positive sense single 
stranded
RNA genome which is complexed with a single species of capsid protein 
(Westaway, 1980).
Chemical analysis of a representative flavivirus, SLE, gave a composition 
as 6% RNA, 66% protein, 17% lipid and 9% carbohydrate (Trent and Neave,
1980). However, the lipid content of the virus (both lipid type and overall 
amount) varies depending on the cell line used to propagate the virus (Trent 
and Neave, 1980). Infectious particles possess a sedimentation coefficient in 
sucrose of 175-218 S (Boulton and Westaway, 1972) and buoyant densities of 
1.22 g/cm  ^ and 1.18-1.20 g/cm  ^ in CsCl and sucrose respectively (Smith et 
al., 1970). Infectivity of flavivirus virions is most stable in the range pH 7-9 
(Brinton, 1986) although tick-borne flaviviruses can tolerate much lower pH 
values (pH 3 for 24 hours) (Pogodina, 1958). Virions are also sensitive to
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ultraviolet, ionic and nonionic detergents, trypsin digestion and temperature with 
50% decrease in infectivity following 10 mins at 50°C (Brinton, 1986; 
Porterfield et ah, 1978).
b) Genome organisation
The flavivirus genome is a single molecule of single stranded RNA (MW 
approximately 4x10*^ ) which is infectious and functions as a messenger RNA 
(mRNA) for the synthesis of both structural and nonstructural proteins (Strauss 
and Strauss, 1977). Flavivirus genomic RNA has a type 1 cap structure at the 
5^  end (m^GpppAmpNJ which probably facilitates binding of RNA to ribosomes 
(Mathukrishnan et at., 1975, 1976; Wengler et al., 1978; Cleaves and Dubin, 
1979). Unlike most other mRNA species, flavivirus RNA lacks a 3' poly(A) 
tract but has a uridylic acid (CUqh) instead (Wengler et al., 1978; Wengler and 
Wengler, 1981; Deubel et al., 1983).
Determination of flavivirus gene sequences has for a long time trailed 
behind that of other viruses. Recently, the complete or partial genome sequences 
have become available for a number of flaviviruses. The first of these sequences 
was for the prototype flavivirus, YF (Rice et al., 1985). Data now exists for; 
WN (Castle et al., 1986; Castle et al., 1985; Wengler et al., 1985), Murray 
Valley encephalitis (MVE) (Dalgamo et al., 1986), SLE (Trent et al., 1987), 
Kunjin (Coia et al., 1988), JE (Hashimoto et al., 1988; Sumiyoshi et al., 
1987), dengue serotypes 1-4 (Mason et al., 1987; Deubel et al., 1988; Osatomi 
and Sumiyoshi, 1988; Zhao et al., 1986) and tick-borne encephalitis virus 
(Mandl et al., 1989a; Pletnev et al., 1990). Sequence comparisons of the
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nucleotide and deduced amino acids for the above viruses revealed a single
uninterrupted open reading frame to exist for most of the genome. For YF
virus, RNA translation initiation is 118 nucleotides from the 5' terminus with 
an open reading frame that spans 10,233 nucleotides and is followed by three
closely spaced termination codons (Rice et al., 1985). There are 511
untranslated nucleotides at the 3' terminus giving a total genome size of 10,862 
nucleotides which is the approximate size of all flavivirus genomes sequenced 
to date. The gene order is the same for all flaviviruses sequenced and follows 
the consensus:
5'-C-preM-M-E-NSl-NS2A-NS2B-NS3-NS4A-NS4B-NS5-3'
The structural genes are located in the 5' one quarter of the genome and the 
nonstructural proteins represent the remaining three quarters of the coding region 
(Rice et al., 1986).
Several regions of the genome contain conserved sequences or structure 
when the available flavivirus sequences are compared. This includes 90 
nucleotides at the 3' terminus which can be organised into a stable hairpin loop 
structure (Brinton et al., 1986; Grange et al., 1985). Also present at the 3' end 
of flavivirus genomes are short conserved repeat sequences (a heptanucleotide 
of 3-GGACACA-5^ which are thought to be important in cyclising RNA 
(Brinton, 1986; Hahn et al., 1987). Although no evidence exists that 
flaviviruses undergo cyclising of RNA prior to replication, cyclisation of 
alphavirus RNA (Frey et al., 1989; Hsu et al., 1973) and bunyavirus RNA 
(Hewlett et al., 1977) is thought to be important to replication. No extensive
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sequence conservation is found in the 5' terminus, but hairpin loop structures 
can be predicted in the region (Brinton and Dispoto, 1988),
c) Structural proteins
Mature flaviviruses contain three structural proteins; a capsid protein (C), 
a membrane protein (M) and an envelope protein (E) (Chambers and Rice,
1987).
The capsid protein (C) of molecular weight 13-16 kilodaltons (kd) is 
composed of a single species of protein and is complexed with the genomic 
RNA molecule to form the nucleocapsid (Rice et al., 1985). C protein is 
poorly conserved among the flaviviruses sequenced and is highly basic in charge 
with 23-25% of deduced amino acids being either arginine or lysine. The basic 
nature of the protein is believed to offset the charged RNA molecule with 
which it is associated (Rice et al., 1986). Purified C protein does not elicit 
neutralising antibody when injected into mice (Brinton, 1986).
The membrane protein (M) is associated with the E protein but is not 
glycosylated. M protein is a minor component of the envelope (MW 7-9 kd). 
Treatment of mature virions with nonionic detergents solubilises M along with 
E (Westaway and Reedman, 1969). The M protein may play a role in virus/cell 
interactions as evidenced by the inability of Banzi virus to attach to cells that 
had been pre-treated with purified Banzi virus M protein (Lee and Schloemer,
1981). Purified M elicits neutralising antibody following inoculation into mice 
(Brinton, 1986).
Flavivirions are occasionally found to contain a nonstructural protein in
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the lipid envelope in addition to or in place of the M protein (Shapiro et al., 
1972a-c; Westaway and Shew, 1977; Wright, 1982). Nucleotide data revealed 
the presence of a glycosylated precursor protein pre-M (MW 19-23 kd) which 
is usually cleaved during translation to produce the non-glycosylated M protein 
(Rice et al., 1985).
The envelope protein (E) is the largest of the flavivirus structural proteins 
(MW 51-59 kd) and is located in the virion lipid envelope to form surface 
projecting spikes (Rice et al., 1985). Large discrepancies in the electrophoretic 
mobility of different flavivirus E proteins are often noted and probably relates 
to the degree of N-linked (asparagine-X-serine/threonine) glycosylation that has 
taken place (Smith and Wright, 1985). As greater numbers of flavivirus E 
genes were sequenced, it became apparent that potential glycosylation sites are 
not conserved between different viruses. For example, two Den-2 isolates each 
possessed two identical potential N-linked glycosylation sites which were in turn 
different from the two potential glycosylation sites on the YF E protein (Hahn 
et al., 1988; Deubel et al., 1988; Rice et al., 1985). Wengler et al. (1985) 
found no potential sites for glycosylation on the E protein of WN virus. 
Although potential glycosylation sites may be present on the protein, it does not 
necessarily follow that attachment of a sugar moiety will take place. For YF 
virus, only one of the two available sites is utilised for sugar attachment 
because the other site is believed to be buried in the hydrophobic 3' region of 
the protein (Rice et al., 1986).
The E protein, being the major component of the virion surface, possess 
most of the sites concerned with biological activity including binding to cell 
receptors (tropism and haemagglutination), eliciting of immunological responses
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(neutralisation, passive protection and antibody dependent enhancement) and 
fusion activity at low pH (Monath, 1989). More recently, monoclonal antibody 
(Mab) analysis has revealed the presence of group-, type-, and strain-specific 
flavivirus epitopes with significant biological activity to reside on the E protein 
(Heinz et al., 1982, 1983; Gentry et al., 1982; Henchal et al., 1982, Peiris 
et al., 1982, Schlesinger et al., 1983, 1984; Kimura-Kuroda and Yasui, 1983; 
Roehrig et al., 1983; Stephenson et al., 1984). The biological data obtained 
with the Mabs has been incorporated with sequence data and enzyme cleavage 
patterns to generate models of the flavivirus E protein. E protein structure 
models exist for WN virus, MVE, Den-2 and a Central European TBE virus 
which were elucidated by di-sulphide bridge and peptide analysis (Roehrig et 
al., 1989; Mandl et al., 1989b; Nowak and Wengler, 1987). Figure 1.1 
displays the proposed model for the TBE virus in which three domains exist 
(domain A, B and C) Domain A contains highly hydrophillic regions and is 
antigenically reactive as determined by sequence analysis of neutralisation escape 
variants (Mandl et al., 1989b; Lobigs et al., 1987). Domain B includes sites 
involved in neutralisation and haemagglutination (Mandl et al., 1989b; Mason 
et al., 1987). Domain C is the most variable region of the E protein and 
possess little serological cross reactivity or biological activity. The C domain 
is also includes the transmembrane hydrophobic spike which is thought to 
anchor the protein in the lipid envelope (Monath, 1989; Mandl et al., 1989b; 
Nowak and Wengler, 1987, Rice et al, 1986).
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Figure 1.1
Structure of the TBE virus E-protein 
(taken from Mandl e t â f l 9 8 9 )
1) A, B, C: correspond to different antigenic protein 
domains recognised by Mabs.
2) Disulphide bridges are marked by connecting solid lines, 
(from Nowak and Wengler, 1987)
3) Thin lines indicate variable sequences.
4) Thick lines indicate hypervariable sequences.
5) Diamonds indicate potential N-linked glycosylation sites 
for TBE and other flaviviruses.
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d) Nonstructural proteins
A total of seven virus specified nonstructural (NS) proteins exist in flavivirus 
infected cells, the function of which are not fully understood.
Nonstructural protein NSl (MW 45-50 kd) is a protein of biological 
importance and is found in both an associated form with the plasma membrane 
of infected cells and a released form as the soluble complement fixing antigen 
(Smith and Wright, 1985). NSl is unusual as a nonstructural protein because 
it is glycosylated and elicits antibody mediated protective immunity (Westaway, 
1975; Schlesinger et al., 1983; Smith and Wright, 1985; Gibson et al., 1988). 
Moreover, the sites utilised for N-linked glycosylation exhibit a marked degree 
of conservation for the flaviviruses sequenced (Stephenson, 1988; Rice et al.,
1986). The protein is largely hydrophillic but the carboxy-terminus of NSl 
contains a hydrophobic region for anchoring the protein in the plasma 
membrane (Rice et al., 1985). Because NSl is expressed on the surface of 
flavivirus infected cells, it is accessible to immune recognition by the host. 
Antibodies to NSl have been shown to be protective (Schlesinger et al., 1985, 
1986, 1987) and recent data has suggests that NSl exists as a dimer in infected 
cells (Winkler et al., 1988). The function of NSl is not fully understood, but 
it may have a role in virus morphogenesis as opposed to virus replication 
(Russell et al., 1980; Chambers and Rice, 1987).
NS3 and NS5 are two of the largest proteins encoded by the flavivirus 
genome with molecular weights of 70kd and lOOkd respectively. Both proteins 
are hydrophobic and highly conserved. The true function of the proteins has yet 
to be defined, however, there is mounting evidence that implicates NS5 in the
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replication process, perhaps as the replicase component (Chambers and Rice,
1987). This possibility was strengthened by the discovery that NS5 contains 
homology with the NS proteins of many plant and animal viruses including the 
RNA dependent RNA polymerase of togaviruses and picornaviruses (Kamer and 
Argos, 1984). NS3 has recently been proposed to have a proteinase/hellease 
type action (Rice et al., 1989).
The nonstructural proteins NS2A, NS2B, NS4A and NS4B are located 
between the large NS3 and NS5 proteins and have deduced molecular weights 
of 18kd, 13kd, 31kd and 12kd respectively (Rice et al., 1986). All the proteins 
are highly hydrophobic and non-glycosylated and represent the least conserved 
of the virus encoded proteins by nucleotide comparison. However, the 
hydrophilicity and hydrophobicity profiles are highly conserved (Rice et al., 
1986). The functions of these proteins has still to be determined but they have 
potential roles in the structural components of the membrane associated RNA 
replication process (Chambers and Rice, 1987).
e) Replication and genome processing
In comparison to alphaviruses (Togaviridae), the specific steps in the 
replication of flaviviruses are not known in any detail. Specific cell surface 
receptors for flavivirus binding to cells have not been characterised although 
work involving WN infection of macrophages suggested that following binding, 
the primary mode of virus entry is by adsorptive endocytosis (Gollins and 
Porterfield, 1984). Acidification of pre-lysosomal vesicles probably triggers
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fusion of the virion with the vesicle membrane giving way to internalisation of 
the genome after uncoating (Gollins and Porterfield, 1986). A latent period of 
approximately 12 hours follows prior to virus macromolecular synthesis and 
hypertrophy of intracellular membranes (Westaway, 1980).
Picornaviruses and flaviviruses share a similar genome organisation and 
it therefore surprising that the two genomes are processed very differently. 
Flavivirus RNA synthesis occurs in the perinuclear region and involves both 
replicative intermediates and replicative form RNA (Cleaves et al., 1981; Ng 
et al., 1983; Chu and Westaway, 1985; Westaway, 1980, 1987). Furthermore, 
when flavivirus RNA is translated in vitro, only the structural proteins or 
multimers of them are detected (Wengler et al., 1979; Svitkin et al., 1984).
Incoming viral RNA is translated from a single initiation codon which 
generates a long polyprotein which is cleaved co-translationally and post- 
translationally (Chambers et al., 1990). Translational events take place in the 
cytoplasm of the cell with recent evidence suggesting that the viral 
RNA/ribosome complex may require translocation to various sites within the cell 
before it is translated in its entirety (Stephenson et al., 1987). Earlier models 
of replication proposed multiple initiation sites within the flavivirus genome for 
translational control (Westaway, 1977, 1980; Westaway et al., 1984). New data 
obtained following the sequencing of the YF virus genome implied a different 
strategy (Rice et al., 1985). Although discrete polyprotein precursors are 
difficult to define, there are a logical and consistent set of cleavage sites along 
the polyprotein (see Figure 1.2). Following initial rapid processing events, two 
series of events take place; (1) the proteins C, pre-M, E and NSl are produced 
utilising a number of hydrophobic segments that act as signal sequences for co-
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Figure 1.2
Organisation and expression of the flavivirus genome.
NC- untranslated non-coding region. Boxes below the genome 
indicate precursors and mature proteins generated by combination 
of host- and virus- encoded proteinases.
U structural proteins. J  Non-structural proteins
I  Long stretches of uncharged amino acids
* Probable NH^ linked glycosylation site for YF virus in 
pre-M and NSl
(Adapted from Brandt, 1990).
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translational processing and insertion of the protein into the membrane of the 
endoplasmic reticulum (Chambers et aL, 1990; Rice et al., 1985; Castle et al., 
1985; Wengler et al., 1985). Cleavage of these proteins is believed to utilise 
a host encoded signalase. Modification of the E protein takes place in the form 
of N-linked glycosylation. The remaining NS proteins are produced using a 
cytoplasmic protease of viral or host origin with a specificity for double basic 
amino acids (Rice et al., 1985; Castle et al., 1986). Because replication takes 
place in the cytoplasm, capping of the viral RNA is thought to be virus coded. 
Minus strand RNAs for the production of genome length mRNA are produced 
at a ratio of 1:10 (Cleaves et al., 1981). Virus maturation occurs on 
intracellular membranes with virus budding from membranes in the endoplasmic 
reticulum and Golgi apparatus (Leary and Blair, 1983). Cleavage of pre-M to 
M is associated with virus release (Rice et al., 1986).
1.4 Yellow fever virus
a) History
Records of yellow fever (YF) epidemics date back to the seventeenth 
century but because of clinical symptoms being confused with other infections, 
including malaria, typhoid, typhus, leptospirosis and other bilious fevers, case 
definitions were difficult (Monath, 1987). YF almost certainly originated in 
Africa and was probably imported to the Americas by sea-fairing explorers like 
Christopher Columbus (Porterfield, 1989). Major epidemics of YF ensued in the
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Caribbean, Central and Southern America and later North America from 1693- 
1905 (Blake, 1968). Spread of YF increased to encroach on other continents 
and 17 deaths were recorded at Swansea in 1865 following the arrival of a 
Cuban vessel (Smith and Gibson, 1986).
The causative agent of YF and its mode of transmission remained a 
mystery until this century. In 1848 Nott proposed that the mosquito was 
responsible for disease transmission but this theory was largely disregarded 
(Warren, 1951). Transmission by mosquito was proposed again by Carlos 
Findlay in 1881 and was duly met with a great deal of scepticism (Warren, 
1951). YF epidemics continued to pose a major public health problem and 
prompted the United States government to establish the Yellow Fever 
Commission in 1900 which was lead by Major Walter Reed. Shortly after, the 
first significant breakthrough in YF research was made. YF was demonstrated 
to be a filterable agent (virus) and experiments showed that the virus was 
present in the blood of infected patients during the first three days of infection 
(Reed and Carroll, 1902). In addition, Reed and Carroll (1902) demonstrated 
that infected Aedes aegypti mosquitoes were able to transmit YF when allowed 
to feed on YF non-immune volunteers, thus confirming the theories of Nott and 
Findlay.
Despite the success of transmitting the disease from mosquito to man, it 
was over a quarter of a century later before the virus was isolated. However, 
in 1918, a Japanese scientist claimed that the disease YF was not caused by 
a virus but was bacterial (Leptospira icteroides) in nature (Noguchi, 1919; 
Noguchi, 1917). The claims were upheld by a number of people and 
unfortunately the YF Commissions’ mosquito abatement campaigns in Africa and
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America duly suffered (Porterfield, 1989). In 1927, a small outbreak of YF 
was occurring in the Gold Coast region of Africa. A sample of blood was 
taken from a 27 year old Ghanian, named Asibi, who was suffering from a 
mild form of the disease. Asibi’s blood was inoculated into a rhesus monkey 
(Macaca rhesus) which was dying from YF four days after inoculation. A 
further monkey was inoculated with the blood of the first animal and mosquito 
transmission studies were also successfully undertaken (Stokes et al., 1928). 
Almost concurrently, Mathis et al. (1928) working in Dakar, Senegal reported 
similar success in establishing the French viscerotropic strain of YF virus. Both 
Asibi and French YF viruses were the progenitors to two live attenuated YF 
vaccines (17D and FNV respectively) which were used to great effect to control 
the disease (see section 1.8).
b) Mosquito vectors and transmission o f YF
YF is a classic example of a zoonotic disease with human infection being 
acquired through the bite of an infected mosquito, traditionally Ae. aegypti. 
Although Ae. aegypti can transmit YF in urban outbreaks in both Africa and 
the New World, the vectors involved in non-urban YF are different in Africa 
(Haddow et al., 1967; Germain et al., 1979) and the Americas (Downs, 1989). 
Primary transmission cycles involve wild non-human primates and various 
sylvatic (tree-hole breeding) aedine mosquitoes. Humans are infected when they 
encroach into jungle regions (jungle YF) with epidemic spread from human to 
human being continued by the sylvatic vector.
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i) The Americas
YF was first recognised in the Americas in 1648 when an outbreak of 
disease occurred in the Yucaton (Blake, 1968). Since the 1940’s, the majority 
of YF outbreaks have been exclusive to South America. In tropical America, 
the howler monkey {Alouatta sp.), spider monkeys (Ateles sp.) and several other 
species of primate are effective viraemic hosts which usually succumb to 
disease. The unstable host-parasite relationship may reflect the recent 
introduction of YF into the Americas (Monath, 1989). Mosquitoes of the genus 
Haemagogus are the principal vectors of jungle YF in tropical areas and 
humans become infected when they enter habitats supporting enzootic/epizootic 
transmission (Monath, 1989). The mechanism of virus maintenance during dry 
seasons is by an unknown method although transovarial transmission has been 
demonstrated (Dutary and Le Duc, 1981). Recent introduction of Ae. albopictus 
into Brazil has raised concern about its potential to transmit YF. Whilst Ae. 
albopictus is a competent vector for YF, it is less efficient than Ae. aegypti 
(Whitman, 1951). Sporadic, endemic cases of YF were notified in South 
America in 1986 and 1987 with the Brazilian Ministry of Health advising 
travellers to be vaccinated against YF because of the occurrence of jungle YF 
in 1988 (Weekly Epidemiological Record, 1989 a,b).
ii) Africa
Outbreaks of YF occurred in Africa much earlier than America with the 
first documented epidemic in 1778 (Freestone, 1988). The World Health
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Organization (1971) in a report on YF suggested that YF virus was either
endemic of epidemic in 29 countries between the latitudes 15°N and 10°S. Many
species of monkey have proved effective hosts and infection infrequently results 
in clinical illness, thus representing a balanced host-parasite relationship.
Ae. africanus mosquitoes are largely responsible for year round transmission in 
African forests. Transmission of disease to humans is usually linked with 
Ae. bromeliae and is responsible for intense inter-human spread during 
epidemics. The ’zone of emergence’ (Germain et al., 1982), has assumed great 
importance in YF ecology. This area contains the savannah vegetational zones 
which support large concentrated populations of monkey and mosquito vectors. 
Virus activity increases during the rainy seasons with sylvatic transmission and 
transmission to man of virus involving Ae. furcifer, Ae. africanus and Ae. 
luteocephalus. In areas subjected to extreme drying (Northern Sudan and 
savannah zones of West Africa) domestic water storage is intensively practised 
and populations of Ae. aegypti are high. Introduction of YF virus may result
in explosive outbreaks of disease (Monath, 1989). The virus is believed to
survive dry periods and over-winter by transovarial transmission (Aitken et al., 
1977; Beaty et al., 1980). YF has also been isolated from ticks in Africa with 
virus undergoing both transstadial and transovarial transmission (Saluzzo, 1980).
c) Human infection
Following the bite of an infected mosquito, the disease course of YF can 
take many different forms thus making diagnosis in the field difficult. A single
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patient presenting with severe disease is easy to identify as opposed to an 
abortive infection (Monath, 1989). YF produces a viscerotropic disease in 
humans and as an infection shares many clinical features with other viral 
haemorrhagic fevers (dengue haemorrhagic fever. Lassa fever and Congo 
Crimean haemorrhagic fever) although hepatic involvement with YF is greater 
(Monath, 1987). The clinical signs of YF infection have been well documented 
in both classical (Kerr, 1951) and recent reviews (Monath, 1987; Freestone,
1988).
Abortive YF infections are usually characterised by fever with headache 
and constitutional problems, however, these signs make it difficult to confirm 
YF infection. Patients usually recover in a few days and suffer no sequelae. 
Severe YF begins abruptly with the disease course being split into three distinct 
phases. The ’period of infection’, during which virus is present in the blood 
and infectious for mosquitoes, lasts three days with physical examination 
revealing chills, severe headache, lumbosacral pain, myalgia, rising temperature 
and a slowing pulse rate (Fagets sign). In classical cases, a ’period of 
remission’ follows which usually lasts upto 24 hours during which time the 
patient feels well. Fever returns rapidly during the ’period of intoxication’ with 
frequent vomiting, epigastric pain, prostration, dehydration and appearence of 
jaundice. Viraemia is generally absent and antibodies appear at this stage. The 
haemorrhagic diathesis is manifested by coffee-grounds haematemesis (black- 
vomit), melena, ecchymoses and difftise oozing from the mucous membranes. 
Figures suggest that approximately 20-50% of patients which enter this phase 
have a fatal outcome that usually occurs between the seventh and tenth day of 
illness. Atypical fulminant cases of YF occasionally occur with death as early
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as three days after onset of symptoms without significant hepatic or renal signs 
(Sérié et àl., 1968). Convalescence and recovery in non-fatal infections is 
complete and rarely prolonged but jaundice has been known to last several 
months (Monath et al., 1984a).
d) Pathogenesis o f YF in humans
Infection with YF results in liver damage which is evident on pathological 
examination. Gross inspection of the liver reveals it to be normal or slightly 
enlarged in size, reddish or yellow in colour and, when cut, the lobular 
markings have been destroyed. Microscopic analysis shows degeneration of 
hepatocytes (Councilman bodies) and appearence of viral antigen in Kupffer cells 
by immunofluorescence (Monath, 1989). Changes in the spleen and lymphatic 
tissue is evident by the depletion of lymphocytes and appearence of large 
mononuclear cells (Klotz and Belt, 1930). The pathogenesis of the haemorrhagic 
diathesis in YF has been linked to decreased synthesis of vitamin K dependant 
coagulation factors by the diseased liver (Monath, 1989). Cerebral involvement 
is a late phase condition of YF infection with petechial and perivascular 
haemorrhage and oedema. Cerebral oedema may be an important component of 
the encephalopathy observed during terminal phase infection (Monath, 1987).
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e) Pathogenesis o f YF in other vertebrates
i) Monkey
The majority of data concerning pathogenesis and pathophysiology of YF 
relies on the observations made with the monkey. The Indian rhesus monkey 
(Macaca rhesus) was the first primate to be successfully infected with YF virus 
(Stokes et al., 1928). Infection with YF virus was soon demonstrated for other 
species of monkey including the South American squirrel monkey, spider 
monkey, howling monkey and woolly monkey (Davis, 1930 a/b). Burgher 
(1951) in his review of primate susceptibility to infection stated that the West 
African monkeys (excluding North African macaques and chimpanzees) have a 
high resistance to YF infection even though the virus undergoes replication. 
Naturally acquired infections in tropical rain forests of S. America resulting in 
the death of howling monkeys has often heralded the appearence of epizootic 
YF (Down, 1989).
Viscerotropism reflects the pathogenicity of YF virus inoculated into 
monkeys by the peripheral route with the disease course being more rapid than 
in humans (death in five to six days post-infection). Viraemia is detected on 
the second day post-infection with titres increasing to the fifth day. No anti- 
YF antibodies develop and hepatocellular degeneration and necrosis proceed 
rapidly during the 24-36 hours before death (Monath et ah, 1981). As in 
human disease, central nervous system involvement is a terminal phase event. 
Monkeys inoculated intracerebrally with YF virus develop encephalitis but die 
of viscerotropic YF (Monath et ah, 1981).
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ii) Mice
Flaviviruses are universally neurotropic in mice with the brain and ganglia 
being major sites of replication. In 1930, Theiler discovered that adult white 
mice were susceptible to YF virus infection when inoculated intracerebrally 
(i.e.), but were, in most cases, resistant to infection following intraperitoneal 
(i.p.) challenge. Neurotropic YF virus infection of mice has been used as a 
model system for studies on the pathogenesis of flavivirus encephalitis (Monath, 
1989). Passage of YF virus in mice lowered its virulence for monkeys whilst 
becoming more virulent for mice as evidenced by the decrease in average 
survival time of infected mice (Theiler, 1951). Newborn mice upto the age of 
two weeks are, in comparison to adult mice, highly susceptible to infection with 
YF virus by either the i.e. or i.p. route. Young mice die with similar 
symptoms to adult mice with neurotropic disease manifestations (Theiler, 1930). 
Considerable variation in neurovirulence for mice exists between strains of YF 
virus used (Barrett and Gould, 1986).
iii) Hedgehog
The European hedgehog (Erinaceus europaeus) is the only non-primate 
animal in which infection of the liver is evident following inoculation with YF 
virus (Findlay and Clarke, 1934). Inoculation of E. europaeus with the Asibi 
strain of YF resulted in death between four and seven days post-infection with 
the liver exhibiting characteristic lesions normally associated with human or 
monkey infections. Little work has been performed since the original
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experiments which presumably reflects the difficulties in handling the animal.
iv) Guinea pigs
Guinea pigs show a marked resistance to i.p. challenge with YF virus 
(Sawyer and Frobisher, 1932). Viraemia was detected and the production of 
anti-YF antibodies. If the guinea pig is inoculated i.e. with Asibi virus, 
encephalitis and death follows with animals dying after an incubation period of 
between five to fourteen days (Theiler, 1933).
v) Rabbits
A number of YF strains have been introduced both i.e. and i.p. into 
rabbits which resulted in no clinical signs of infection (Whitman, 1935; Theiler,
1951). Whitman, (1935) demonstrated that challenge of rabbits with virus was 
accompanied by production of anti-YF antibodies, the titre of which increased 
when a second dose of virus was given six weeks after the first.
1.5 West Nile virus
a) History
West Nile (WN) virus is a mosquito borne flavivirus which belongs to 
the same antigenic complex as MVE, SLE and JE viruses. The original
34
isolation of WN virus was made in 1937 thus making it one of the first 
recognised arbovirus diseases of man (Smithbum et al., 1940). WN strain 
Smithbum (the prototype WN virus), was isolated from a woman presenting 
with a febrile illness in the West Nile province of Uganda. Subsequent 
serological surveys revealed widespread occurrence of people possessing antibody 
to WN virus, particularly in East and Central Africa (Smithbum and Jacobs, 
1942; Smithbum, 1952).
The earliest epidemics attributed to WN vims were recognised 
retrospectively by serological surveys. A large epidemic took place in Israel in 
the 1950’s which was centred around Tel Aviv; some 500 people were 
hospitalised as a result of infection (Klingberg, 1959). Mosquitoes were 
implicated as the vector following studies in the Sindbis sanitary district of 
Egypt between 1952 and 1954 (Taylor et al., 1953). Culex mivittatus was 
proposed as the principal vector of African WN disease and was shown to be 
highly efficient in transmission experiments (Taylor et al., 1956). Follow-up 
studies revealed that mosquitoes were the only vector that can be infected and 
transmit WN vims. Soft and hard ticks that were inoculated experimentally were 
unable to transmit disease to suckling mice (Hurlbut, 1956).
Outbreaks of disease were also recorded in France around the Rhone delta 
region in 1962 (Panther et al., 1968). No vims activity has been recorded in 
the area since 1966 (Rodhain and Hannoun, 1980). The largest epidemic to date 
occurred in South Africa in 1974 and resulted in thousands of infections 
(McIntosh et al., 1976). An epidemic outbreak of Sindbis vims developed 
simultaneously and was thought to be caused by similarities in the transmission 
cycle by the mosquito vector (Hayes, 1988).
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b) Mosquito vector and transmission o f WN virus
WN virus has been isolated from a number of mosquitoes, the species 
of which varies depending on geographical location. The vectors of primary 
importance in regions of Africa and the Middle East are Cx. univittatus and 
Cx. pipiens molestus (Hayes, 1988). The significance of Cx. univittatus became 
more apparent in Egypt when 23 strains of WN virus were isolated from the 
vector and febrile children over a period of months (Taylor et al., 1956). The 
predominant vector of South African lowlands and a number of other coastal 
African countries is Cx. neavi (Jupp, 1972). Virus has been isolated from 
Mansonia sp. mosquitoes in Uganda and from Cx. purina and Cx. weschi in 
the Central African Republic (Hayes, 1988). Cx. tritaeniorrhyncus and Cx. visnui 
are important vectors in tropical Asia (Hayes et al., 1982; Dandawante et al., 
1969). The French epidemic of 1962 was caused principally by two distinct 
strains of WN virus which were transmitted by Cx. modestus mosquitoes. 
Although virus was not isolated from Cx. pipiens in this outbreak,
Cx. modestus was nevertheless suspected to be the vector involved with 
transmission of virus to birds because of its strong ornithophagic lifestyle 
(Mouchet et al., 1970). Wild birds are strongly implicated as viraemic hosts 
in the transmission cycle of WN virus. Birds have been shown to maintain a 
high viraemia after experimental infection (McIntosh et al., 1969). Apart from 
birds, high antibody titres have been found in domestic animals although the 
viraemia was too low from infection of mosquitoes in subsequent experiments 
(Hayes, 1988).
Although WN virus has been isolated from ticks on several occasions.
36
their role in transmission cycles has not been fully determined and are deemed 
of little epidemiological importance (Hayes, 1988).
c) Human infection
Transmission of infection to man is via the bite of an infected mosquito 
usually of the Culex species. The incubation period is generally one to six days 
depending on the age of the patient. Inapparent infections are very common. 
WN infection is characterised by a rapid onset of fever which peaks between 
38 and 40°C and lasting upto six days. Malaise, headache, myalgia, and 
anorexia, and pain associated with eye movement are common symptoms of 
disease. A rash is present in approximately half of the cases which defined as 
maculopapular and occurs during or just after the febrile phase. Enlargement 
of lymph nodes is common along with pharyngitis and gastrointestinal problems. 
Acute pancreatitis may be responsible for the abdominal pain associated with 
WN infection (Perelman and Stern, 1974). Convalescence following disease is 
usually rapid although prolonged periods of upto two weeks have been 
documented (Taylor et al., 1956; Goldblum, 1959; Goldblum et al., 1954; 
Marberg et al., 1956)
Children generally suffer a milder illness than adults with infection 
sometimes resulting in aseptic meningitis of meningoencephalitis. However, 
studies conducted in India found that infection can be severe in young children 
(George et al., 1984), in which three cases out of four documented were fatal. 
Severe meningoencephalitis is conunon in elderly patients. In 1957 a number
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of cases were reported in elderly homes in Israel of which four patients from 
49 died after a fiilminant infection (Spigland et al., 1958).
d) Pathogenesis o f WN virus in humans
The pathogenesis data available for WN virus infection was derived after 
experimental infection of advanced cancer patients (Southam and Moore, 1952; 
South am and Moore, 1954). Encephalitic signs or symptoms were seen in very 
few patients and only generalised fever was commonplace. Patients which 
subsequently succumbed to neoplastic disease were analysed post-mortem for 
evidence of WN virus infection. Virus was isolated from the spleen, lymph 
nodes, liver and lungs (Southam and Moore, 1954), which is similar to the 
distribution of virus in experimental animals (see below). Pathologically, focal 
necrotic areas with polymorphonuclear leucocytes and mononuclear macrophages 
were detected in the central nervous system (CNS). In three cases investigated, 
CNS lesions attributed to WN virus infection were found in both grey and 
white matter of the brain and spinal cord. The lesions were similar to those 
associated with other arbovirus encephalhides (Newman and Southam, 1954).
e) Pathogenesis o f WN virus in mice
Mice of all ages are susceptible to lethal infection by WN virus following 
i.e. inoculation. Resistance to infection by peripheral routes develops with age
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although some virus isolates remain pathogenic. In a comparison of isolates of 
WN virus from Nigeria, Odelola and Fabiyi (1977), showed that two out of 
seven isolates exhibited similar growth in the organs of mice whilst the others 
varied. A similar study revealed heterogeneity amongst six Indian isolates of 
WN virus for adult mice following i.p. inoculation (Umrigar and Pavin, 1977). 
Newborn mice are highly susceptible to WN virus infection by any route 
(Odelola and Oduye, 1977). The increase in resistance to WN virus challenge 
with increasing age of mice in contrast to the situation in humans where 
increasing age is associated with more severe disease (Monath, 1986).
Pathogenically, infection of mice by any route with WN virus results in 
changes in behaviour and orientation before onset of acute disease which is 
manifested by hind limb paralysis (Duffey et al., 1958). In experimental 
infection of adult mice by the intranasal route, invasion of the CNS occurred 
by passage of virus along the olfactory nerve. Virus was present in the 
olfactory bulbs to high titres prior to invasion of the brain proper (Nir et al., 
1965). Pathological lesions in infected mice are usually limited to the CNS 
regardless of the route of inoculation (Nir et al., 1965).
1.6 Dengue virus
a) History
Dengue is a human disease of global significance with upto 100 million 
cases per year worldwide with the most susceptible hosts being children
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(Halstead, 1988). The first epidemics of dengue were recognised in the 18“* 
century when Benjamin Rush described an outbreak of disease that engulfed 
Philadelphia in 1780 (Shope, 1980). Epidemics attributable to dengue were 
widespread throughout the 18“* and 19* centuries encompassing North America, 
the Caribbean, Asia and Australia (Carey, 1971). Transmission of infection by 
Aedes aegypti mosquitoes was demonstrated by Siler et al., (1926), and
confirmed by Simmons et al., (1931), although the concept of dengue being a 
mosquito-borne zoonoses was first proposed by Bancroft in 1906 (Monath,
1989). Dengue (Den) virus was shown to be a filterable agent in 1906 but it 
was 1944 before the virus was isolated following passage in mice (Sabin and 
Schlesinger, 1945; Monath, 1989). Den virus exists as four distinct serotypes 
that were established by cross-protection studies in human volunteers (Sabin,
1952). All four serotypes can cause classical dengue fever which is usually a 
self-limiting febrile illness with no sequelae. However, a more severe and
sometimes fatal form of dengue can occur (Halstead, 1980).
It was not realised until the 1950’s that Den virus could cause a
haemorrhagic fever/shock syndrome of dramatic swiftness. The term 
‘haemorrhagic fever’ was first used to describe an epidemic in the Phillipine 
Islands which took place in 1953. The term was used to describe the outbreak 
because of similarities to Korean haemorrhagic fever which was common in that 
area (Shope, 1980). Quintos et al. (1954), noted a subtle difference between the 
Korean and Phillipine illnesses and proposed the term ‘infectious acute 
thrombocytopaenic purpura’. It was not until Hammon et al. (1969) isolated 
Den virus from children suffering haemorrhagic complications to classical dengue 
infection that the term dengue haemorrhagic fever/dengue shock syndrome
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(DHF/DSS) was introduced. Records suggest that DHF/DSS probably occurred 
earlier in history than was first thought with outbreaks in Australia (1897), 
Greece (1928) and Formosa (1931) (Johnson et al., 1967). In comparison to 
classical dengue fever, DHF/DSS is often manifested by gastro-intestinal 
bleeding followed by death (Halstead, 1988). DSS is rarely seen in 
malnourished children but the syndrome is usually associated with pre-infection 
dengue antibody acquired either actively or passively (Halstead, 1988). Hammon 
and Sather (1973) and Rosen (1986), suggested that viruses associated with DSS 
were more pathogenic than the viruses causing classical dengue infection, thus 
refuting claims of an immunological basis for the disease. Recent data has 
claimed that maternal antibodies may enhance the risk of DHF/DSS occurrence 
in infants that become infected with a heterologous Den-serotype (Kliks et al.,
1988).
b) Mosquito vector and transmission
Whilst YF virus has been confined to forested locations in Africa and 
South America, Den viruses have kept pace with the urban encroachment of Ae. 
aegypti mosquitoes. Ae. aegypti is currently distributed worldwide in tropical 
and temperate areas and favours locations with a high population density, 
therefore increasing the threat of explosive outbreaks of disease. Den viruses 
are principally located in tropical Asia, Oceania, Africa, Australia and the 
Americas. In areas of particularly high populations of human hosts and vectors. 
Den virus can become endemic. The infection rate in endemic and hyperendemic
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areas can be alarming, so much so that children by the age of seven have 
usually experienced infection with one or another Den serotype (Monath, 1989).
Den virus is maintained in a cycle involving humans and mosquitoes. 
Ae.aegypti is the most important vector in transmission of disease, although Ae. 
albopictus, Ae. polynesiensis and Ae. scutellaris play roles in rural and insular 
areas of Asia and the Pacific (Monath, 1989). Geographic variation between 
strains of Ae. aegypti and Ae. albopictus and variation in vector efficiency 
(infection by the oral route) exist although the epidemiological importance of 
such differences is not known (Gubler et al., 1979). The primary mosquito 
vector (Ae. aegypti) is usually found in urban areas and breeds in artificial 
water containers in and around human habitats. The mosquito principally feeds 
during the day time and humans are often bitten.
Recently, 60 strains of Den-2 virus were isolated from four West African 
species of sylvatic mosquito which were generally considered part of the YF 
sylvatic cycle (Rosen, 1982). These were Ae. africams, Ae. luteocephalus, Ae. 
opok and Ae. furcifer-taylori, all of which were captured from the Ivory Coast 
and Upper Volta regions of Africa. A previous isolation of Den virus from Ae. 
luteocephalus in Senegal (1974) was ignored (Comet et al., 1979). These results 
imply the possible existence of a sylvatic cycle for the maintenance of Den 
virus in nature. Information from Malaysia supported this theory when a Den- 
4 virus was isolated from a number of forest-canopy mosquitoes (Ae. niveus 
group). Therefore, although Den virus transmitted by Ae. aegypti is important 
in human epidemiology, the virus may be new and relatively unimportant in the 
natural history of Den virus. It has to be remembered that Ae. aegypti 
originated in Africa but has been disseminated throughout the world only
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recently by human activity.
The isolation of Den virus from the forest mosquitoes does not, however, 
explain the long term existence of the virus unless, like certain other 
flaviviruses, transovarial transmission occurs. Rosen (1982), showed that all four 
Den serotypes can undergo transovarial transmission in the laboratory. Ae. 
aegypti larvae isolated in the field along with male mosquitoes of the Ae. 
furcifer-taylori group suggest that transovarial movement occurs in nature 
(Gubler, 1987).
c) Human infection
i) Classic dengue fever
Clinical symptoms of classical ‘dengue fever syndrome’ have been 
reviewed by Siler et al., (1926) and Sabin (1952). Dengue fever presents as 
a mild, self-limiting infection, the severity of which is age dependant. In young 
children the disease appears as an undifferentiated febrile illness or a mild 
upper respiratory tract infection (Carey et al., 1968). In adults and adolescents, 
dengue fever syndrome is often seen, an outline of which is given below.
Dengue fever syndrome typically begins abruptly following an incubation 
period of 2-7 days with a generalised fever which may reach 103-106°F. Fever 
is accompanied by headache, retrobullar and lumbosacral pain. Viraemia 
coincides with the onset of fever (Simmons et al., 1931). A transient rash is 
often visible during the first 24-48 hrs of beginning the febrile phase, with
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nausea and vomiting being common. Fever and symptoms usually disappear at 
this stage, however, a second maculopapular rash soon becomes evident and 
body temperature rises again. A temperature profile reveals a biphasic type 
illness to be common in most dengue fever syndrome patients (Halstead, 1980). 
Generalised lymphadenopathy and depressed white cell counts mark the terminal 
phase of the illness. Myocarditis and various neurological manifestations are 
uncommon following initial dengue fever infection but are more common 
following DHF (see below) (Gubler et al., 1984). Convalescence may be 
prolonged and accompanied by weakness, depression and bradycardia. Although 
arthritic symptoms are not a usual sequelae to dengue infection, it may belie 
an underlying infection with alphaviruses such as Ross River or Chikungunya 
viruses (Halstead, 1980).
ii) Dengue haemorrhagic fever/dengue shock syndrome (DHF/DSS)
The incubation period associated with DHF is at present unknown, 
however, onset of disease is similar to that of dengue fever syndrome (see 
above). Generally, there is a deterioration in health of the patient 2-5 days after 
infection, the syndrome being very characteristic in children (Johnson et at., 
1967). Disease progresses from a mild fever to a severe form associated with 
prostration, restlessness and irritability. Deterioration is rapid and manifested 
with cold, clammy extremities, a warm trunk and flushed face in conjunction 
with complaints of mid-epigastric pain. Scattered petechiae on the forehead and 
extremities along with ecchymoses and bleeding at the sites of venepuncture 
suggest DHF without shock. Gross haematuria, gastro-intestinal bleeding and
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intracerebral bleeding are relatively rare but may be life-threatening. Central 
nervous system disorders include encephalopathy and peripheral mononeuropathy 
or polyneuritis (Gubler et al., 1984).
If the pulse rate is narrow and weak, the case is considered DHF with 
shock or DSS. The significance of identifying DSS lies with the poor prognosis 
of the patient, often a child. Case fatality rates are in the order of 50% in 
untreated situations, but if recognised early and supportive therapy is available, 
fatality rates may be as low as 1% (Monath, 1989).
d) Pathogenesis o f Den virus in humans
There is no satisfactory animal model with which to examine Den virus 
pathogenesis in vivo. Therefore, the available information is largely the result 
of post-mortem examinations performed on children and adults that died from 
complicated Den virus infection (DHF/DSS). The pathogenesis and pathobiology 
of Den virus infection has been reviewed (Halstead, 1988; Bhamarapravati et 
al., 1967; Burke, 1968; Reyes, 1966).
Gross pathological findings indicate petechiae, ecchymoses, focal visceral 
haemorrhages with serous bloody effusions and in some cases enlargement of 
the liver. Disseminated intravascular coagulation is rare in DHF/DSS (Fresh et 
al., 1969).
Histological changes include diffuse small vessel alterations in viscera and 
soft tissue accompanied by leakage of plasma. Necrosis of thymus-dependant 
areas of the spleen and lymph nodes is apparent in a large proportion of
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DHF/DSS cases (Aung-Khin et al., 1975). Lesions in the liver resemble the 
early phase of experimental YF in rhesus monkeys (Bearcroft, 1957; Tigertt et 
al., 1960; Monath et al., 1981), in which hepatocellular necrosis is minimal 
and includes hypertrophy and necrosis of Kupffer cells and central or 
paracentral coagulative necrosis of hepatocytes. Skin biopsies from patients with 
DHF revealed swelling and occasional necrosis of endothelial cells along with 
subcutaneous deposits of fibrinogen (Boonpucknavig et al., 1979 a/b). The 
etiology of haemorrhagic disturbances in DHF/DSS are complex although 
microvascular injury, thrombocytopaenia and platelet dysfunction are implicated. 
DHF is primarily a disease of children who have been infected with at least 
one heterologous Den serotype (Sangkawibha, 1984). The concept of antibody 
dependant immune enhancement of Den virus replication in monocytes is thought 
to be crucial although attempts to model this in vivo in non-human primates has 
largely failed (Halstead, 1980). The lack of pathologic findings in major organs 
in most cases of fatal DHF/DSS and the rapid recovery of those who survive 
the critical period suggest that physiologic dysfunction is secondary to the action 
of biological mediators that are capable of producing severe illness with minimal 
structural injury. Among possible mediators, complement components C3a and 
C5a have been implicated because of the massive activation of the complement 
system in DHF/DSS (Kurane et al., 1989).
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e) Pathogenesis o f Den virus in other vertebrates
i) Monkey
Non-human primates are susceptible to infection by all Den virus 
serotypes by peripheral inoculation (Whitehead et al., 1970; Halstead et al., 
1973). The incubation period following infection is variable but viraemia is 
usually detected between 2-5 days post-infection. Viraemia is followed by the 
production of anti-Den virus antibody which is quantitatively and qualitatively 
equivalent to that of humans (Halstead et al., 1973).
A detailed experiment was conducted by Marchette et al., (1973), to 
examine the distribution of Den virus following infection of a monkey. Three 
distinct phases of infection were noted. A ‘pre-viraemia’ stage following 
subcutaneous inoculation in which virus was detected in the axillary lymph 
nodes. During the first 24 hrs post-infection, virus spreads from the axillary 
lymph nodes to more widespread lymphatic sites. During viraemia large 
quantities of virus is detectable in the lymphatic tissue and later in organs rich 
in lymphatic cells: spleen, lung and the gastro-intestinal tract. The ‘post- 
viraemia’ phase proved to be surprising because virus was recovered from 
tissues after circulating virus was no longer detectable. Virus was present at the 
initial site of inoculation and regional lymph nodes, spleen and viscera. More 
recently, the same observation has been made in a human suffering from Den- 
2 infection (Halstead, 1980).
Monkeys that received a second dose of virus following cessation of the 
first inoculation again exhibited disease though the distribution of virus in
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various tissues did not vary (Marchette et al., 1973).
The monkey has been used to examine DHF/DSS both clinically 
(Whitehead et al., 1970) and physiologically (Halstead et al., 1973). Whitehead 
et al. (1970) observed haemorrhaging and recovered virus from the liver, lung 
and lymph nodes of a monkey dying on day nine following secondary challenge 
with Den-1 virus. Halstead et al., (1973) sequentially inoculated four Den 
viruses into groups of rhesus monkeys at 2, 6 , 12 and 26 weeks. A single 
animal had physiological signs similar to that seen in DHF. Enhancement of 
Den virus viraemias in rhesus monkeys has been demonstrated following transfer 
of small amounts of Den antibody to the primate (Halstead, 1979).
ii) Mice
In general, mice are refractive to Den virus infection (Karabatsos, 1985). 
Den viruses usually have a high tissue/host specificity and will produce different 
symptoms in different species of host (Boonpucknavig et al., 1981). The viruses 
replicate in the brains of suckling mice inoculated i.e., however, unadapted 
strains usually produce subclinical infections or only scattered illness with 
paralysis and death. Cole and Wisseman (1969), found that after several 
passages in adult mouse brains, Den-1 virus produced unique neurological 
symptoms in adult mice. Adult mice inoculated with highly mouse neuroadapted 
Den-1 or Den-2 strains of virus became infected with or without overt 
encephalitis (Boonpucknavig et al., 1981). immunofluorescence revealed Den 
virus antigen in the reticuloendothelial cells, lymph nodes, spleen and liver 
soon after inoculation. Five days post-infection, antigen was located in
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monocytes which suggested replication was taking place in these cells. At no 
time was virus detected in the blood (Boonpucknavig et al., 1981). Recent 
studies of Den virus infection in mice have made use of a special inbred mouse 
strain (Balb/cj) which allows the titration of Den virus infectivity after i.e. 
challenge (Kaufman et al., 1989). Neuroadapted Den viruses produce typical 
encephalitic lesions in the brain of mice, predominantly in the rhinencephalus 
of infant, weanling and adult mice. Athymic nude mice peripherally inoculated 
with neuroadapted Den viruses develop fatal encephalitis with viral antigen 
present in neurons, skeletal muscle, myocardium and Kupffer cells (Monath, 
1989).
1.7 Tick-borne flaviviruses
a) History
Tick-home encephalitis (TBE) was clinically described in the Far Eastern 
Soviet Union in 1910 when a number of wood cutters and hunters became 
infected (Shope, 1980). Ovine encephalitis (louping-ill) was recognised in the 
19* century when it caused widespread outbreaks of disease in sheep in 
Scotland (Van Rooyen and Rhodes, 1948). The tick-borne flaviviruses, like the 
mosquito-borne flaviviruses, represent some of the earliest recognised causes of 
infectious disease.
TBE viruses from the Soviet Union were designated the Far Eastern sub-
Uîse)
type such as Russian Spring Summer encephalitis''virus. \  Case fatality
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rates from infection with RSSE virus range between 1 and 30% depending upon 
the availability of supportive therapy. In 1937, the causative agent of RSSE 
from a human brain and soon after, tick transmission of the virus was 
successfully achieved (Smorodintsev, 1958). An outbreak of TBE took place in 
Czechoslovakia in 1940 in which a virus similar to RSSE was isolated 
(Stephenson, 1988). The two viruses, however, differed markedly in case fatality 
rates, the Czech isolate (Central European subtype) was less pathogenic with a 
mortality rate of <5% (Silber and Soloviev, 1946; Blaskovic et al., 1967). 
Since then, other outbreaks of TBE have occurred across Europe and the Soviet 
Union. Transmission of TBE virus to man has been documented following the 
ingestion of raw-unpasteurised goats milk in Russia and Europe (Monath, 1989).
TBE viruses have been shown to be antigenically related by serological 
studies (Clarke, 1962). There is, however, considerable confusion surrounding 
the term TBE and this is further complicated by the recognition of 
epidemiologically and pathologically distinct forms of the disease as mentioned 
above (Far Eastern and Central European diseases). The agents associated with 
each both cause encephalitis but as yet, only one virus (RSSE) is registered as 
TBE virus (Calisher, 1988). At least five other antigenically related tick-borne 
flaviviruses (louping-ill, Kyasanur Forest disease, Omsk haemorrhagic fever, 
Negishi and Powassan) cause encephalitis in man. The TBE flaviviruses, 
including viruses closely related to RSSE, are antigenically distantly related to 
the mosquito-bome flaviviruses but the relationship is phylogenetically 
noteworthy. Evolutionary pressures may have created a divergence of 
virus/vector relationships- perhaps from a common source (WNV replicates 
almost as well in ticks as in its preferred Culex mosquito vector) (Calisher,
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1988). Furthermore, SLE and YF viruses have both been isolated from ticks 
in nature. Powassan, a tick-borne isolate from Canada and the USSR, is widely 
divergent from the mosquito-borne flaviviruses but has been isolated from 
Anopheles mosquitoes and from the larvae of Aedes togoi mosquitoes in the 
USSR (Calisher, 1988).
Most of the known tick-borne flaviviruses that cause disease in man are 
neurotropic. However, two viruses (Kyasanur Forest disease and Omsk 
haemorrhagic fever disease) cause viscerotropic and haemorrhagic disease similar 
to YF virus with encephalitis being seen as a terminal phase event.
b) Tick vector and transmission
The geographic distribution of TBE follows the distribution of Ixodes ticks 
which transmit the causative viruses (Shope, 1980). Where the region is 
unfavourable for Ixodes species of tick, other species are found to be efficient 
vectors.
Far Eastern subtype of TBE (RSSE) is principally transmitted by Ixodes 
persulcatus ticks with various wild rodents and forest birds acting as primary 
and amplifying hosts (Cerney, 1976). Transovarial transmission of RSSE virus 
has been documented for at least three consecutive generations in 7. persulcatus 
(Burghdorfer and Varma, 1967).
Geographical movement towards the West results in a change from the 
Far Eastern to the Central European (Central European encephalitis [CEE]) 
subtype of TBE virus. These viruses are principally transmitted by 7. ricinus
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species of tick. 7. ricinus encroaches into Western USSR but is not associated 
with the transmission of RSSE virus. CEE is found in European USSR, 
Hungary, Czechoslovakia, Poland, Bulgaria, Yugoslavia, Austria, Romania, 
Sweden and Finland. Louping-ill virus is also transmitted by 7. ricinus ticks in
N. Ireland, N.W. England and Scotland. Vertebrates act as amplifying and
primary hosts for 7. ricinus ticks and include a number of ground birds and 
rodents although a considerable number of goats have been infected (Monath,
1989). Transovarial transmission of virus in 7. ricinus ticks has been 
documented and occurs in approximately 6 % of experimentally infected ticks. 
However, isolation of infected larvae in nature suggests that this method of 
transmission does occur (Burghdorfer and Varma, 1967).
Other species of tick are important for the transmission of other medically 
important TBE flaviviruses. Omsk haemorrhagic fever (OHF) virus is transmitted 
by Dermacentor pictus. Rodents, particularly water voles (Arvicola terrestris) act 
as the primary viraemic host. Direct rodent to rodent transmission of the virus 
is thought to occur frequently but man is usually infected via the epizootic 
host, the muskrat (Monath, 1989). D. pictus ticks have a much wider 
distribution than does OHF virus hence the hypothesis that an as yet undefined 
vector is responsible for disease transmission (Shope, 1980). Kyasanur Forest 
disease (KFD) virus uses Haemaphysalis species of tick as the primary vector, 
although other ticks may be important reservoirs (Banerjee, 1988). Transovarial 
transmission was demonstrated for KFD virus by Singh et al. (1963). Monkeys 
develop high viraemias and are effective accumulators of Dermacentor larvae 
from the forest floor. Monkeys, therefore, probably serve as the amplifying host
for KFD virus (Boshell, 1969).
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Diseases caused by tick-borne flaviviruses are usually at their highest peak 
from May to June and from September to October which coincides with adult 
ticks most active periods (Monath, 1989). Although ticks act as a natural 
reservoir and overwintering mechanism for virus, horizontal transmission between 
vectors and vertebrates is required for endemicity (Monath, 1989).
c) Human infection
i) Far Eastern subtype (RSSE)
RSSE is characterised as a gradual onset disease following 10-14 days 
incubation after the transmission of virus from the bite of an infected tick. The 
patient suffers a prodromal phase characterised by severe headache, nausea, 
photophobia, weakness, fever and chills. The body temperature may rise as high 
as 41°C and the fever lasts 5-7 days. These symptoms are followed by a stiff 
neck, sensorial changes, visual disturbances and variable neurological dysfunction 
including paresis, paralysis, sensory loss and convulsions (Silber and Soloviev, 
1946). In fatal cases, death occurs within the first week after onset with case 
fatality rates of approximately 30% (Gresikova and Beran, 1981). Disease in 
children is of a greater severity than is seen in adults. Recovery from infection 
is prolonged with neurological sequelae in 30-60% of survivors which is 
manifested by residual flaccid paralysis of the shoulders and arms.
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ii) Central European subtype
In comparison to the above, infection with CEE types of virus is much 
milder with a number of abortive infections. The description of disease that 
follows is similar following infection by louping-ill and Powassan viruses. CEE 
infection has a diphasic course in approximately 50% of cases. The first phase 
is a non-specific illness which lasts upto a week in duration and is followed 
by one to three days of remission. Symptoms of the second phase begin 
abruptly and takes the form of a benign meningitis, or, in severe cases, 
encephalitic symptoms may appear with tremors, dizziness, altered sensoria, 
diplopia and paresis (Radsel-Medvescek et al., 1980a). Case fatality rates of 1- 
5% are usually recorded although 20% of survivors suffer neuropsychiatrie 
sequelae of a minor degree (Radsel-Medvescek et al., 1980b). Interestingly, a 
small percentage of patients which recover from CEE have a progressive 
chronic encephalitis with remissions and relapses (Silber and Soloviev, 1946).
iii) Kyasanur Forest disease and Omsk haemorrhagic fever
Both KFD and OHF possess similar characteristics of infection in man 
but differ largely because OHF survivors may develop neurological sequelae.
Onset of disease is sudden following exposure to the bite of an infected 
tick (KFD virus) or contact with faeces, blood or urine (OHF virus), with the 
patient complaining of headache and malaise, muscle pains, fever, flushing of 
the face and conjunctivitis. Fever lasts approximately 6-11 days and is 
accompanied by haemorrhagic signs including haemorrhagic enanthema of the
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soft palate, haematemesis, epistaxis and metrorrhagia. There often follows an 
afebrile phase which may be anything between 9-21 days in length which 
occurs prior to the return of fever and signs of meningoencephalitis. The 
second phase of illness is seen in 25% of patients, the remaining 75% recover 
with a prolonged convalescence. Of the 25% progressing to second phase of 
disease, approximately 50% develop bronchopneumonia. Myocarditis with 
arrhythmia is frequent, but only 1 -2 % of patients have profuse haemorrhage. 
Gastro-intestinal bleeding carries a poor prognosis (Work, 1958; Webb and Rao, 
1961). Death occurs in about 5% of those that become sick (Banerjee, 1988). 
Convalescence is prolonged, with weakness and headaches and encephalitic 
complications sometimes occurring in children (Monath, 1989). Neurological 
sequelae are frequent in patients recovering from OHF but are rare in KFD 
patients.
d) Pathogenesis o f TBE infections in humans
Pathological responses due to infection with tick-borne flaviviruses largely 
involves the virulent Far Eastern subtypes of virus along with KFD and OHF. 
CEE is a mild disease course but where death occurs, the neurological 
pathology is similar to that of the Far Eastern sub-types.
The pathology of TBE disease in humans has been reviewed by Silber 
and Soloviev (1946) with the findings being comparable to other flavivirus 
encephalitides. Gross changes include swelling, congestion and petechial 
haemorrhages. Far Eastern sub-types have a tropism for neurons of the grey
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matter of the medulla oblongata and upper cervical cord. Localisation leads to 
a syndrome affecting motor and sensory fimctions of the upper neck followed 
by atrophy and flaccid paralysis. Histopathological findings confirm the 
pathological situation with alterations including meningeal perivascular 
inflanimation, neuronal degeneration and necrosis, neuronophagia and glial nodule 
formation involving cerebral and cerebellar cortex, brain stem, basal ganglia and 
spinal cord.
Post-mortem examination in KFD cases reveals haemorrhagic pneumonia 
and necrotic changes in the liver and spleen, reticuloendothelial cell proliferation 
and a marked erythrophagocytosis (Iyer et al., 1960; Liu and Griffin, 1982). 
OHF cases have a similar pattern of pathological signs with basic lesions 
involving dilatation and increased permeability of the capillaries without 
inflammation or destructive processes. However, the pathogenesis of haemorrhage 
is not well understood (Shope, 1980).
e) Pathogenesis o f TBE infections in other vertebrates
i) Monkeys
Monkeys primarily develop degenerative sequelae in the central nervous 
system (CNS) as a result of infection with TBE viruses. Anterior horn cells of 
the spinal cord are involved in conjunction with the cerebellar cortex. These 
sites appear to be selectively more vulnerable to infection by TBE viruses 
rather than other neuronal sites (Nathanson et al., 1966). Further studies
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revealed that the primary target for a number of tick-borne flaviviruses were 
the Purkinje cells of the cerebellum. Zlotnik et al., (1976), observed the 
response of rhesus and vervet monkeys to challenge with TBE virus isolates. 
A proportion of the animals with inapparent infections and a number of 
monkeys which recovered from the acute phase of infection, developed 
degenerative lesions in the cerebellum. The changes affected either a few or 
many folia of the cerebellum and consisted of neuronal and spongy degeneration 
of the Purkinje and granular layers. The degeneration was associated with a 
marked astrocyte proliferation and hypertrophy in the granular and molecular 
layers. The affinity of the virus for the Purkinje cells may explain to a large 
extent the degenerative sequelae that was observed (Zlotnik et al., 1976).
Monkeys that have been inoculated either i.e. or i.n. with certain strains 
of CEE subtype of TBE virus develop a chronic encephalitis in which virus can 
be isolated from monkey tissue by co-cultivation and explant procedures as long 
as 383 days after inoculation (Pogodina et al., 1981). Persistence was 
demonstrated after the resolving of motor defects in the primate. Primates 
inoculated with KFD virus exhibit a classic haemorrhagic involvement, but 
interestingly, also show encephalitic lesions characterised by focal demyelination 
(Silber and Soloviev, 1946).
ii) Mice
Mice inoculated with TBE viruses exhibit signs of infection which are 
pathogenically recognised as neuronal and glial cell damage, which is caused 
directly as a result of viral injury and is characterised by cell shrinkage and
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neuronophagia. Infection is often accompanied by endothelial cell proliferation 
and necrosis, perineural and perivascular oedema with spongy degeneration and 
focal haemorrhages (Vince and Grecevic, 1969). An unusual property of a 
number of TBE virus strains is the ability to establish persistent infections in 
experimental animals, though the possibility of this occurring in humans has not 
been dismissed (Monath, 1989). Mice infected i.p. with KFD virus survive for 
months with paralysis and low titre of virus in the brain but with the absence 
of neutralising antibody (Price, 1966).
iii) Sheep
For comparative purposes, louping-ill (LI) virus infections of sheep reveal 
interesting differences from other TBE viruses. Encephalitis in sheep follows a 
subacute or chronic progressive course. The virus causes neuronal degradation 
and inflammatory changes in the brain-stem and cerebellum of sheep producing 
the characteristic ataxic disease (Doherty and Reid, 1971). In conjunction with 
the damage to the cerebellum there is severe chromatolysis and astrocytosis that 
are characteristic of TBE infections seen in other vertebrates (Monath, 1989).
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1.8 Control of flavivirus diseases
a) Yellow fever
i) French neurotropic vaccine (FNV)
The FNV virus was developed at the Institut Pasteur at Dakar, Senegal 
in 1940. The vaccine was derived by passaging the wild-type French 
viscerotropic virus (FVV- isolated by Mathis et al., 1928) intracerebrally in 
adult mice until loss of viscerotropism for monkeys occurred following 
peripheral challenge and also loss of mosquito competence. The first attenuated 
variant was obtained after 128 mouse brain passages and the first vaccine 
viruses were established and used at passage 237 (see Figure 1.3). Interestingly, 
whilst the FNV virus had lost its viscerotropic characteristic, it possessed an 
enhanced neurotropism for monkeys and mice.
The FNV received widespread use in French speaking areas of Africa and 
was responsible for the virtual disappearance of YF from these areas between 
1939-1980. An estimated 80 million doses of the vaccine were administered 
during the above period. Unfortunately, despite the vaccines’ excellent levels of 
heat stability and ease with which it is administered (scarification), the vaccine 
was responsible for a number of encephalitic cases. One of the best documented 
was by MacNamara (1953), who recorded 83 post-vaccinal encephalitis cases 
which resulted in 32 deaths following the vaccination of approximately 42,000 
people in Nigeria. In addition to this, virus was isolated from the brains of 
four cases. The incidence rate in children following the Nigerian vaccination
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Figure 1.3
Derivation of the French neurotropic vaccine viruses. 
(Modified from Barrett, 1987).
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( French viscerotropic virus fFW ] )
In tra cerebral 
passage in mice
Original FNV virus (p 128)
In tra cerebral 
passage in mice
First FNV administered (p237)
Intracerebral 
passage in mice
Later vaccines (p260)
Name of the patient ‘ Françoise Mayali ’ from which the 
virus was isolated by Mathis et al. 1928.
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campaign was 0.3-0.4%, with a case fatality rate of 40%. The WHO banned 
the administration of the FNV to children below the age of 14 years, and 
because of the fall in popularity, the vaccine was discontinued in 1980.
ii) 17D vaccines
In 1937, Max Theiler and his colleagues succeeded in generating a live 
attenuated YF vaccine which to date represents probably the finest human 
vaccine available (Theiler and Smith, 1937 a/b).
Vaccine development began with the wild-type YF virus Asibi which had 
been isolated in 1927 from a mild case of YF in a young Ghanian (Stokes et 
al., 1928). YF virus strain Asibi was primarily passaged in mice to increase 
virus titre but it was also noted that an increase in monkey virulence had taken 
place following peripheral challenge. After 18 passages in mouse tissue, the 
virus was consecutively passaged in whole chick embryo for a further 50 
passages. The following 108 passages were then performed in chick embryo that 
unlike the initial passages had no head or spine, thus removing the majority 
of the nervous tissue. By passage 176, a strain of virus had been produced 
which had lost mosquito competence and the ability to cause fatal encephalitis 
in rhesus monkeys following intracerebral challenge. The candidate virus, 
designated 17D, was unusual in the above respect because isolates derived at 
the same time by a similar method (17A, B, C, etc) were not sufficiently 
attenuated. Moreover, Theiler was unable to generate the 17D strain in repeat 
experiments (Theiler and Smith, 1937 a/b; Theiler, 1951).
Passage of strain 17D continued in chick embryo and at passage 204
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(p204), a safe and effective vaccine was produced.
The YF 17D vaccines used today are derived from the p204 virus and 
are maintained as two distinct subtypes. The 17D-204 vaccines are currently at 
p233-240 from the Asibi parent, whilst the 17DD YF vaccines (separate 
derivation from pl95) are at p286-288 from the Asibi parent. Figure 1.4 details 
the derivation of the 17D and 17DD vaccines along with the countries licensed 
by the WHO to manufacture YF vaccines.
Preliminary vaccine trials began in YF immune and YF non-immune 
volunteers (Theiler and Smith, 1937a) without apparent side effects. Between 
1937 and 1938, the 17D vaccine received extensive usage in Brazil where 
approximately 59,000 doses of vaccine were administered, again with no 
documented sequelae (Barrett, 1987). A number of laboratories were responsible 
for YF vaccine production which were all maintained independently with vaccine 
‘lots’ being produced when required. In 1943, a number of problems began to 
arise because there was no quality control for vaccine production. Certain high 
level 17DD vaccine preparations (p300-350 from Asibi) were found to be over­
attenuated thus failing to immunise following inoculation. This problem was 
overcome by returning to earlier passage levels for vaccine production (Theiler, 
1951). A further problem concerned a batch of vaccine which caused central 
nervous system disorders in Brazilian children that were inoculated with it. Fox 
et al. (1942) discovered that the degree of encephalitis observed was related to 
the vaccine substrain which was used. The stability of the YF 17D vaccines 
was not ideal in field situations and led unwittingly to the addition of human 
serum into a number of vaccine preparations. Serum hepatitis ensued in a 
number of English, Brazilian and American army personnel (Strode, 1951).
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Figure 1.4
Derivation of the yellow fever 17D vaccine viruses 
and their WHO approved manufacturers.
(Adapted from Barrett, 1987)
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Heat stability of the vaccine was greatly enhanced following an increase in the 
concentration of egg protein present in the lyophilised vaccine. In an attempt 
to control YF vaccine preparation and to overcome the earlier problems, the 
seed lot/batch system was introduced in 1945 (Barrett, 1987).
Despite the administration of millions of doses of YF 17D vaccine, there 
have been few documented problems relating to inoculation. A single case of 
fatal encephalitis has been recorded following inoculation of a young girl 
(Anonymous, 1966). A virus serologically identical to the vaccine virus was 
isolated from the brain at post-mortem examination.
The WHO controls the production of vaccine, and any manufacturer 
wishing to produce 17D vaccine must meet certain criteria. Twelve countries 
are currently licensed to produce vaccines, two have recently ceased production 
(Holland and Colombia), however, two countries have recently begun activities 
(Nigeria and USSR) (WHO, 1981; WHO, 1988). The vaccine is still produced 
in embryonated eggs which may or may not be contaminated with avian 
leukosis virus (ALV), depending on the manufacturer. It is realised that the 
presence of ALV in vaccine preparations lowers its heat stability which is a 
major problem when reliable ‘cold-chains’ for transport of vaccine are not 
available (Lloyd, 1977). Therefore, stable ALV free vaccine strains have been 
produced which have been shown to give good immune responses in recipients 
and a few transient side effects (Moss-Blundell et a/., 1981). Brazil is currently 
the largest manufacturer of YF vaccine (approximately 12 million doses 
annually) but uses ALV contaminated stock. Recent work to improve the 
thermal stability of the 17D vaccine has involved addition of lactose, sorbitol, 
histidine, and alanine into the lyophilised preparation (Barme and Bronnert,
66
1984). In field trials, the vaccine was found to have favourable stability with 
lyophilised material remaining effective for 5 months at 10°C (Georges et al.,
1985).
Monkeys are used to quality control test the vaccines as a safeguard 
against revertant viruses. The WHO (WHO Technical Report, 1981) stipulates 
that the test primate must preferably be a rhesus monkey or a primate of 
similar susceptibility. Monkeys should be inoculated with a dose of not less 
than 5000 mouse LD5 0  and not more than 50,000 mouse LD5 0  in a 250/rl 
volume which is injected into the frontal lobe under anaesthetic. The animal 
should be observed for 30 days for signs of encephalitis (instability, paralysis 
or death) which should not occur in more than 1 0 % of the study group.
Inoculation of 17D vaccines in humans gives high seroconversion rates 
(>96% ) and neutralisation indices (>12.0) (Freestone et al., 1977). Immunity 
is prolonged and may be lifelong after a single vaccination (Poland et al., 
1981) but revaccination is recommended at 10 yearly intervals. Vaccination is 
contraindicated for children < 6  months of age or pregnant women. Persons 
suffering with an immune deficiency (including clinical HIV) or on 
immunosuppressive drugs should also not receive vaccination (Monath 1989).
iii) Vector control
Wherever there are high concentrations of Ae. aegypti mosquitoes, the 
possibility of urban YF exists. Ae. aegypti mosquitoes are often associated with 
human habitats, using potable water supplies as primary breeding sites (Monath,
1989). By the application of low levels of insecticides in the water, vector
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levels can be reduced to such a point that outbreaks of YF may be considered 
low. A novel method of reducing concentrations of Ae. aegypti larvae is to 
place Gambusia minnows into the water. These fish actively eliminate mosquito 
larvae, and under a controlled programme have been shown to be most effective 
(Monath, 1989). If an outbreak of mosquito-bome YF is established in a 
population, application of ground and aerial ultra low volume (ULV) adulticides 
has been proven to be effective. Ground and aerial ULV was used to suppress 
Ae. africams mosquitoes in forest habitats in West Africa for a short time. 
During this period, it was believed that the sylvatic transmission cycle had been 
interrupted (Bang et al., 1980).
b) West Nile
No studies have been performed concerning the prevention or control of 
either endemic or epidemic WN disease (Hayes, 1988). Because man is not the 
primary host for WN virus, epidemics are often not recognised until infection 
rates by the mosquito vector are very high. In the event of epidemics, the use 
of insecticide sprays may rapidly control the spread of the vector. Genetic 
studies in Pakistan were undertaken to develop a strain of Culex tritaeniorhyncus 
mosquito that was refractory to WN virus. It was hoped to introduce the 
• Seiecw. mosquito into the environment and replace the wild vector 
populations over a period of time (Hayes et al., 1984). Unfortunately, 
preliminary results were not encouraging (Hayes, 1988).
There is no vaccine available for the control of WN virus. Development
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of vaccines is a low priority in most countries because the majority of cases 
are very mild and too infrequent. One situation where the use of vaccines 
would be warranted concerns the movement of large populations of WN non- 
immune people into WN endemic areas such as the Nile Delta in Egypt 
(Monath, 1989; Hayes, 1988).
c) Dengue virus
Den viruses continue to cause large outbreaks of disease worldwide and 
will continue to do so until an effective prophylactic measure is available. 
Whilst vaccines to a number of viruses have been prepared, development of 
Den virus vaccines has been slow. One of the primary reasons for this is 
because Den viruses grow to low titres in tissue culture thus precluding an 
inactivated vaccine (Stephenson, 1988). Recently, the WHO have initiated a 
Programme of Development for a Den virus vaccine against all serotypes. Some 
progress has been made with live attenuated vaccines (see below) and with 
genetically engineered vaccines which present portions of the genome to the 
immune system.
The earliest vaccine to Den virus was developed by Sabin and Schlesinger 
in 1946. A Den-1 isolate from Hawaii was passaged repeatedly in mouse brains 
and inoculated into human volunteers. The vaccine underwent trials in Puerto 
Rico in 1943 and was found to elicit moderate titres of neutralising antibody, 
although there were some side effects associated with the vaccine (Sabin and 
Schlesinger, 1945; Sabin, 1955). Following the studies with the Den-1 virus
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vaccine, mouse brain passage was used to attenuate the New Guinea B strain 
of Den-2 virus (Schlesinger and Frankel, 1952). This vaccine, like the Den-1 
preparation, gave reasonable protection to the human vaccinees. Both the Den- 
1 and Den-2 isolates were also passaged in avian fibroblast cultures in the 
1950’s with the result that attenuated variants were obtained which had similar 
properties to the mouse brain derived vaccines following administration into 
human volunteers (Schlesinger et al., 1956). The use of avian fibroblasts to 
derive putative Den virus vaccines was undertaken by Wisseman and his
colleagues (Wisseman et al., 1963) who passaged a Den-1 virus to generate the 
MD-1 vaccine strain. MD-1 had few vaccine associated side effects in 
comparison to the mouse brain prepared vaccines, but it was of low
immunogenicity hence no fiirther studies were conducted with this virus.
Modern attempts to develop vaccines to Den viruses have centred on the 
passage of virus in established cell lines and the presence of in vitro markers 
of attenuation. A Den-2 isolate from Puerto Rico (Den-2 PR-159) which was 
isolated from a patient with classic dengue fever was passaged in primary green
monkey kidney cells to develop the stable SI clone. The clone (Den-2
PR-159/S1), produced small plaques on LLC-MK2 (monkey kidney) cells and 
replicated only at temperatures below 39.5°C, hence the virus was temperature 
sensitive (ts). Den-2 PR-159/S 1 was successfully tested in human volunteers with 
only a single case of mild fever recorded. The vaccine candidate evoked high 
levels of neutralising antibody in the vaccinees and has since gone forward to 
more extensive trials (Eckels et al., 1976; Bancroft et al., 1981; Scott et al., 
1983; Miller et al., 1982). Interestingly, seroconversion rates in YF non-immune 
recipients was low at 61%, whereas YF immune recipients seroconverted at an
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enhanced rate (90%) (Scott et al., 1983). A synergistic response to vaccines has 
been reported by other workers (Schlesinger et al., 1956). One of the most 
promising candidate Den virus vaccines has been developed in Thailand 
(Bhamarapravati et al., 1987). The virus (Den-2 16681) was derived from a 
human case of uncomplicated dengue fever and after preliminary passage in 
tissue culture and mosquitoes, the virus was attenuated by 53 passages in 
primary dog kidney cells (Den-2 16681-PDK53). This vaccine, like Den-2 PR- 
159/Sl, possessed the in vitro markers of attenuation (ts and small plaque 
morphology) and protected human volunteers without apparent side effects. A 
Den-4 strain (Den-4 1036-PDK48) was attenuated by 48 passages in primary 
dog kidney cells and caused no signs of illness when inoculated into rhesus or 
cynomolgus monkeys. The vaccine virus evoked a good antibody response in 
the primates and has been recommended for human vaccine trials 
(Angsubphakorn et al., 1988).
However, the use of in vitro markers of attenuation for deriving candidate 
vaccines is in doubt. A Den-1 candidate vaccine (45AZ5) was prepared by 
passage of virus in foetal rhesus lung cells with the addition of 5-azacytidine 
in the selection protocol to enhance the production of mutants (McKee et al., 
1987). The vaccine strain was selected by cloning virus that produced only 
small plaques and was ts above 39.5°C. Following the inoculation of human 
volunteers, two cases of severe unmodified dengue fever occurred. The 
experience pointed to the uncertain relationship between in vitro virus growth 
characteristics and virulence factors for humans. This point was stressed again 
recently following the failure of a Den-3 virus candidate (clone 24/28) which 
possessed the phenotypic markers of attenuation but was responsible for severe
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vaccine related side effects (Schoepp et al., 1990).
Brandt (1990) has recently reported on the trials of a bivalent live Den 
vaccine which incorporated both Den types 1 and 4, or 2 and 4. All the 
vaccines were produced in primary dog kidney cells. The level of antibody 
response to the vaccines in each mixture was equal to that of individual 
inoculation. Studies conducted with Den-1 serotype vaccines produced not only 
homologous antibody following immunisation but also antibody that was reactive 
with the other Den virus serotypes. Brandt (1990) concluded that sequential 
rather than simultaneous inoculation of Den serotypes over a period of six 
months may prove more beneficial in protection against the four serotypes of 
Den virus.
Whilst attempts to derive a successful live attenuated Den virus vaccine 
continue, a number of different approaches to vaccine design are also being 
explored. Genetically engineered Den-4 baculovirus recombinants have been 
constructed which express both E and NSl proteins in insect cell cultures. The 
expression products induce protective immunity in mice which are able to resist 
challenge with the wild-type virus (Brandt, 1990). Purified native NSl protein 
has also been shown to induce protective immunity in mice (Schlesinger et al., 
1987). This novel approach does not involve native virus antigens and thus may 
not produce enhancing antibodies which are believed to be of great importance 
in eliciting DHF/DSS.
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d) lick-borne encephalitis virus
i) Far Eastern subtype (RSSE)
Prior to the advent of World War II, the only vaccines available to 
combat RSSE were inactivated mouse brain preparations. The vaccine 
represented the first flavivirus vaccine to be used in man and only the third 
vaccine to be developed (Stephenson, 1988). The vaccine, which was a formalin 
inactivated mouse brain suspension was also used to effectively protect sheep 
and horses in endemic regions of the USSR. Smorodintsev and his colleagues 
used a similar preparation of 2.5-5% formalin inactivated mouse brain 
suspension to protect selective human populations (Lebkovich and Smorodintsev, 
1940; Smorodintsev et al., 1940). Studies conducted to determine the efficacy 
of the vaccine revealed that two doses gave 90% protection rates which were 
shown to be excellent in preventing disease, and moreover, there were few side 
effects and no vaccine associated fatalities (Smorodintsev and Il’enko, 1962). 
Any post-vaccinal side effects that did occur were due to bacterial contamination 
of the mouse brain preparation itself. Although the inactivated mouse brain 
vaccine was highly effective, the presence of myelin protein resulted in a 
number of allergic responses in vaccinees. In an attempt to overcome this, the 
vaccine preparations were centrifuged to remove the contaminating proteins. 
Unfortunately, centrifugation also removed significant amounts of viral antigen 
thus rendering the vaccine non-immunogenic (Lebkovich et al., 1966). Attempts 
to produce the vaccine in sheep brain and chick embryo fibroblast cultures also 
resulted in a loss of immunogenic potential, although the inclusion of aluminium
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hydroxide as an adjuvant greatly improved the preparation (Lebkovich et al., 
1966).
From 1955 onwards, a large number of continuous cell lines were used 
to develop vaccines with varying degree of success (Lebkovich et al, 1966). 
Chick embryo fibroblasts were extensively used but often resulted in problems 
associated with lack of protection in volunteers and in some cases, post-vaccinal 
TBE (Shapoval, 1980). During the late 1970’s, two highly purified chick 
embryo fibroblast grown vaccines derived from the Russian Sofyn isolate of 
RSSE virus were developed. The vaccines were purified by a combination of 
either centrifugation, chromatography or percolation through macroporous glass. 
Later vaccines were purified by ultracentrifugation on sucrose gradients by a 
method of continuous flow zonal centrifugation (El’bert et al., 1985). Vaccines 
were inactivated by the addition of formalin and were effective in animals and 
a small number of human volunteers. However, for vaccination of humans it 
was necessary to include approximately SOOfig /il human serum albumin in 
order to preserve the immunogenicity of the preparation. Purification of virus 
by elution through macroporous glass was not without its problems (El’bert et 
al., 1981). Whilst virus was readily concentrated prior to formalin inactivation, 
upon vaccination into human volunteers, the preparation was found to be 
moderately reactogenic and hence vaccine trials ceased (Popov et al., 1985).
The use of transformed cell lines to produce a number of flavivirus 
vaccines has been quite successful (Den virus vaccines). In recent years, a 
number of workers have attempted to adapt strains of RSSE virus to the green 
marmoset heteroploid kidney cell line 4647. Such cell cultures have been used 
for the propagation of the Sofyn strain of RSSE. Experimental vaccines have
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appeared highly immunogenic in man, but there is some doubt over the 
reactogenicity of the vaccine (Grachev et al., 1985).
Interest in the use of other strains of TBE virus for vaccination increased 
following the disclosure that inactivated TBE vaccines were unable to induce 
immune responses of broad specificity (Il’enko et al., 1968). One particular 
virus which received a great deal of attention was a naturally attenuated TBE 
virus from Malaysia (Gordon-Smith. 1956). The isolate (Langat virus strain TP- 
2 1 ) was apathogenic in rodents and no disease had been recorded in man hence 
it was an ideal candidate for live virus vaccine trials. Apathogenic clones 
proved to be immunogenic on inoculation into man and monkeys with the added 
advantage of being cross-protective and eliciting few side effects. An attenuated 
clone of Langat TP-21 was developed (E5) by adaptation of the virus to avian 
cells (Thind and Price, 1966) and was shown to possess a high degree of 
genetic stability whilst maintaining a low level of virulence. The E5 clone was 
a better immunogen than earlier strains of Langat virus and in volunteers 
produced humoral and cell mediated immunity. Interestingly, it appeared that the 
cell mediated immune response was of greater importance in protection against 
virus challenge (Gajdosova and Mayer, 1978). Despite the optimism surrounding 
the use of Langat virus as an immunogen, high levels of reactogenicity in 
humans has precluded further development.
ii) Central European TBE
The earliest vaccines produced against the Central European subtype of 
TBE virus were produced in Czechoslovakia during the 1950’s (Danes and
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Benda, 1960a). A tick-borae isolate (B3) was propagated in primary avian 
fibroblast cell cultures prior to formalin inactivation of the crude cell 
supernatant (Danes and Benda, 1960b). The vaccine was highly immunogenic 
when inoculated into a number of laboratory animals (Benda and Danes, 1961), 
and also human volunteers (Danes and Benda, 1960b). In humans, the vaccine 
induced a high level of neutralising antibody and only mild reactions were 
noted in a few vaccinees. Similar vaccines were prepared against further isolates 
of TBE virus including the highly pathogenic Hypr virus. This vaccine was 
limited to trials in experimental animals alone (Blaskovic et al., 1962).
A collaborative programme between Austrian and U.K. scientists was 
established in the 1970’s with the aim of producing an immunogenic vaccine 
to control TBE in Europe. An Austrian TBE virus isolate (Neudorfl) was 
chosen and cloned in chick embryo cells. Virus was amplified in suspension 
flasks of chick embryo cells and formalin inactivated prior to clarifying of the 
supernatant by centrifiigation and partial purification by hydroxylapatite 
chromatography. The addition of an adjuvant (aluminium hydroxide) was made 
in order to enhance immunogenicity (Kunz et al., 1980). High seroconversion 
rates were found amongst vaccinees (Kunz et al., 1980). Some vaccine 
associated side effects were recorded which included headache and fever which 
were probably due to extraneous proteins present in the vaccine preparation. 
Further vaccine batches underwent a modified purification programme involving 
continuous flow zonal centrifugation in an attempt to remove the contaminating 
proteins (Heinz et al., 1980). Further trials of the vaccine revealed loss of side 
effects without a reduction in the vaccines immunogenicity (Kunz et al., 1980).
In a similar manner to RSSE, attempts to produce a live attenuated
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vaccine to Central European subtypes of TBE have failed. A recent 
Czechoslovakian isolate (Skalica) is a promising candidate for live attenuated 
virus vaccine trials. Skalica has been shown to be naturally attenuated for mice 
and an inactivated vaccine preparation afforded good protection in a number of 
experimental animals (Gresikova and Sekeyova, 1980; Gresikova et al., 1986).
iii) Louping-ill (U) virus
LI, a disease of sheep, was the first flavivirus to be controlled by the 
use of a vaccine (Gordon, 1934). The vaccine was prepared from the brain, 
spinal cord and spleen of LI infected sheep which were then formalised and 
clarified by centrifugation. Field studies showed that the crude vaccine protected 
sheep against challenge with live virus (Gordon et al., 1962), although a single 
dose of vaccine did not fully protect the animal (Williams and Thorburn, 1961). 
The vaccine was later withdrawn from use because of hazards associated with 
its manufacture, therefore, a tissue culture grown virus was used in further 
vaccines. Brotherston and Boyce (1970), succeeded in propagating LI virus in 
secondary sheep kidney cells prior to clarification and formalin inactivation of 
the preparation. Vaccine was given in two doses in conjunction with an 
adjuvant and was shown to fully protect sheep from exposure to LI virus 
(Shaw and Reid, 1981).
iv) Kyasanur Forest disease (KFD) and Omsk haemorrhagic fever (OHF)
Formalised, KFD infected, tissue culture fluid was developed as a vaccine
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to KFD virus by Mansharamani et al., (1967). The vaccine was inoculated into 
monkeys and a small group of human volunteers. Vaccine given to human 
subjects evoked a high degree of neutralising antibody in 72% of those 
inoculated (Banerjee et al., 1969). No unfavourable reactions were detected in 
the volunteers. However, the vaccine is not widely available at the present time 
(Banerjee, 1988).
Little research has been undertaken concerning production of a vaccine 
to OHF virus. A formalinised vaccine prepared in mouse brain had been used 
with some success (Los et al., 1949). The use of vaccine has now been 
discontinued due to adverse reactions to mouse brain components in the 
preparations (WHO Technical Report, 1985).
e) Japanese encephalitis (JE) virus
The earliest vaccines available to counteract the spread of JE infection 
were of the formalin inactivated type. Crude mouse brain preparations of IE 
virus which were inactivated by formalin were inoculated into a number of 
Japanese school children in the late 1940’s with the vaccine affording some 
protection (Tigerrt and Berge, 1957). A similar formalin inactivated mouse brain
preparation underwent trials on U.S. soldiers in Korea between 1948 to 1951
(Pond and Smadel, 1954). Both of the above vaccines were prepared using the 
Nakayama strain of JE virus but were withdrawn from use because of
encephalitic side effects and incomplete protection following vaccination
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(Stephenson, 1988). An improvement in the vaccines against JE virus infection 
appeared following protamine sulphate purification of mouse brain prepared 
Nakayama-NIH strain of JE virus (Matsuda, 1962). There were still a number 
of undesirable side effects recorded after vaccination, but a further purification 
step involving centrifugation on a sucrose cushion improved the vaccine (Takaku 
et al., 1972). A high degree of strain variation exists between JE isolates and 
it was feared that the vaccine preparation containing the single Nakayama-NIH 
strain would afford incomplete protection against different strains of JE virus. 
However, a number of studies revealed that frequent booster doses of vaccine 
increased protection against challenge with different strains of JE virus variants 
to an adequate degree (Okuno et al., 1987). Recently, Hoke et al. (1988) 
showed that a bivalent inactivated vaccine based on strains Beijing-1 and 
Nakayama-NIH was no more efficacious than the monovalent vaccine based on 
strain Nakayama-NIH.
Because of the vaccine associated encephalitic problems of the earlier 
preparations, the Chinese government instituted a programme for the 
development of an inactivated JE virus vaccine produced in baby hamster kidney 
cells (BHK). An inactivated JE BHK vaccine, based on strain P3, was used in 
China for a number of years with children between the ages of 1 to 10 
receiving vaccination (Stephenson, 1988).
Development of live attenuated JE vaccines has been undertaken with 
some success. One of the first live attenuated JE strains was the M-strain 
which was developed from the Mukai isolate of JE virus after repeated passage 
in embryonic mouse skin cultures (Inoue, 1964). In field trials, the vaccine 
elicited good protection in pigs which was reported to be long lasting (Kodama,
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1968). A further live attenuated JE virus was derived from serial passage of 
a wild-type JE strain in primary hamster kidney cells (Hammon et al., 1963). 
The attenuated OCT-541 strain has been tested in humans, and unfortunately 
there was little immune response produced in those vaccinated and it was 
therefore discontinued (Hammon et al., 1966). An attenuated strain which has 
received widespread use in humans was derived from the Chinese SA 14 strain 
of JE virus. SA14 was repeatedly passaged in primary BHK cells with a 
resulting decrease in virus virulence for mice occurring after 2 0  passages and 
a ftirther reduction after 100 passages. Several clones were later derived, of 
which, clones 5-3 and 14-2 and have been used in clinical trials in humans (Yu 
et al., 1988).
f) Wesselsbron (WSL) virus
WSL virus causes a disease in sheep and cattle primarily in South Africa 
and is effectively controlled by vaccination. Originally, the animals were 
protected by vaccination with a formalin inactivated mouse brain preparation of 
WSL virus (Coetzer and Barnard, 1977). The present method of control uses 
a live attenuated virus vaccine. WSL virus was passaged 110 times in primary 
lamb kidney cells and a ftirther 3 times in BHK-21 cells (Weiss et al., 1956). 
The vaccine is used on non-pregnant sheep and cattle prior to the mosquito 
season and affords good protection with revaccination not required.
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g) Israel Turkey Meningoencephalitis (ITME) virus
Following the explosive outbreaks of ITME virus in Israel between 1958 
and 1959, methods of protecting turkey populations from infection were sought 
(Komarov and Kalmar, 1968). The first vaccine was derived from the virus 
responsible for the 1958-59 outbreak which was serially passaged 24 times in 
embryonated hens eggs. The resulting virus was attenuated for turkeys and mice 
but failed to give adequate protection from ITME infection as evidenced by the 
death of a number of vaccinated turkeys during the severe ITME outbreak of 
1970 (Shope, 1980). ITME virus isolated from the latter outbreak was adapted 
to growth in the Japanese quail in which a persistent infection was established. 
Virus was isolated from the brain and spleen of infected birds and was found 
to be attenuated for turkeys. The quail derived virus has been successfully used 
to control ITME virus (Shope, 1980).
1.9 HeLa cells
a) Derivation
HeLa cells were the first human tumour cells to be established as a 
continuous cell line. The cell line was isolated in February, 1951 from a 
cervical carcinoma of a 31 year old Negro woman (Henrietta Lang) who later 
died from the cancer (Gey et al., 1952). Recent re-examination of the original 
slides revealed the tumour to be adenocarcinoma-like (Jones et al., 1971).
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The original cell line was delivered to W.F. Scherer as a blood clot in 
1952, which was washed and maintained in a medium consisting of 40% human 
serum supplemented with 2% chick embryo extract and 58% Hanks’ balanced 
salt solution. In 1954 the cell line was frozen and stored until 1959 (Scherer 
et al., 1954). The American Type Culture Collection resuscitated the cell line 
in November 1961 and maintained an ‘original’ stock of cells at the 76-88 
passage level for worldwide distribution. Since its origin, HeLa cells have been 
one of the most widely studied cell lines.
b) Properties o f HeLa cells
A number of derivatives of the original HeLa cell exist (for example 
HeLa S3, HeLa JJ, HeLa 229) but ultrastructural analysis failed to reveal any 
differences between the clones (Puck et al., 1956). At the ultrastructural level, 
the nucleus of HeLa cells appears no different from any other cell when 
essential components are compared (Journey and Goldstein, 1961). The cell 
surface of the HeLa cell is composed of two types of microvilli, which are 
uniform in diameter (O.l/tm) and extend from the cell surface for approximately 
2/im. The other type of extension is found at the periphery of the cell, the 
details of which are unknown (Cooper and Fisher, 1968). HeLa cells contain 
a well developed Golgi system and a number of annulate lamellae which are 
also present in KB cells (oral carcinoma cells) (Epstein, 1961). The HeLa cell 
is epithelial-like in morphology and on average multiplies 15-fold every 7 days. 
HeLa cells are 100% aneuploid and possess a small telocentric chromosome in
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98% of cells.
1.10 HeLa cell attenuation of virus virulence
a) Venezuelan equine encephalomyelitis (VEE) virus
VEE Virus is a member of the alphavirus genus of the family 
Togaviridae. The virus causes an epizootic disease in horses which is rapidly 
fatal but also infects man when the virus is in epidemic form (Shope, 1980). 
VEE virus possesses one of the widest host ranges of any viral agent and 
readily grows in a variety of cell lines (Shope, 1980).
In 1955, Murphy et al. (1955a/b) undertook a study of the passage 
characteristics of VEE virus in HeLa cells. The wild-type Trinidad donkey 
strain of VEE virus was passaged 21 consecutive times in HeLa cells. 
Replication of the virus took place at each passage as determined by cpe. After 
infection of the HeLa cell monolayers, cpe was usually evident between 36-120 
hours post-infection. HeLa cells were found to be slightly less accurate for 
determining the infectivity titre of a given passage level when compared to the 
standard titration in mice. However, the rapidity at which the result could be 
obtained with the HeLa cells off-set the slight errors that were incurred 
(Murphy et al., 1955a). The virulence of VEE HeLa p21 virus was titrated by 
i.e. inoculation of virus into adult mice. No attenuation was observed for the 
HeLa passaged virus when compared to the wild-type VEE parent. A further 
study by Murphy et al., (1955 b) increased the number of HeLa passages from
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21 to 65 from the parent virus before a similar set of virulence experiments 
were performed. The results obtained were interesting on several accounts, the 
first of which being the presence of an age dependent variation of virus 
virulence. At HeLa p23, an alteration in pathogenicity was evident by the 
reduction in virulence for mice inoculated i.p. with virus. By HeLa p65, the 
virulence of VEE virus had decreased markedly and was considered avirulent 
by the i.p. route. However, i.e. inoculation of VEE HeLa p65 resulted in death 
of the mice. The change in pathogenicity was demonstrated by i.p. inoculation 
of 28 day old mice, therefore, younger mice (1, 7, 14 and 21 days of age) 
were also examined for susceptibility to infection with HeLa passaged VEE 
virus (Murphy et al., 1955 b). VEE HeLa p40 virus was inoculated i.p.into 
the younger mice which resulted in mice of 1-14 days of age succumbing to 
a lethal infection; however, mice of 2 1  days of age were more refractive when 
inoculated by the i.p. route. Further titrations of later HeLa passaged virus in 
14 day old mice indicated that younger animals were becoming less susceptible 
to virus challenge by the i.p. route. Rabbits inoculated either i.e., i.p., sub- 
cutaneously or intra-muscularly with VEE HeLa p20 virus died, whereas, 
inoculation of VEE HeLa p60 revealed the virus to be avirulent by all routes 
(i.e. inoculum of 10'’ mouse ICLD50). The stability of HeLa passaged VEE 
virus was examined by passaging VEE HeLa p42 virus five times in mouse 
brain. When brain derived HeLa virus was subsequently inoculated into mice 
i.p., the virus remained avirulent for the animals; although passage of HeLa 
virus in chick embryos enhanced virus virulence.
Although VEE HeLa modified virus was attenuated after a significant 
number of passages, Murphy et al., (1955 b) considered the use of the HeLa
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passaged virus as an immunogen. Guinea pigs were immunised intradermally 
with a single dose of various passage levels of the HeLa modified VEE virus. 
Subsequent challenge with 1,000 and 10,000 infective doses of virulent VEE 
virus had no apparent effect on the guinea pigs, the animals thus being 
protected from lethal virus challenge.
b) Yellow fever (YF) virus
Hardy (1963), succeeded in cultivating wild-type YF strain Asibi in HeLa 
cells. Preliminary results suggested that HeLa cells were amongst the least 
sensitive of the cell lines tested to low doses of infecting virus. Nonetheless, 
the HeLa cells exhibited the greatest capacity to support the growth of Asibi 
strain of YF virus (Hardy, 1963 a). Hardy (1963a) also obtained four different 
clonal types of HeLa cell (derived from the parent cell line by cloning 
procedure) which differed morphologically. Results relating to susceptibility of 
the HeLa cell clones to infection with wild-type YF strain Asibi, and also the 
degree of replication showed that all types were susceptible, comparable in 
capacity but varied in their susceptibility to infection.
In an accompanying study (Hardy, 1963b), wild-type YF virus strain 
Asibi was passaged in HeLa cells in an attempt to modify its pathogenicity for 
mice and monkeys. This followed the work of Hallauer (1959) and Schindler 
and Hallauer (1963), who demonstrated that 44 passages of 17D vaccine strain 
of YF and the wild-type Asibi in KB cells (human epidermoid carcinoma of the 
mouth) led to reductions in virulence for mice and monkeys respectively.
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Passage of wild-type Asibi in HeLa cells resulted in no detectable cpe until 
passage three, after which, appearence of cpe became regular and predictable 
by passage 6  (p6 ). Since the parent Asibi virus did not cause cpe in HeLa 
cells, whereas Asibi HeLa p6  virus did, the HeLa modified virus was 
considered a variant (Hardy, 1963 b). Assay of virus virulence in mice and 
monkeys revealed two contrasting sets of data. Both parent Asibi virus and the 
HeLa p6  derivative were virulent for mice; however, a lower average survival 
time for mice suggested that the HeLa passaged virus was of enhanced 
virulence. Monkeys inoculated with Asibi HeLa p6  virus did not succumb to 
a lethal infection which was characterised by inoculation of monkeys with the 
wild-type Asibi virus (Hardy, 1963 b). Therefore, in a similar manner to 
Hallauer (1959), passaging of YF strain Asibi in either KB or HeLa cells 
resulted in the loss of viscerotropic disease for monkeys.
The phenomenon of HeLa cell attenuation of wild-type YF Asibi was 
analysed further by Hearn et al. (1965). Wild-type YF virus strain Asibi was 
passaged either once or three times in HeLa cells before biological 
characterisation was made. The results largely supported the findings of Hardy 
(1963 a/b) but expanded them with the discovery that changes in biological 
markers occurred much earlier than HeLa p6 . Following a single passage in 
HeLa cells, wild-type Asibi virus did not exhibit cpe, yet, by the third Hela 
cell passage, cpe was significant. Asibi HeLa pi virus was virulent for 
monkeys challenged by the aerosolised virus at high relative humidity (80%); 
whereas Asibi HeLa p3 virus was attenuated for monkeys when challenged by 
the same route. The virus population at HeLa p3 was considered modified for 
a number of reasons other than attenuation of virulence for primates. The peak
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infectivity titre of virus was obtained much quicker for HeLa passaged virus 
(day 3 post-infection) as opposed to the parent Asibi virus (day 5 post­
infection). Hearn et al., (1965) also reported the isolation of atypical HeLa 
passaged Asibi viruses (i.e. HeLa pi virus that exhibits cpe), thus suggesting 
that further passage selects for mutants in the population. From a genetic 
viewpoint, the authors considered the HeLa pl-p3 virus populations to be highly 
unstable. Hearn et al., (1966) continued the passage of Asibi virus upto HeLa 
p7 and then characterised the infectious dose required to elicit infection in 
monkeys. Whereas wild-type Asibi virus is virulent for monkeys between 1-10 
infectious doses, Asibi HeLa p7 virus requires inoculation of over 700,000 
infectious doses to elicit a similar response. Hearn et al., (1966) summarised 
that a pronounced loss of virulence rapidly occurred when YF virus was 
serially passaged in HeLa cells. They reported that as early as the third HeLa 
passage, virus had become significantly attenuated for monkeys by their inability 
to cause viscerotropic disease by the i.p. route. However, passage of virus in 
HeLa cell cultures did not appreciably reduce the ability of the virus to induce 
immunity in the animals. A small study conducted in the 1970’s again 
established that following six passages in HeLa cells, wild-type YF strain Asibi 
is significantly attenuated for monkeys (Converse et al., 1971). A similar 
conclusion was derived by Converse et al ., 1971 to the previous workers that 
selection of avirulent unstable virions from the mixed population of virions at 
pO was occurring. Selective enhancement of the virions continues until at HeLa 
p6  there is a relatively homogeneous group of viruses of similar biological 
characteristics.
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Aims of the thesis
Previous work has shown that yellow fever (YF) virus strain Asibi 
becomes highly attenuated for monkeys and newborn mice following six 
passages in HeLa cells. The aims of this thesis were primarily two-fold:(1) to 
determine whether or not attenuation by passage in HeLa cells was unique to 
wild-type YF strain Asibi or that other members of the Flaviviridae could be 
similarly attenuated and (2 ) to examine the viruses biologically for changes 
that may relate to attenuation of virus virulence following six passage in HeLa 
cells. The study was extended by incorporating flavivirus strains which differed 
not only in their antigenic relatedness but also in virulence and vector 
preference.
In order to study the effects of six HeLa cell passages on dengue virus 
virulence, an effective animal model with which to assay virus infectivity would 
have to be developed.
Attenuation of virus virulence has often been associated with changes in 
virus tropism. To explore whether changes in virus tropism account for the 
high degree of attenuation observed for YF strain Asibi after six passages in 
HeLa cells, the ability of HeLa and non-HeLa passaged YF viruses to bind to 
liver cell receptor preparations was examined.
The results will be discussed with reference to the use of HeLa cells for 
exploring the basis of attenuation of certain flaviviruses.
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Chapter 2. Materials and Methods
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Materials and Methods
2.1 Cell culture
Cell lines used in this study were obtained from the liquid nitrogen stock 
at the University of Surrey and maintained for growth and virus assay (Table 
2 .1).
HeLa cells (Flow laboratories, UK) derived from human cervical 
carcinoma cells (Gey et al., 1952), Vero cells derived from African green 
monkey (Cercopithicus aethiops) kidney cells (Yasmura and Kawakita, 1963), 
LLC-MK2 cells derived from Rhesus monkey (Macaca rhesus) kidney cells 
(Evans et al., 1973), SW13 human adenocarcinoma cells (Leibowitz et al., 
1973) and the invertebrate cell line C6-36 derived from Aedes albopictus 
mosquito larvae (Igarashi, 1978) were used for various assays.
2.2 Cell maintenance
Cells were grown and maintained in the presence of Eagles minimal 
essential medium (EMEM, Flow laboratories UK) supplemented with L-glutamine 
(2mM, Flow laboratories UK) and non-essential amino acids (ImM Flow 
laboratories UK). In addition, media required sodium bicarbonate (20mM, Flow 
laboratories UK), 100 units/ml penicillin G (Sigma,UK), 0.1 mg/ml streptomycin 
sulphate (Sigma, UK) and 1% (v/v) or 5% (v/v) foetal calf serum (FCS, Flow
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laboratories, UK) for either maintenance or growth medium respectively.Cells 
were incubated at 37°C (except C6-36 cell line incubated at 28°C) in the 
presence of 5% carbon dioxide prior to sub-culturing.
Sub-culturing of cells was accomplished by trypsinisation of the confluent 
monolayer (trypsin, 2.5% w/v in Hanks salts. Flow laboratories, UK), prior to 
seeding of a fresh tissue culture flask (Falcon laboratories, UK) as described 
by Lenette and Schmidt (1969). Cells were normally amplified at a split ratio 
of 1:5. C6-36 cells were incubated at 28°C without carbon dioxide and were 
amplified from stock monolayers by agitation to remove the cells from the 
surface of the flask prior to seeding of a fresh tissue culture flask.
2.3 Cell line storage and preservation
All cell lines were treated in a similar manner with the exception of the 
C6-36 cell line (trypsin not used for detaching of cells from flasks). Cell lines 
which were 80-90% confluent were detached from the flask in accordance with 
the method above and 2-3ml of growth medium supplemented with 10% FCS 
plus 7.5% dimethyl sulphoxide (BDH AnalaR grade) added to the cell 
suspension. The cells were aliquoted into liquid nitrogen ampoules (Nunc) and 
placed at -70°C for 24 hours. Following this period the ampoules were stored 
in liquid nitrogen (-190°C).
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2.4 Resuscitation
When required, one ampoule of the desired cell line was removed from 
liquid nitrogen and defrosted rapidly in a 37°C water bath. The ampoule was 
centrifuged at 2000rpm for 5 mins to pellet the cells. The supernatant, 
containing dimethyl sulphoxide (DMSO), was pipetted off and 1ml of fresh 
growth medium supplemented with 10% FCS added. The cell suspension was 
pipetted into a 25cm  ^ flask and incubated at 37°C in a 5% carbon dioxide 
atmosphere and grown to confluency before passage.
2.5 Viruses
The passage histories of viruses used in this study are included in 
Table 2.2. The five types of flavivirus were plaque purified and propagated in 
different cell lines: YF virus in SW13 cells, WN, TBE and JE viruses in Vero 
cells and Dengue viruses in LLC-MK2 cells.
Cell monolayers were washed once with PBS and virus stocks were 
prepared by inoculation of 80% confluent cell monolayers with a multiplicity 
of infection of 0.1-1.0 pfii/cell. Virus was allowed to absorb to the cell sheet 
by incubation at room temperature for 30mins prior to the addition of cell 
maintenance medium supplemented with 1% FCS. Following production of 
cytopathic effect (CPE) to 80% or 90% cell supernatants were harvested, 
clarified by low speed centrifugation (2000 rpm), aliquoted and stored at -70°C 
in cryotubes (Nunc, UK).
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Plaque purification of viruses was performed by removing an agar plug 
containing virus from a six well dish (Nunc, UK) that had produced isolated 
plaques by a dilution series in PBS (see plaque assays below). The agar plug 
was broken-up by dispelling through a fine bored pipette in 1ml of EMEM 
supplemented with 1% FCS. The plaque purified virus was then amplified on 
the appropriate cell line to obtain working stocks of virus for passage in HeLa 
cells.
2.6 Passage o f virus in HeLa cells
HeLa cells were grown to monolayers in EMEM containing 5% FCS. 
HeLa cells were seeded into 25cm2 flasks (Nunc) for the first four passages, 
then passages 5 and 6  were carried out in 80cm  ^ flasks (Nunc). Prior to 
infection with virus, the monolayers were washed with PBS and infected with 
virus at an moi of between 1 and 5 pfu. After 30 mins absorption EMEM 
containing 1% FCS was added and flasks were incubated for upto 3 days or 
until 80% cpe was evident, whichever came first.
2.7 Infectivity titrations
Infectivity was determined by both plaque assay and tissue culture 
infectious dose 50 (TCID^). Plaque assays were performed on either LLC-MK2,
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Vero or HeLa cell monolayers that had been seeded in six well plastic dishes 
(Nunc). Tenfold dilutions of virus were prepared in PBS, 0.1 ml samples of 
appropriate dilutions were inoculated into wells that had been washed with PBS. 
Following adsorption for 30 mins at room temperature the monolayers were 
then overlayed with 5 ml of 1% Noble agar (Sigma UK) in EMEM 
supplemented with 1% DEAE dextran (Sigma UK) and 1% FCS (Flow 
laboratories UK). Viral plaques were visualised after 3-7 days depending on the 
virus strain by staining with neutral red (Barrett et al., 1989). TCID5 0  assays 
were performed in triplicate using HeLa cells. The cells were seeded into 24 
well plastic dishes (Nunc) and allowed to grow to 80% confluence. Before 
infection the cell growth medium was removed and the cell sheet washed in 
PBS. Tenfold dilutions of the virus were made in PBS and 0.1 ml was added 
to the appropriate well which had been previously washed with PBS. After 
30 min of adsorption at room temperature 1 ml of EMEM supplemented with 
1% FCS was added. The plates were incubated at 37°C and examined daily for 
the appearence of cpe. When cpe was present, or at day 4 post-infection 
(whichever was earlier), the cell sheet was fixed with 0.5 ml of 10% 
formaldehyde solution and then stained with 0.25% crystal violet solution. The 
endpoint for the assay was determined visually as 50% destruction of the cell 
monolayer.
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Antigenic analysis of viruses with monoclonal antibodies
2.8 Hybridoma culture
Mouse ascitic fluid contains approximately a 1000 fold higher 
concentration of monoclonal antibody (Mab) than hybridoma cell culture 
supernatant. To obtain ascitic fluids, the following procedure was followed.
An ampoule of the required hybridoma line was removed from liquid 
nitrogen and thawed rapidly in a water bath at 37°C. The ampoule was then 
centrifuged at 2000 rpm for 5 mins to pellet the hybridoma cells. The 
supernatant containing DMSO was removed by pipette and the hybridoma cells 
resuspended in Leibowitz (L-15) medium (Flow, UK) supplemented with 10% 
FCS and placed in a 25 cm^  flask (Nunc). Amplification of the hybridoma cells 
did not require the use of trypsin for their removal from the tissue culture 
flask as the cells are not anchorage dependent. The hybridoma cells were 
amplified upto a 175 cm^  flask and then centrifuged at 2000 rpm for 5 mins 
to pellet the cells. The cells were then washed once in PBS and centrifuged 
as before. The cell pellet was resuspended in 1ml of PBS to yield 
approximately 10® cells per/ml. This was used to inoculate three six week old 
female Balb/c mice, that had been pretreated with 0.5ml of pristane (2, 6, 10, 
14-tetra methyl pentadecane. Sigma UK), each receiving 0.3ml (approximately 
10^ "* cells) intraperitoneally. Following 2-4 weeks post injection of the 
hybridoma cells, the peritoneal cavity of the mouse was aspirated for ascitic 
fluid using a needle and the fluid collected in a suitable sterile vessel. The 
ascitic fluid was centrifuged at 2000 rpm for 5 mins to remove cell debris and
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stored at -20°C. Subsequent harvests of ascitic fluid were added to the original 
harvest for storage and aliquoting when all ascitic fluid had been collected from 
the mice. The ascitic fluid was then aliquoted in 0.5ml amounts in eppendorf 
tubes (Treff, UK) and stored at -70°C.
2.9 Properties o f the Mabs used in this study
Panels of Mabs raised to specific antigens and of varying reactivities in 
indirect immunofluorescence were used in a number of biological assays. Tables 
2.3 and 2.4 list the Mab specificities and where applicable the source of the 
Mab which originated from outside our laboratory.
2.10 Virus neutralisation using a '100 pfu' screen
Mabs were screened for neutralising activity against appropriate viruses 
using a ’100 pfu’ initial screening. The test was performed in six well dishes 
(Nunc, UK) which had been seeded with LLC-MK2 cell and were just sub­
confluent. The infectivity titre of the viruses had been previously determined 
by plaque assay as described above. The virus under study was diluted to give 
100 pfii per 100/il in PBS and mixed with an equal volume of a 1/20 dilution 
of Mab containing ascitic fluid and left at +4°C overnight. Following 
incubation, 100/il of the virus/Mab solution was pipetted onto the appropriate 
monolayer of a six well dish containing LLC-MK2 cells which had been
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Table 2.3 Properties of C-, H-, and S- series Mabs 
used in this study
Mab Immunogen Specificity PRNT
C9 JE SA14-14-2
Partially 
group reactive
C ll +
C13
C23
C26 -
H3 17DD-Brazil YF type +
H5 YF vaccine
H6 YF 17D vaccine +
H25 Flavivirusgroup +
S17 YF B4.1 YF wild-type -
S18 YF wild-type +
S44 Flavivirusgroup -
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Table 2.4 Properties of Mabs obtained from other sources
Mab Immunogen Specificity PRNT# Source
117 YF Asibi YF wild-type - E.A. Gould
411 YF 17D-204 UK YF vaccine - E.A. Gould
6A3C4 SLE virus Group reactive + J.T. Roehrig
6B3B3 SLE virus Group reactive + J.T. Roehrig
#  Mab possesses plaque reduction neutralising capacity
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washed with PBS. The plate was left at room temperature for 30 mins to 
allow virus adsorption. After incubation the wells were overlayed with 1% 
Noble agar in maintenance medium as above. After incubation at 37°C for the 
requisite number of days plaques were visualised by the addition of 1 % crystal 
violet.
2.11 Plaque reduction neutralisation test (PRNT)
If >80% neutralisation of virus was obtained by a Mab in the 100 pfu 
test above, the virus and Mab were examined in detail in PRNT tests carried 
out on LLC-MK2 monolayers to accurately determine the neutralisation index 
of the Mabs. Tests were performed using a constant antibody concentration 
whilst varying the amount virus. Mab was diluted 1/20 in PBS and 180/d of 
the dilution pipetted into an eppendorf tube, 2 0 /d of virus was added to the 
first tube and vortex mixed. Tenfold dilutions of virus were then made, 
usually upto lO**. Following incubation plastic six well dishes containing LLC- 
MK2 monolayers were washed as previously described and lOO/il of 
virus/antibody solution added to the appropriate well. The plate was then 
incubated at room temperature for 30 mins after which time the monolayer 
was overlayed with maintenance medium in 1 % Noble agar (Sigma, UK) 
supplemented with 1% DEAE dextran (Sigma UK) and 1% FCS (Flow 
laboratories UK). After incubation at 37°C for the requisite number of days, 
plaques were visualised by staining with neutral red. Virus titres were expressed 
as logio reduction in virus titre.
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2.12 Indirect immunofluorescence (IIF) assay
Indirect immunofluorescence (IIF) assays were performed for the 
investigation of reactivities of Mabs with virus antigen in infected cells. 
Monolayers of either Vero or HeLa cells were grown to 80% confluency in 
25cm  ^ flasks (Nunc) inoculated with virus and incubated, with EMEM 
supplemented with 1% FCS, at 3TC  for 2 days in the case of all viruses 
except HeLa passaged viruses where six hours incubation was employed. After 
incubation, the cells were removed from the flask by trypsinisation, washed
with 20ml PBS and centrifuged in a ’V’ bottomed universal (Nunc) at 2000rpm
for 5 mins. The supernatant was discarded and the cells resuspended in 3ml 
of EMEM supplemented with 1% FCS. Following resuspension, 25/il volumes 
were pipetted onto the wells of a teflon coated spot slide (Hendley Essex, UK). 
The spot slides were then incubated in a moist chamber at 37°C for a minimum 
of 4 hours to allow for cell attachment. The cells were fixed to the spot slides 
by rinsing the slide carefully in PBS to remove traces of EMEM and FCS and 
then transfer to an acetone bath for fixation at 4°C for 10 mins. After fixing, 
the slides were stored at -20° C for use.
Detection of viral antigen was accomplished by incubation of a 1/50
dilution of Mab with the spot slide for 30 mins at 37°C. The slide is then 
washed for 30 mins in PBS to remove unbound antibody prior to the addition 
of a 1/50 dilution of fluorescein conjugated goat-anti-mouse IgG (Sigma UK) 
which binds to attached antibody. Following extensive washing in PBS and 
deionised water, fluorescence microscopy was performed using a Leitz Dialux 
2 0  microscope.
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2.13 Temperature sensitivity (ts) assay
Virus infectivity was measured by a plaque assay on LLC-MK2 cells as 
described above at 31, 35, 37, or 39.5°C for the requisite number of days, 
before staining with neutral red and visualisation of plaques. A virus was 
termed temperature sensitivity (ts) if a > 2  log,o reduction in virus titre was 
observed from the optimum growth temperature.
To confirm ts, the efficiency of plating (eop) was calculated, this 
determines the relative ability of viruses to replicate at superoptimal 
temperatures.
eop =  39.5°C (suneroptimafi
37.0°C (optimal)
2.14 Pathogenesis study
a) Adult TO and Balb/C mice
Female outbred (strain TO) and male inbred (strain Balb/c) white mice 
(Olac. UK) of 4-5 weeks of age and weighing between 25-30g were used to 
determine virus pathogenicity. Mice were inoculated with virus diluted in PBS 
by one of three routes: intraperitoneally (i.p.) by inoculation of lOO/il of virus, 
intranasally (i.n.) by placing 2 0 /d of virus dilution on the nostrils of a partially 
anaesthetised (diethyl ether, BDH UK) mouse or intracerebrally (i.e.) by 
inoculation of approximately 2 0 /il into a partially anaesthetised mouse.
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Following inoculation, mice were observed for a period of upto 21 days 
after which the average survival time (AST) and pfu/LDjo were calculated using 
the formulae below:
Average survival time +. standard error of the mean
AST= No of deaths/davs +. ^
En Vn
Determination of the pfu/LDg*
Logio dilution of virus pfu/LD^o = log,o highest diln + 0.5 - X +  Y +  Z
X Y Z
b) Newborn mice
Newborn mice (strain TO) (Olac, UK) were inoculated i.e. with 
approximately 5/il of virus diluted in PBS or i.p. with 50/xl of virus diluted 
in PBS. The mice were observed daily for growth and development. Following 
observation for the 21 day test period the AST and where applicable the 
average weight of the mice were calculated. Results were compared to PBS 
mock-infected control mice.
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Average weight +. standard error of the mean
Ex ±  ^
n Vn
2.15 Administration o f sodium aurothiomalate (SATM)
Studies incorporating SATM were performed on adult TO and adult 
Balb/c mice. SATM has been shown to increase the susceptibility of mice to 
certain virus infections (Allner et al., 1974) when introduced into the peritoneal 
cavity of the mouse prior to inoculation of virus. Briefly, Ig of SATM 
(Aldrich, UK) was reconstituted in 1ml of sterile water and diluted to yield 
lOOmg per ml. Adult mice were inoculated intraperitoneally with lOO/il of 
diluted SATM three hours before inoculation of virus. Virus was then 
inoculated either intra-cerebrally (2 0 /xl) or intra-peritoneally ( 1 0 0 /d) and the mice 
observed for 21 days after which the average survival time and pfti/LDjo were 
calculated where appropriate.
2.16 Haemagglutination (HA)
Flaviviruses possess a haemagglutinin which is located on the envelope 
protein of the virus and is active over a narrow pH range. A number of red 
blood cells have been used but goose (Anser cinereus) red cells are often the
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choice. Flavivirus HA is inactivated when ffeeze-thawing is repeated hence virus 
antigen for HA assays was prepared by growing virus in tissue culture prior 
to storage at +4°C and used within 1-2 weeks.
HA assays were performed according to Clarke and Casals (1958) with 
modifications for use with plastic disposable plates by Sever et al (1964). For 
the purposes of the test ’V’ bottom plates were used as end point determination 
was thought to be more conclusive.
To each row of eight wells was added 50/tl borate buffered saline (50mM 
boric acid, 120mM sodium chloride) pH 9 containing 0.4% bovalbumin. Viral 
antigen (50/d) was added to the first well of each row producing a 1/2 dilution 
of the stock. Doubling dilutions were then made by transfer of 50/d volumes 
using a multi-channel pipette (Flow, UK). Following standardisation (see 2.17) 
of the goose red cells, a 1 / 2 2 0  dilution of the cells was made in the 
appropriate pH buffer and 50/il added to the corresponding row of wells. After 
addition of the red cells the plate was shaken briefly and left at room 
temperature for one hour. The results were read using a light box (Genetic 
Research Instruments, UK) and wells showing agglutination of the red cells 
were marked positive whereas wells in which the red cells had dropped to the 
bottom to form a pellet were taken as negative. The endpoint of the HA 
titration was the last dilution in which HA occurred.
2.17 Standardisation o f goose red blood cells
On arrival in the laboratory the goose red cells were washed three times
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in dextrose gelatin veronal (DGV) buffer (0.058% [w/v] veronal [barbitone], 
0.038% [w/v] sodium barbitone, 0.06% gelatin, 0.14mM calcium chloride, 
0.49mM magnesium chloride, 1.45 M sodium chloride, 55.6mM D-glucose, pH 
7.4) and centrifuged at 2,000 rpm for 5 mins. After the final wash the goose 
cells were stored as an 8 % stock suspension, this represents a concentration 
approximately 24 times higher than the dilution at which they will be used for 
HA and haemagglutination inhibition HI tests. Dilution of the stock suspension 
of cells to yield an optical density (OD) of 0.75 as determined using a Pye 
Unicam Model PU 2280 at 490nm. Generally, a 1:24 dilution of the 8 % stock 
gives 0.75 OD. The volume for final concentration is obtained by the following 
formulae:
Final volume =  initial volume X observed OD
desired OD
2.18 Haemagglutination (HA) test using human O red blood cells
Human red blood cells are not efficiently agglutinated by flaviviruses in 
HA assays. Flaviviruses possess an envelope which is derived from the host 
cell and it is likely that a number of host cell proteins may be incorporated 
into the envelope of the virion. Therefore, changes in biological activity of 
the may result when virus is grown in different cell lines. In these studies, 
flaviviruses were passaged in HeLa cells which were derived from a human
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cervical carcinoma and therefore the envelope of the virus may contain unique 
proteins derived from the HeLa cell. HeLa and non-HeLa passaged viruses were 
assayed for agglutination of human red blood cells using a method as described 
in above. Following obtaining of fresh human O cells, contaminating proteins 
were removed from the blood cells by sequential washes with DGV as 
described earlier. The blood cells were then standardised to yield a stock 
solution which was stored at +4°C for use. Influenza virus was included as a 
positive control for the agglutination of the human red blood cells at a 
concentration of 0.003% (as used for flavivirus assays) and the usual 0.8% as 
used for influenza HA assays.
2.19 Liver membrane preparation
Virus binding assays were performed with liver homogenates and 
membrane preparations. The liver was of monkey origin (Cynomolgous) and was 
obtained from the National Institute for Biological Standards and Control. 
Following removal from the primate, the liver was transported on ice to the 
authors laboratory and the isolation of liver membranes initiated in under two 
hours to prevent the degeneration of membrane receptors.
The method for generating liver cell membranes was based on that of 
Witkin and Herden (1981). The homogenisation medium was 145mM sodium 
chloride, 2mM magnesium chloride, 20mM Tris, pH 7.5. Storage medium was
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250mM sucrose, 5mM magnesium chloride, 50mM Tris, pH 7.5. All steps were 
performed at 4°C as described below.
The liver which weighed 70g, was scissor minced and homogenised in 
10 volumes of homogenisation medium using a S il verson homogeniser (vortex 
mixer/emulsifier). The homogenate was then centrifuged at low speed (2000 rpm 
in an MSB HS21 coolspin centrifuge) for 10 minutes. The pellet was discarded 
and the supernatant centrifuged at 15000 rpm in an SW28Ti rotor (Beckman) 
for 15 minutes (Beckman L5-65 centrifuge). After centrifugation, the supernatant 
was discarded and the pellet resuspended in 25-30 mis of homogenisation 
medium using a Potter homogeniser. The suspension was then centrifuged at 
15000 rpm for 15 minutes as before after which, the supernatant was discarded 
and the procedure of resuspension and centrifugation of the pellet repeated. The 
purified liver membranes were finally resuspended in storage medium prior to 
aliquoting in 1ml amounts into cryotubes (Nunc, UK). The homogenates were 
snap-frozen in liquid nitrogen and stored for use at -70°C.
2.20 Virus binding assays involving liver membranes
Prior to performing the experiment, one aliquot of frozen membrane tissue 
was removed from -70°C and thawed rapidly in a 37°C water bath and stored 
at 4°C for use. The membrane preparation was diluted 1:2 with Tris buffer 
(50mM Tris, pH 7.6) to produce the working membrane solution. The virus 
binding study was performed according to the protocol described below.
A 100/xl aliquot of neat virus solution was added to 900/d of the
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membrane preparation and vortex mixed prior to incubation at 37°C for 30 
minutes. After incubation, the virus/membrane solution was centrifuged at 13000 
rpm for 1 0  minutes to remove the liver membranes and membrane bound 
viruses. Residual infectivity was then assayed for by titrating the supernatant 
on LLC-MK2 cells using the plaque assay technique described in section 2.7.
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Chapter 3.
Passage of wild-type yellow fever virus in HeLa cells
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3.1 Introduction
Attenuation of yellow fever (YF) virus was achieved by Theiler and Smith 
in 1937 following the passage of wild-type YF strain Asibi virus 176 times in 
chick embryo tissue (Theiler and Smith, 1937). The 17D vaccines, as they are 
known, vary in the number of passages from the parent Asibi virus: 17D-204 
substrains between 233-243 and 17DD substrains between 286-289 from Asibi. 
A study of the changes on the genome between wild-type Asibi virus and its 
vaccine derivative 17D-204 (243 passages from the parent), revealed 6 8  
nucleotide and 32 amino acid changes, which represents a divergence in the two 
sequences of 0.63% at the nucleotide level and 0.94% at the amino acid level 
(Rice et a/., 1985; Hahn et al., 1987). A relatively large number of amino 
acid changes were found to occur in the envelope glycoprotein and the authors 
concluded that such differences could be responsible for the reduced 
viscerotropism displayed by the vaccine.
The 17D YF vaccine described above represents a virus which has 
accumulated a number of mutations during its empirical derivation due to 
passage in chick embryo tissue. It is not known, at the present time, which of 
the changes are responsible for the attenuation of YF virus. Therefore, a model 
system for analysis of attenuated variants of YF virus that were obtained after 
very few passages in cell culture would contribute to elucidation of attenuating 
mutations in the virus genome.
In 1963, it was demonstrated that after only six sequential HeLa cell 
passages of wild-type YF virus strain Asibi, the virus had lost its ability to 
cause viscerotropic disease in monkeys (Hardy, 1963). In contrast, the 17D
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vims was first shown to have a lowered viscerotropism after 176 passages in 
whole and minced chick embryo (Theiler and Smith, 1937). The original work 
of Hardy was later confirmed and extended (Hearn et al., 1965, 1966; 
Converse et al., 1971). More recently, Barrett et al. (1990) have passaged 
wild-type Asibi vims six times in HeLa cells and demonstrated that the vims 
is attenuated for both monkeys and newborn mice. Furthermore, they 
demonstrated that the Asibi HeLa p6  vims was antigenically different to the 
parent non-HeLa passaged vims.
In this Chapter, two strains of wild-type YF vims were passaged in HeLa 
cells in an attempt to attenuate the vimses for newborn mice. The HeLa and 
non-HeLa passaged YF vimses were also analysed and compared in a number 
of antigenic and biologic tests.
3.2 Experimental work
a) Viruses
Asibi large plaque clone (Asibi- LP) was obtained CDC Fort Collins, 
Colorado, U.S.A. The vims was a large plaque variant in the mixed Asibi 
wild-type population that was selected by plaque picking and purifying in Vero 
cells. Prior to this study, the vims was amplified in the mosquito cell line 
C6-36. Wild-type YF strain FVV (French viscerotropic vims) was twice 
amplified in C6-36 cells prior to passage in HeLa cells.
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b) Virulence model
Due to the expense and scarcity of monkeys, the mouse model was an 
effective alternative for the examination of YF virus virulence. It has been 
shown that the outcome of disease following i.p. inoculation of YF virus into 
young mice depends upon the age of the mice (Fitzgeorge and Bradish, 1980). 
If mice are less than 5 days old, wild-type YF viruses cause lethal infections 
in mice following peripheral inoculation although the AST’s differ depending on 
the strain of virus. The use of newborn mice in determining the virulence of 
HeLa cell passaged YF strain Asibi virus in comparison to the non-HeLa 
passaged parent virus has already been demonstrated by Barrett et al. (1990). 
Therefore, newborn mice (not more than 48 hours old) were used to assay the 
virulence of both wild-type and HeLa passaged YF Asibi- LP and YF FVV 
viruses. Mice were inoculated i.p. with lOOpfu of virus in 50/il of PBS. Mice 
were monitored for upto 2 1  days post-inoculation and , where possible, the 
average survival time plus or minus the standard error of the mean was 
calculated.
c) Antigenic analysis o f viruses with monoclonal antibodies
The envelope protein of the YF viruses studied in this Chapter were 
analysed with a panel of Mabs raised against different strains of YF virus. The 
specificities of the Mabs are shown in Table 3.1.
114
Table 3.1 Specificities of the YF virus reactive Mabs
Mab hnmunogen Specificity*
117 YF Asibi YF wild-type^
S17 YF B4.1 YF wild-type#
S18 YF B4.1 YF wild-type
411 YF17D-204U.K. YF vaccine ^
(17D-204,17DD,FNV)
H5 YF17DD-Brazil YF vaccine
(17D-204,17DD,FNV)
H6 YF17DD-Brazil YF 17D vaccine
(17D-204,17DD)
H3 YF17DD-Brazil YF type
S44 YF B4.1 Flavivirus group
*Mab specificity determined by indirect immunofluorescence 
#  Mabs were provided by B.K. Sil, except for those 
designated ^  which were obtained from E.A. Gould.
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3.3 Passage o f YF Asibi- LP and YF F W  viruses in HeLa cells
Both wild-type Asibi- LP and FVV viruses were passaged six times in 
HeLa cells at an m.o.i. of between 1 and 5 with virus being harvested on or 
before day 3 post-infection depending on the degree of cpe. Passage of the 
wild-type YF viruses did not cause significant cpe during the first few passages 
(HeLa passages 1-2 for Asibi- LP and 1-3 for FVV) (Table 3.2). However, cpe 
was rapid at HeLa p3 for Asibi- LP virus and HeLa p4 with FVV virus. The 
infectivity titres, determined by plaque assay on LLC-MK2 and TCID5 0  on 
HeLa cell monolayers revealed a gradual reduction in virus titres until HeLa 
p5 where significant amounts of infectivity were present (Table 3.2 and Figure 
3.1). An interesting feature of HeLa passage was the effect on plaque 
morphology. Asibi- LP virus was uniformally large plaque in size and remained 
so throughout the six passages in HeLa cells. However,at HeLa p5, there was 
an alteration in both plaque size and the duration before their appearence on 
plaque assays. Asibi- LP HeLa p5 and p6  viruses produced plaques in excess 
of 0.5cm in 24 hours (previously 0.4cm after 6 - 8  days) on LLC-MK2 
monolayers. A similar scenario was observed for FVV virus. Non-HeLa 
passaged FVV virus produces small plaques (0.1-0.2cm) after approximately 7- 
9 days post-infection on LLC-MK2 cell monolayers; whereas FVV HeLa p5 and 
p6  viruses produce the rapidly appearing large plaque morphology (>  0.5cm) 
after 24 hours on LLC-MK2 cells. The large plaque morphology coincided with 
enhanced infectivity titres of virus (Figure 3.1).
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Table 3.2
Characteristics of YF Asibi LP and F W  viruses following 
passage in HeLa cells
Virus
HeLa passage
0 1 2 3 4 5 6
Asibi LP
CPE + - - + + + +
Plaque size" LP LP LP LP LP LP* LP*
LogjpPfu/ml# 5.2 4.6 4.2 4.2 3.7 1 5 6.8
LogjJCID^Anl# 4.0 4.0 4.0 4.0 4.0 7.0 7.0
FVV
CPE + - - - + + +
Plaque size SP SP SP SP LP LP* LP*
Log^^pfu/ml 6.2 5.2 5.0 4.4 4.6 7.0 7.0
Loê,„TCID^/inl 6.0 5.0 5.0 4.0 5.0 7.0 7.0
LP, Large plaque SP, Small plaque
* LP, Large plaque with diameter > 5 mm
#  Plaque assays performed on LLC-MK2 and TCID ^  
assays performed on HeLa cell monolayers
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Figure 3.1
HeLa cell passage of YF viruses showing the effects on virus infectivity 
titre
* Appearence of CPE in < 3 days on HeLa cell 
monolayers.
  Asibi LP
  F W
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8.0
7.0
CPE*6.0
^  5.0 
^  4.0
3.0
CPE
2.0
1.0
0.0
0 21 3 6
HeLa cell passage
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3.4 Reactivity o f HeLa and non-HeLa passaged Asibi- LP and F W  viruses with 
monoclonal antibodies in indirect immunofluorescence (IIF) tests
A  panel of YF envelope protein reactive monoclonal antibodies (Mabs) 
were tested against HeLa and non-HeLa passaged Asibi- LP and FVV viruses. 
Barrett et al. (1990) have shown that passaging of YF virus strain Asibi in 
HeLa cells changes certain epitopes as detected by IIF tests. The panel of Mabs 
used in this study varied in their specificities and included; YF wild-type, YF 
vaccine, YF type and flavivirus group in reactivity. The epitope recognised by 
Mab 117 (YF wild-type specific) was present on both non-HeLa passaged parent 
viruses by IIF (Tables 3.3 and 3.4). Following six passages in HeLa cells, re­
examination with Mab 117 revealed that the epitope was still present, which 
was in contrast to the finding of Barrett et al. (1990). In comparison, two 
other YF wild-type specific Mabs (SI7 and SI 8 ) had lost their reactivity when 
Asibi- LP HeLa p6  and FVV HeLa p6  viruses were analysed in IIF tests. 
Examination of the intermediate HeLa passages of Asibi- LP and FVV viruses 
showed that reactivity with Mabs S17 and S18 ceased after a single passage in 
HeLa cells. A partial fluorescence (i.e. only some infected cells contained 
antigen recognised by the Mab) was observed for HeLa passaged FVV virus 
with Mab SI 8 , although the degree was much less than that of the parent non- 
HeLa passaged virus. Reactivity of virus with the YF vaccine specific Mabs 
(Mabs 411, H5 and H6 ) produced a number of interesting observations. First, 
that following a single passage in HeLa cells, a vaccine specific epitope 
recognised by Mab 411 is present in both Asibi- LP and FVV virus infected 
cells whereas the non-HeLa passaged virus infected cells do not possess the
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epitope (Tables 3.3 and 3.4). The other vaccine specific Mabs (H5 and H6 ) 
were negative with the HeLa p i virus infected cells but positive at HeLa p6 . 
Therefore, IIF assays were performed with the intermediate passage levels of 
each of the YF viruses in turn. Reactivity of Mabs H5 and H6  occurred 
between HeLa p2 and HeLa p3 for Asibi- LP virus infected cells whereas for
FVV infected cells, Mab H5 was positive in IIF tests at HeLa p2.
Interestingly, Mab H6  which is 17D vaccine specific, remained non-reactive with 
HeLa passaged F W  infected cells.
IIF tests were also performed with YF vaccine viruses for reference and 
comparison purposes, YF 17D-204, 17DD and FNV vaccine virus infected cells 
lacked the YF wild-type epitopes recognised by Mabs 117, S17 and SI 8 . All 
vaccine specific Mabs reacted with the vaccine virus infected cells with the
exception of Mab H6  which did not recognise an epitope on the FNV YF
vaccine virus infected cells.(Table 3.3 and 3.4).
3.5 Reactivity o f HeLa and non-HeLa passaged YF Asibi- LP and F W  viruses 
in plaque reduction neutralisation tests with Mab SI 8
Of . the panel of YF reactive Mab, only Mab SIS possessed neutralising 
capabilities and was used to examine HeLa and non-HeLa passaged viruses in 
PRNT tests. Mab SIS is YF wild-type specific in reactivity as determined by 
IIF tests and accordingly recognises an epitope present on the surface of the 
non-HeLa passaged YF viruses Asibi- LP and FVV. Following six passages in
6bes
HeLa cells, Mab SIS''not detects an epitope on the YF viruses therefore
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suggesting that a change(s) has taken place on the envelope protein. PRNT tests 
performed on LLC-MK2 cells with Mab S18 revealed that the infectivity titres 
of non-HeLa passaged Asibi- LP and FVV viruses were reduced by 1.5 and 
1.2 logio respectively (Table 3.5). Following six passages in HeLa cells, both 
Asibi- LP and FVV viruses escaped neutralisation by Mab S18 (see Table 3.5).
3.6 Haemagglutination o f goose red blood cells by HeLa and non-HeLa 
passaged Asibi- LP and F W  viruses.
The biological activity of HA is performed by most flaviviruses when in 
the presence of a standardised solution of goose red blood cells at the correct 
pH. In HA assays performed with wild-type YF virus strains Asibi- LP or 
FVV, agglutination of goose red blood cells occurs (Tables 3.6 and 3.7). 
Calculation of the log,o pfu/HA ratios derives figures of 1.8 and 2.5 for Asibi- 
LP and FVV viruses respectively and gives an indication to the quantity of 
antigen required to elicit HA. Following six passages in HeLa cells, neither of 
the YF viruses were able to elicit HA of the goose red blood cells. The HA 
assays were performed over a range of pH values from 5.7 to 7.2 but to no 
effect (Tables 3.6 and 3.7). Therefore, at some point during the passage of the 
viruses in HeLa cells, loss of HA ability took place. The intermediate HeLa 
cell passages of the two YF viruses were tested in HA assays over the pH 
ranges and found to be negative. The pfu/HA ratios of ^ 3 .0  and > 3 .6  
respectively for Asibi- LP HeLa pi and FVV HeLa pi viruses indicate that 
sufficient antigen was present in the 50fi\ test volume for HA to occur (Tables
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Table 3.5 Plaque reduction neutralisation tests of HeLa 
and non-HeLa passaged YF Asibi- LP and F W  viruses, 
with Mab S18
Virus
HeLa
passage HF SNI#
Asibi-LP pO + 15
p6 - *
F W pO + 1 . 2
p6 - -
#  SNI, Serum neutralisation index, expressed as log jq 
reduction in virus infectivity titre.
* -  SNI of <0.3
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Table 3.6
HA activity of HeLa and non-HeLa passaged Asibi- LP virus 
for goose and human red blood cells
HeLa Infectivity HA units* HA/pfu
Virus passage titre# goose human ratio
Asibi-LP pO 5.2 128 1.8
pi 4.6 <2 >3.0
p2 4.2 <2 < 2 > 2 6
p3 4.2 <2 >26
p4 3.7 <2 >15
P5 1 5 <2 <2 >5.9
p6 6.8 <2 <2 ^4.4
Influenza A - ND >1024 ^1024 ND
#, Infectivity titre determined by LLC-MK2 plaque assay 
expressed as log pfu/ml
*, per 50ul HA test volume 
ND, not done
126
Table 3.7
HA activity of HeLa and non-HeLa passaged F W  virus 
for goose and human red blood cells
HeLa Infectivity HA units* HA/pfu
Virus passage titre# goose human ratio
F W  pO 6.2 256 2.5
pi 5.2 < a < 2 ^3.6
p2 5.0 <2 >3.4
p3 4.4 <2 >^8
p4 4.6 <2 >3.0
p5 7.0 <2 < 2 >5.4
p6 7.0 <2 >5.8
Influenza A - ND ^1024 ^ 0 2 4 ND
# , Infectivity titre determined by LLC-MK2 plaque assay 
and expressed as log pfu/ml
*, per 50ul HA test volume
ND, not done
127
3.6 and 3.7). For each HeLa passaged virus, there was only one point during 
the passage series at which the pfu/HA ratio was low enough to suggest that 
too little antigen was available (HeLa p4 for Asibi- LP and HeLa p3 for FVV 
viruses) (Tables 3.6 and 3.7). Because flaviviruses possess a host cell derived 
envelope, it was thought possible that the there had been a shift in the 
specificity of the HA portion of the virus envelope for the red blood cell type. 
To test this hypothesis, HA tests were repeated with HeLa and non-HeLa 
passaged Asibi- LP and FVV viruses with a standardised solution of human red 
blood cells. The results in Tables 3.6 and 3.7 show that no HA occurred with 
the human red blood cells over the pH range of S.7-7.2. As a control for the 
experiment, influenza type A virus was included which effectively agglutinated 
both the goose and human red blood cells (Tables 3.6 and 3.7). The lack of 
reactivity of HeLa passaged YF viruses in HA assays meant that the reactivity 
of these viruses could not be examined with the panel of Mabs in 
haemagglutination inhibition (HAI) tests.
3.7 Effect o f passaging HA negative Asibi- LP HeLa p6  and F W  HeLa p6  
viruses in SW13, LLC-MK2 and Vero cells on HA ability
It was not known whether loss of HA following passage in HeLa cells 
was due to a genetic or conformational change to the virus. In an attempt to 
determine this, the HeLa p6  viruses were passaged in different vertebrate cell 
lines (SW13, LLC-MK2 and Vero) prior to retesting the viruses in HA assays. 
Asibi- LP HeLa p6  and FVV HeLa p6  viruses were passaged three times in
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each of the vertebrate cell lines at an m.o.i. of between 0.1 and 1. Passage 
of YF HeLa p6  viruses in Vero cells was accompanied by very rapid cpe 
(approximately 24 hours post-infection) which was similar to passaging the virus 
in HeLa cell monolayers. However, when either of the YF HeLa p6  viruses 
were passaged in SW13 or LLC-MK2 cells, a delay in the appearence of cpe 
was evident (approximately 36-48 hours), which was uncharacteristic of a HeLa 
passaged virus. Virus infectivity titres were determined by plaque assay on 
LLC-MK2 cell monolayers and showed that virus yields were roughly equal for 
each of the cell lines (Tables 3.8 and 3.9). Asibi- LP HeLa p6  and FVV HeLa 
p6  viruses that had received three passages in either SW13 cells or LLC-MK2 
cells were positive in HA tests with goose red blood cells. In comparison, YF 
HeLa p6  viruses that had received three passages in Vero cells remained HA 
negative for goose red blood cells over the pH range 5.7-T.2 (Tables 3.8 and 
3.9). Because three passages in SW13 or LLC-MK2 was undertaken to return 
HA ability to the HeLa p6  viruses, it was possible that selection of minor HA 
positive sub-populations from the HeLa p6  viruses may be taking place. An 
experiment was duly performed in which the YF HeLa p6  viruses were plaqued 
on HeLa cells, plaque picks were taken and amplified in HeLa cells. The 
plaque picked populations were tested in HA assays with goose and human red 
blood cells over the pH range and were confirmed as HA negative. Passaging 
of the HA negative plaque picked viruses in the three different cells lines was 
then done with virus being inoculated at an m.o.i. of between 0.1-1. A similar 
pattern of growth characteristics was observed with the plaque picked viruses; 
rapid generation of cpe for virus grown in Vero cells, whereas a delayed 
appearence of cpe for viruses grown in SW13 or LLC-MK2 cells. HA assays
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Table 3.8
Effects of passaging Asibi- LP HeLa p6 virus through SW13, LLC-MK2 and 
Vero cells on HA activity for goose and human red blood cells
Virus Passage
Infectivity
titre#
HA units* 
goose human
HA/pfu
ratio
Asibi-LP pO 5.2 128 <2 1.8
p6 6.8 <2 <2 M.4
p6 + 3xSW13 85 512 <2 45
p6 + 3x LLC-MK2 7.6 512 <2 3.6
p6 + 3x Vero 8.0 <2 <2 ^6.4
pp p6 + 3xSW13 6.5 128 <2 3.1
pp p6 + 3x LLC-MK2 65 512 <2 25
pp p6 -t- 3x Vero 7.0 <2 <2 ^5.8
Influenza A ND ^1024 .>1024 ND
#, Infectivity titre determined by plaque assay on LLC-MK2 cells and 
expressed as log ^^pfu/ml
*, per 50ul HA test volume
pp, plaque picked virus
ND, not done
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Table 3.9
Effects of passaging F W  HeLa p6 virus through SW13, LLC-MK2 and 
Vero cells on HA activity for goose and human red blood cells
Virus Passage
Infectivity
titre#
HA units* 
goose human
HA/pfu
ratio
F W pO 6.2 256 <2 2.5
p6 7.0 <2 <2 >5.4
p6 + 3xSW13 7.0 128 <2 3.6
p6 + 3xLLC-MK2 7.8 128 <2 4.4
p6 + 3x Vero 8.0 <2 <2 ^6.4
pp p6 + 3x SW13 65 64 <2 3.4
pp p6 + 3x LLC-MK2 7.4 512 <2 3.4
pp p6 + 3x Vero 7.4 <2 <2 >5.8
Influenza A ND >1024 ^1024 ND
#, Infectivity titre determined by plaque assay on LLC-MK2 cells and 
expressed as log^  ^pfu/ml
*, per 50ul HA test volume
pp, plaque picked virus
ND, not done
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revealed that SW13 and LLC-MK2 passaged viruses were HA positive whilst 
Vero passaged virus remained HA negative (Tables 3.8 and 3.9). The pfu/HA 
ratio obtained for HA negative Vero passaged virus exceeded the value for the 
HA positive parent virus hence the lack of agglutination was not due to 
insufficient antigen. Although return of HA ability was evident after three 
passages in SW13 or LLC-MK2 cells, discernable HA activity was noticed at 
HeLa p2 with the plaque picked viruses (data not shown).
3.8 Reactivity o f HA positive SW13/LLC-MK2 passaged and HA negative Vero 
passaged Asihi- LP HeLa p6  and F W  HeLa p6  viruses in IIF tests with Mabs
Passage of YF HeLa p6  viruses in either SW13 or LLC-MK2 cells 
restored the HA ability to the viruses for goose red blood cells whereas 
passage of the YF HeLa p6  viruses in Vero cells did not. Therefore, the HA 
positive and HA negative HeLa passaged YF viruses were examined in IIF tests 
with the panel of Mabs used earlier in this Chapter (Table 3.1). This was 
undertaken to determine whether or not passage of YF HeLa p6  viruses in 
different vertebrate cell lines had changed the Mab reactivity patterns. The 
results obtained for SW13, LLC-MK2 and Vero cell passaged YF HeLa p6  
viruses were identical to the IIF reactivity pattern obtained for the native YF 
HeLa p6  viruses used to inoculate the different cell lines. The results are 
shown in Tables 3.3 and 3.4.
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3.9 Virulence o f HeLa and non-HeLa passaged Asibi- LP and F W  viruses for  
newborn mice
Newborn mice offered a susceptible animal model with which to assay 
the virulence of both HeLa and non-HeLa passaged YF viruses. Mice were 
inoculated i.p. with lOOpfu of virus diluted in PBS. Non-HeLa passaged Asibi- 
LP and FVV viruses were lethal for newborn mice. The average survival times 
(AST’s) of mice infected with Asibi- LP and FVV viruses following i.p. 
inoculation were short at 4.1 and 3.1 days respectively (Table 3.10). Inoculation 
of Asibi- LP HeLa p6  and FVV HeLa p6  viruses i.p. into newborn mice 
revealed that the viruses were very attenuated with only a single fatality (on 
day 11 post-infection) being recorded for a mouse that received Asibi- LP HeLa 
p6  virus (Table 3.10). To examine the attenuation process, all intermediate 
HeLa cell passages of the YF viruses were inoculated into mice as above. The 
results in Table 3.10 show a number of interesting facts. There are apparent 
differences between the two YF viruses relating to the point at which 
attenuation occurs following passage in HeLa cells. YF strain FVV exhibited 
attenuated characteristics following a single passage in HeLa cells with only 8 % 
mortality being recorded in conjunction with an extended AST value in 
comparison to the parent virus (Table 3.10). By HeLa p3, FVV was highly 
attenuated for newborn mice as shown by no fatalities being recorded. In 
comparison, Asibi- LP virus displayed a gradual decrease in lethality for 
newborn mice. Asibi- LP HeLa pi virus was as virulent for newborn mice as 
the parent virus with 100% mortality although the AST showed a slight 
increase (Table 3.10). The mortality rate had decreased to 64% for mice that
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Table 3.10
Virulence of HeLa and non-HeLa passaged Asibi- LP and 
F W  viruses for newborn mice
Virus
HeLa
passage
Virulence#
survivors 
total mortally 
inoculated
AST(±S.E.M.)*
Asibi-LP pO 0/13 100 4.1+0.4
pi 0/10 100 63+0.4
p2 5/14 64 5.9+0.2
p3 11/12 8 80+00
p4 13/14 7 80+0.0
P 5 10/10 <10 NA
p6 9/10 10 11.0+0.0
17D-204USA pO 12/12 100 11.2+0.3
F W pO 0/14 100 3.1+01
pi 11/12 8 7.0+00
p2 9/10 10 50+00
p3 13/13 <8 NA
p4 12/13 7 90+0.0
P 5 10/10 <10 NA
p6 10/10 <10 NA
FNV-IP pO 10/10 100 8.5+02
#, Newborn mice inoculated with 100 pfu of virus diluted 
in PBS.
*, Average survival time + standard error of the mean.
NA, Not applicable
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were inoculated with the HeLa p2 preparation and essentially possessed a 
high degree of lethality for newborn mice. However, following three passages 
in HeLa cells, Asibi- LP was highly attenuated for newborn mice (Table 3.10).
Newborn mice that were challenged i.p. with either 17D-204 USA (derived 
from YF Asibi) or FNV-IP (derived from FVV) YF vaccine viruses died with 
AST’s of 11.2 and 8.5 days respectively. In comparison to the parent viruses 
from which they were derived, the viruses exhibited a marked decrease in 
virulence as determined by AST. Nonetheless, the viruses still caused 100% 
mortality for newborn mice which was in contrast to the highly attenuated 
viruses obtained following six passages in HeLa cells (Table 3.10).
3.10 Virulence o f HA positive and HA negative Asibi- LP HeLa p6  and F W  
HeLa p 6  viruses for newborn mice.
Previous studies in this Chapter showed that HA negative Asibi- LP HeLa 
p6  and FVV HeLa p6  viruses regained their HA ability following passage in 
SW13 or LLC-MK2 cells but not in Vero cells. IIF studies had revealed that 
the HA positive and HA negative HeLa p6  viruses retained the Mab reactivity 
pattern of the native YF HeLa p6  viruses. The question remained as to whether 
HA had any bearing on the virulence of YF viruses for newborn mice or
simply that by passaging the attenuated virus in different cell lines caused a
reversion to virulence. Due to the large numbers of animals involved in a full
study, only the HA positive SW13 p3 passaged and HA negative Vero p3
passaged YF HeLa p6  viruses were assayed in newborn mice. Virus was
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inoculated as before with mice receiving lOOpfu of virus by the i.p. route. The 
results in Table 3.11 show that although some fatalities were recorded, the 
deaths were sporadic and the AST’s of mice were extended in comparison to 
the parent viruses. Both HA positive and HA negative YF HeLa p6  viruses 
were apathogenic for newborn mice.
3.11 The virulence o f a plaque picked F W  HeLa p i  virus for newborn mice.
Wild-type FVV was inoculated onto HeLa cells and incubated for 6  days 
after which an isolated plaque was removed with a Pasteur pipette. Because 
the plaques were small, the plaque pick was amplified once in HeLa cells prior 
to the inoculation of newborn mice. A HeLa cell TCID5 0  assay which received 
extended incubation showed a low infectivity titre of 10^  TCIDjo/ml. However, 
if the virus possessed the virulence characteristics of the parent virus, then 
sufficient virus was present to cause a lethal infection. Mice were inoculated 
with the plaque picked FVV HeLa pi virus and observed daily for the duration 
of the test period. Unfortunately, three of the mice in the litter disappeared and 
were presumed to have been eaten by the mother. However, the remaining 
seven animals survived the 21 day test period (Table 3.12).
3.12 Reactivity o f the plaque picked F W  HeLa p i  virus in IIF tests with a 
panel o f YF reactive Mabs
The previous section detailed that a plaque picked FVV virus that had
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Table 3.11
Lethality of HA positive and HA negative Asibi- LP HeLa p6 
and F W  HeLa p6 viruses for newborn mice
Virus Passage HA
Virulence
survivors % 
total mortality AST(±S.E.M.)
Asibi-LP pO* + 0/13 100 4.1+0.4
p6* - 9/10 10 11.0+0.0
p6 + 3xSW13 + 13/13 <8 NA
p6 + 3x Vero - 14/14 < 7 NA
F W pO* + 0/14 100 3.1+0.1
p6* - 10/10 <10 NA
p6 + 3xSW13 + 9/9 <11 NA
p6 + 3x Vero - #11/14 8 9.0+0.0n=l
+; HA positive reaction _ : HA negative reaction 
NA: not applicable
* Data from previous Tables in this Chapter
#  Two mice eaten by the mother and not attributable to virus inoculation 
Mice were inoculated i.p. with 50ul of virus containing lOOpfu
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undergone a single passage in Hela cells was highly attenuated for newborn 
mice. The plaque picked virus was therefore analysed in IIF tests with the 
panel of YF reactive Mabs that were used earlier in the Chapter. The results 
of the IIF tests are incorporated in Table 3.12. Following a single HeLa cell 
passage, the virus infected cells contain the vaccine epitope recognised by Mab 
411. The YF vaccine specific Mab (H5) and the 17D specific Mab (H6 ), were 
not positive in IIF tests (Table 3.12). However, whereas previously the YF 
wild type specific epitope recognised by Mab S17 was lost after a single HeLa 
cell passage, the attenuated HeLa pi plaque picked virus still maintained the 
epitope (Table 3.12)
3.13 Temperature sensitivity (ts) o f HeLa and non-HeLa passaged Asibi- LP and 
F W  viruses
Temperature sensitivity is a phenotypic marker of some attenuated viruses. 
The high degree of attenuation observed for the two YF viruses following 
passage in HeLa cells may be correlated with the appearence of ts. 
Accordingly, both HeLa and non-HeLa passaged YF viruses were assayed for 
ts by incubating plaque assays at 31, 35, 37 and 39.5°C. The results in Table
3.13 show that both the HeLa and non-HeLa passaged viruses are non-ts with 
virus replicating at all the temperatures examined. Calculation of the efficiency 
of plating (e.o.p.) confirmed the observation (Table 3.13).
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Table 3.13
Temperature sensitivity (ts) of HeLa and non-HeLa passaged 
Asibi-LP and F W
HeLa
passage
Temperature ° C
Virus 31 35 37 39.5 e.o.p.*
Asibi-LP pO 5.2# 5.0 5.2 5.0 0.6
p6 7.0 7.0 7.0 7.0 1.0
F W pO 6.0 6.0 6.2 5.9 05
p6 7.0 7.0 7.0 7.0 1.0
#, Infectivity titres expressed as log^^pfu/ml as determined 
by LLC-MK2 plaque assay
*, Efficiency of plating (39.5/37 °C )
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3.14 Discussion
During the 1950’s, Murphy et al. (1955), demonstrated that passage of 
Venezuelan equine encephalomyelitis (VEE) virus in HeLa cells resulted in the 
virus becoming attenuated for adult mice that were inoculated by the i.p. route. 
Attenuation of VEE virus was only observed following a large number of 
passages (65 HeLa cell passages) which tends suggest an empirical approach 
to reducing virus virulence. Between 1963 and 1966, a number of experiments 
were performed with wild-type YF virus strain Asibi concerning the attenuation 
of virulence of the virus for monkeys after only six passages in HeLa cells. 
It was surprising that so few passages in HeLa cells generated such a variant 
virus which was highly attenuated for monkeys (>700,000 pfu required to elicit 
disease in monkeys) (Hardy, 1963; Hearn et a/., 1966). More recently, wild- 
type YF strain Asibi has been successfully attenuated for monkeys and newborn 
mice following six sequential passages in HeLa cells by Barrett et al. (1990). 
Furthermore, it was shown that attenuation of virus virulence was accompanied 
with antigenic changes to epitopes present on the major surface protein 
(envelope protein) (Barrett et al., 1990). Also, Miller and Adkins, (1988) 
showed that the HeLa p6  Asibi virus had lost its mosquito competence.
The work in this Chapter extends the current knowledge pertaining to the 
attenuation of wild-type YF viruses following six passages in HeLa cells. Two 
strains of YF virus were analysed and compared relating to their passage 
characteristics and biologic characteristics. Two strains were chosen to determine 
whether attenuation of YF virus on passage in HeLa cells was unique to YF 
strain Asibi. Because of the scarcity of primates along with the expense and
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general inconvenience in handling, the newborn mouse was used as a model 
for demonstrating attenuation of virulence.
The two wild-type YF viruses probably originated from the same outbreak 
that occurred in the Gold Coast region of Africa in 1927. The two viruses, YF 
strain Asibi and YF strain FVV, represented the first YF viruses to be isolated 
(Stokes et al., 1928; Mathis et al., 1928). A large plaque clone of Asibi virus 
(Asibi- LP) was used in this study, a virus which has been shown to virulent 
for monkeys that were inoculated subcutaneously (Barrett et al., 1990). Asibi- 
LP and FVV viruses were passaged six times in HeLa cells with some 
interesting observations. Passaging of virus was performed at a high m.o.i. 
(approximately 5), because previous work (Hardy, 1963) had shown HeLa cells 
to be relatively refractive to infection by wild-type YF virus. CPE on HeLa 
cells was not apparent on HeLa cells until HeLa p3 and p4 for Asibi- LP and 
FVV viruses respectively. This observation was in standing with previous 
studies in this field (Hardy, 1963; Hearn et al., 1966; Barrett et al., 1990). 
Following the appearence of cpe in under three days post-infection, virus titres 
increased rapidly and it was noticeable that virus present at HeLa p5 and p6  
was highly modified. The plaque morphology of both YF viruses over the latter 
passages was very large (>5mm in diameter) and appeared in 24 hours in 
contrast to the smaller plaque morphology (2-4mm) after 5-9 days incubation 
associated with the wild-type progenitors. The data supports the theory of Hearn 
et al. (1966) who proposed that YF viruses at the lower HeLa passages (HeLa 
pl-p3) were highly unstable and of mixed biological activity. This would appear 
to be the case; a primary selection process upon a single passage in HeLa 
cells. By HeLa p5 and p6 , the virus present is highly stable, growing to high
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titre. It is suggested that mere selection is not the process by which attenuated 
YF variants arise following passage in HeLa cells, but that a combination of 
primary selection and selective pressure exerted by the HeLa cells manifested 
as genetic changes are rapidly acquired upon passage. A simple process of virus 
selection has also been dismissed as a prominent reason for obtaining variants 
because the viruses were plaque purified and thus, as far as RNA populations 
of virus can be, were thought to represent a homogeneous collection of virions. 
Furthermore, the plaque purification of non-HeLa passaged FVV virus on HeLa 
cells, subsequent amplification and examination of virulence properties supports 
the proposal of a genetic change in YF virus following passage in HeLa cells.
The essential part of the study was whether or not following passage in 
HeLa cells, Asibi- LP and FVV viruses were attenuated for newborn mice that 
were inoculated i.p. with 100 pfu of virus. Both Asibi- LP Hela p6  and FVV 
HeLa p6  viruses were highly attenuated for newborn mice following passage in 
HeLa cells with all mice surviving challenge with virus. This was in 
comparison to the mice that were inoculated with non-HeLa passaged YF 
viruses which uniformally succumbed to a lethal infection. Complete avirulence 
for newborn mice after generating variants of YF virus is not unusual. It was 
shown that generation of Mab resistant escape variants of YF vaccine viruses, 
(YF vaccine viruses cause a lethal infection in newborn mice), were 
apathogenic when inoculated peripherally into newborn mice (T.N. Ledger, 
personal communication). Because of the availability of newborn mouse litters 
and their effectiveness at demonstrating attenuation of virulence, it was possible 
to assay each of the intermediate HeLa cell passages for their individual 
virulence characteristics. The results revealed that significant attenuation of
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Asibi- LP virus was apparent following three passages in HeLa cells and not 
before. The virulence of FVV virus was highly attenuated after a single passage 
in HeLa cells. The observation of attenuation at HeLa p3 for Asibi- LP virus 
coincided with the appearence of cpe and relative stability of the HeLa passaged 
virus. Unfortunately, the same observation cannot be applied to FVV virus. 
Hearn et al. (1966) were able to obtain a number of attenuated ’atypical’ 
clones of YF Asibi virus after a single passage in HeLa cells. Although the 
whole population present at HeLa pi was virulent for monkeys, the clones that 
were obtained were not. This suggests that selection may have taken place from 
the starting population and upon subsequent passages in HeLa cells the virus 
was selectively amplified and genetic modification stabilised the phenotype of 
the HeLa p5 and p6  populations. To examine this point further, a plaque 
picked FVV virus was taken following a single passage of virus in HeLa cells. 
Because the plaque was small in size, it was necessary to amplify the virus 
once in HeLa cells prior to inoculation into newborn mice. The FVV HeLa pi 
plaque picked virus was avirulent for newborn mice which implied that selection 
may have taken place at the first passage in HeLa cells. Nonetheless, data 
obtained in subsequent tests revealed that modifications at the genome level may 
have taken place (see below). Unfortunately, time only allowed a single plaque 
picked virus to be analysed hence, no firm conclusions can be drawn from such 
an observation. Moreover, the experiment will need to be repeated with Asibi- 
LP virus which took more than a single passage in HeLa cells before 
attenuation was observed.
Attenuation of viruses has been linked in certain situations to the 
generation of defective interfering (DI) particles, this being particularly so if
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virus was passaged at a high m.o.i. (Barrett and Dimmock, 1986). A number 
of facts tend to offset the argument that DI viruses are responsible for the 
attenuation of virulence for newborn mice of Asibi- LP and FVV HeLa p6  
viruses. First, attenuation was observed following a single HeLa cell passage 
of FVV virus and following three passages for Asibi- LP virus, hence 
populations of DI virus accrued to this point would probably be too low to 
interfere with infection. Second, it is well documented that generation of DI 
particles in HeLa cells is particularly difficult (Stark and Kennedy, 1978). 
Third, Barrett et al. (1990), performed yield reduction assays to detect the 
presence of DI particles in their attenuated HeLa p6  virus preparations, the
result of which revealed no DI virus.
The important area of research which had remained unexplored was to 
determine whether the HeLa cell attenuated YF viruses could be differentiated 
from the wild-type parent virus in antigenic tests. In order to do this, the 
parent and all HeLa passages of Asibi- LP and FVV were reacted in IIF tests 
with a panel of YF envelope protein reactive Mabs with varying specificities. 
The data showed that attenuation of Asibi-LP and FVV viruses were 
accompanied with changes to envelope protein epitopes as evidenced by the loss 
or gain in Mab reactivity. In comparison to the work of Barrett et al. (1990), 
the YF wild-type specific epitope recognised by Mab 117 was still present after 
six passages in HeLa cells. The reasons for the difference are numerous but
may be related to the fact that different clones of HeLa cell were used to
produce each of the variants. This study used HeLa cells while Barrett et al. 
(1990) used the S2 clone of HeLa cells. Loss of wild-type epitopes recognised 
by Mabs S17 and S18 did occur after a single passage in HeLa cells for both
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the YF viruses. The gaining of vaccine specific epitopes following the HeLa 
passage was also noted for Asibi- LP and FVV viruses. By assaying the 
intermediate HeLa cell passages of each YF virus with the panel of Mabs, it 
was determined at which passage changes in Mab reactivity occurred and this 
was related to changes in virus virulence for newborn mice. Despite the 
presence of a vaccine specific epitope on Asibi- LP HeLa pi virus (recognised 
by Mab 411), the virus was highly pathogenic for newborn mice which 
suggested that other changes, whether present on the envelope protein or 
elsewhere on the virus genome, were responsible for the attenuation. Two other 
Mabs, a YF vaccine specific Mab (H5) and a 17D vaccine specific Mab (H6 ), 
were found to react with Asibi- LP virus after three passages in HeLa cells. 
Importantly, a significant degree of attenuation for newborn mice was recorded 
for Asibi- LP virus after three passages in HeLa cells for. It is possible that 
appearance of the vaccine epitope(s) recognised by Mabs H5 and H6  are 
responsible for attenuation of virulence of Asibi- LP virus for newborn mice. 
It is not known whether Mabs H5 and H6  recognise related or different 
epitopes however, information obtained with FVV virus following passage in 
HeLa cells implies that the two epitopes are separate. Whilst two passages of 
FVV virus in HeLa cells results in the acquisition of the vaccine epitope 
recognised by Mab H5, there was no evidence of reaction over the six passages 
in HeLa cells for FVV with Mab H6 . This is not surprising because Mab H6  
recognises a 17D vaccine specific epitope which is only found on the attenuated 
derivatives of YF strain Asibi. The importance of such epitopes in the 
attenuation process can only be determined by obtaining Mab escape variants. 
Unfortunately, of the Mabs examined, only wild-type specific Mab S18
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possesses neutralising capabilities; accordingly the study is limited. Nevertheless, 
the FVV HeLa pi plaque picked virus may give some insight into the 
importance of certain epitopes in attenuation of FVV virus and perhaps more 
generally YF viruses. Analysis of the Mab reactivity pattern of the attenuated 
FVV HeLa pi plaque picked virus revealed that unlike the HeLa p6  attenuated 
variant, it possessed the YF wild-type specific epitopes recognised by Mabs 
117, S17 and S18 in IIF tests. However, the plaque picked virus was also 
positive in IIF tests for the vaccine specific epitope recognised Mab 411. 
Therefore, the epitope recognised by Mab 411 may have a functional role in 
the attenuation of virulence. It has been shown that a number of attenuated 
variants present in YF vaccine preparations possess wild-type epitopes, hence 
their role in attenuation remains unclear.
Further evidence that changes to virus envelope protein epitopes had 
occurred following passage in HeLa cells came from the neutralisation studies 
with Mab S18. Both wild-type YF viruses were neutralised by Mab SI 8 , 
whereas their HeLa p6  derivatives escaped neutralisation with this Mab. As yet, 
the intermediate HeLa passages of the YF viruses have not been analysed in 
neutralisation assays to determine at which point virus escapes neutralisation 
from Mab SI 8 . The importance of such a change to YF virus virulence 
remains uncertain at the present time. Therefore, it will be necessary to obtain 
Mab S18 escape variants from the wild-type YF population and to determine 
their virulence for newborn mice before any firm conclusions can be drawn.
The appearence of a ts phenotype of a has, for a number of years, been 
used as biological marker of attenuated dengue viruses for use as putative 
vaccines (Eckels et al., 1976). Passage of the two wild-type YF viruses six
147
times in HeLa cells was accompanied by a high degree of attenuation for 
newborn mice hence, it was possible that attenuation of virulence may be 
accompanied by restricted growth at elevated temperatures. In experiments 
conducted to detect the presence ts for YF Asibi and FVV HeLa p6  viruses, 
no evidence was found to suggest that the viruses had restricted growth at any 
of the temperatures examined.
Other biological differences were found to occur following passage of YF 
viruses in HeLa cells. Haemagglutination (HA) is a biological activity of a 
number of viruses the importance of which to virus virulence varies. Passaging 
of both Asibi- LP and FVV viruses in HeLa cells removes the ability of the 
viruses to agglutinate goose red blood cells. Moreover, it was discovered that 
a single passage of either YF virus in HeLa cells rendered the virus HA 
negative. Thus, it was considered possible that HA activity may be important 
to attenuation of virulence of YF virus. Loss of HA ability was not permanent 
as shown by the ease at which HA ability for goose red blood cells was 
restored following passage of YF HeLa p6  viruses in either SW13 or LLC- 
MK2 cells. Passaging of YF HeLa p6  viruses in Vero cells did not restore HA 
ability to the viruses. Because changes in HA ability occurred so readily 
depending on the cell line in which the virus was propagated, a conformational 
change of the virus envelope protein rather than a genetic change would seem 
to be responsible. This was not the case for Echovirus type 11 which also lost 
HA ability following passage in HeLa cells (Cova and Aymard, 1980). Passage 
of HA negative Echovirus 11 in a number of different cell lines did not restore 
HA activity to the virus. The group concluded that loss of HA was probably 
due to genetic modification of the virus genome which was expressed as the
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loss of HA. The return of HA ability to HeLa passaged YF viruses upon 
passage in SW13 or LLC-MK2 cells did not alter the Mab reactivity profile 
of the virus which remained identical to the attenuated HeLa p6  YF viruses.
Assay of the pathogenicity of the HA positive and negative HeLa viruses 
showed the viruses to be attenuated. Whether or not HA plays a function in 
the virulence of YF is not certain, but on the data presented here, further work 
needs to be done in order to disregard it as an attenuating factor. Also, the 
epitope changes seen for virus grown in HeLa cells are not unique to virus 
grown in HeLa cells but may be involved in the attenuated phenotype of the 
viruses. Finally, it can not be concluded whether the epitope changes have a 
role in the attenuation of wild-type YF virus or are coincidental. However, it 
is clear from the lethality studies in newborn mice that other mutations in 
addition to those identified in the envelope protein gene contribute to 
attenuation. Ultimately, the contribution of envelope protein epitopes (i.e. amino 
acids) will only be elucidated by the manipulation of YF virus infectious clones 
(Rice et ah, 1989).
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Chapter 4. Passage of YF vaccine viruses in HeLa cells
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4.1 Introduction
Following the successful attenuation of two wild-type strains of YF virus 
for newborn mice, it was decided to observe the effects of six passages in 
HeLa cells on YF vaccine viruses. Since both of the wild-type strains were 
viscerotropic in character for man and monkeys, whereas the YF vaccine viruses 
possess a neurotropic potential, there was the possibility that the tropism of the 
virus had a bearing on the attenuation of YF virus following passage in HeLa 
cells.
The newborn mouse model was used to determine virus virulence with 
mice being inoculated i.p. with either the YF 17D-204 vaccine manufactured 
in the United Kingdom UK or FNV-IP YF vaccine. It has been shown that 
17D vaccine viruses will only kill mice upto 5 days old when inoculated i.p., 
whereas FNV vaccine viruses will kill mice upto 21 days old by the same 
route (Fitzgeorge and Bradish, 1980). These results suggest basic differences in 
the neuroinvasive capacities of the two YF vaccine viruses and probably reflects 
their mode of derivation (17D- passage in chick embryo, FNV- passage in 
mouse brain).
4.2 Experimental work
a) Viruses
The 17D-204 UK virus was used as a representative virus from the 17D
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vaccine lineage whilst the representative virus for the FNV vaccine lineage was 
FNV-IP. Both viruses were amplified in SW13 cells at an m.o.i. of O.l-l.O to 
produce a primary virus stock for passage in HeLa cells and assay of virus 
virulence in newborn mice.
b) Virulence model
Newborn mice of not more than 48 hours old were used to determine the 
lethality of the YF vaccine viruses and their HeLa passaged derivatives. Mice
{a >09**!
were inoculated i.p. with lOOpfu of virus diluted in PBS and observed for 21 
days after which the average survival time and the mortality rates were 
calculated where appropriate.
4.3 The characteristics ofYF  vaccine viruses 17D-204 UK and FNV-IP following 
passage in HeLa cells
Each of the YF vaccine viruses were passaged six times in HeLa cells 
at an m.o.i. of approximately five. CPE was evident following the first HeLa 
cell passage after approximately three days incubation (Table 4.1). The rapidity 
at which CPE occurred increased as the passage through HeLa cells advanced. 
By HeLa p6 , both 17D-204 UK and FNV-IP viruses exhibited traits which 
identified them as a HeLa cell modified virus preparation; large plaque 
morphology on LLC-MK2 cells and rapid CPE (24 hours post-infection). Virus 
infectivity titres were determined by LLC-MK2 plaque assays alone and revealed
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Table 4.1
Passage characteristics of YF vaccine viruses 17D-204 U.K. and 
FNV-IP following passage in HeLa cells
HeLa passage
Virus 0 1 2 3 4 5 6
Y F 17D-204 U.K.
CPE + + + + + + +
Plaque size LP* LP LP LP LP LP LP
Logj  ^pfu/ml# 7.2 6.4 6.6 7.2 83 80 80
YF FNV-IP
CPE + + + + + + +
Plaque size LP LP LP LP LP LP LP
Log^  ^pfu/ml 5.7 5.0 5.0 5.9 7.0 7.4 7.0
* LP: large plaque morphology on LLC-MK2 cell monolayers. 
#: Plaque assays performed on LLC-MK2 cell monolayers.
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Table 4.2
Virulence of HeLa and non-HeLa passaged YF vaccine viruses 
for newborn mice.
Virus
HeLa
passage
Virulence
survivors % 
total #  mortality AST(±S.E.M.)*
YF 1 7 D - 2 0 4 U .K . pO 0 /1 2 10 0 1 2 5 ± 0 . 3
p6 1 0 /1 0 < 1 0 NA
YF FNV-IP pO 0 /1 0 10 0 85+05
p6 0 /1 0 1 0 0 7 .5 + 0 .3
* Average survival time + standard error of the mean.
#  Survivors/total number inoculated.
NA: not applicable.
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high levels of infectivity (Table 4.1).
4.4 Virulence o f HeLa and non-HeLa passaged YF vaccine viruses 17D-204 UK 
and FNV-IP fo r newborn mice
As a the study centred on the attributes of HeLa cell passaged YF 
vaccine viruses, only the parent strains and the HeLa p6  derivatives were 
assayed in newborn mice. Animals that received non-HeLa passaged vaccine 
virus died with AST’s of 12.5 and 8.5 days for 17D-204 UK and FNV-IP 
respectively (Table 4.2). Inoculation of 17D-204 UK HeLa p6  virus into 
newborn mice resulted in no deaths being recorded. Newborn mice inoculated 
with FNV-IP HeLa p6  however, died following challenge with an AST of 7.5 
days which was comparable to that of the parent vaccine virus (Table 4.2).
4.5 Discussion
YF vaccine viruses differ in cell tropism to the parent wild-type viruses 
with neurotropism being characteristic of the former and viscerotropism 
characteristic of the latter virus. Wild-type YF virus strain Asibi- LP and FVV 
were highly attenuated following six passages in HeLa cells. YF vaccine viruses 
were passaged six times in HeLa cells to determine whether or not virus 
tropism played a role in the HeLa attenuation process. The experiment was 
enhanced by including two different types of YF vaccine virus, the 17D and
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FNV strains which were derived from wild-type Asibi and FVV viruses 
respectively. One interesting fact was that previous work had demonstrated that 
FNV viruses were highly neuroinvasive in mice in comparison to the 17D 
viruses with lower AST’s being recorded in newborn mice (Fitzgeorge and 
Bradish, 1980).
After passage in HeLa cells the vaccine viruses possessed similar 
characteristics to HeLa passaged wild-type virus populations. Following 
inoculation into newborn mice, the two vaccine strains differed markedly. The 
17D-204 UK HeLa p6  virus was avirulent for newborn mice with all animals 
surviving the test period. In comparison, non-HeLa passaged 17D-204 UK 
vaccine preparation was lethal for newborn mice with an AST of 12.5 days 
(Table 4.2). Both FNV-IP HeLa p6  virus and the FNV-IP vaccine virus were 
virulent for newborn mice that were challenged i.p. with virus. The AST’s of 
7.5+0.3 and 8.5+0.5 days respectively were not statistically different.
The differences observed between the vaccine viruses with respect to 
virulence probably reflects the method by which the vaccine viruses were 
derived. The 17D vaccine viruses were derived by the passage of Asibi virus 
in chick embryo tissue with the final passages being conducted in chick 
embryos without nervous tissue (Theiler and Smith, 1937). Therefore, the 
adaptation of virus to nervous tissue was likely to have been reduced by the 
latter step. In contrast, the FNV vaccine strains were derived by passaging 
FVV virus in mouse brains. Adaptation o f YF virus has been shown to take 
place rapidly when introduced into mice (Theiler, 1951). It is highly likely that 
the FNV vaccine is particularly adapted to the nervous tissue of mice and 
hence slight alterations in the attenuation of virulence of FNV after HeLa cell
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passage would be difficult to discern. The possibility exists that the highly fixed 
neurotropism exhibited by FNV vaccine viruses cannot be altered significantly 
following six passages in HeLa cells; whereas neurotropism of a less aggressive 
nature, as exhibited by the 17D vaccine viruses, is more susceptible to change 
following passage in HeLa cells. Greater numbers of passages in HeLa cells 
may be required before the FNV vaccine loses its virulence for newborn mice. 
This point is supported by the fact that 65 passages in HeLa cell were required 
before attenuation of the highly neurotropic VEE virus occurred for mice 
(Murphy et al., 1955a/b). These results suggest that it may prove difficult to 
attenuate neurotropic flaviviruses by six passages in HeLa cells. This possibility 
will be examined later in the thesis.
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Chapter 5. Passage of West Nile virus in HeLa cells
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5.1 Introduction
Attenuation of two strains of wild-type yellow fever (YF) virus has been 
demonstrated (Chapter 3). Attenuation of wild-type YF virus by HeLa cell 
passage was accompanied by changes on the major surface protein (envelope 
protein) as determined by Mab reactivity in neutralisation and indirect 
immunofluorescence assays. Furthermore, it appears that attenuation of virulence 
of YF for newborn mice coincides with the appearance of epitopes associated 
with vaccine strains of YF virus. Since YF virus had received only six HeLa 
cell passages it is likely that there are few mutations responsible for the 
attenuated phenotype and these should be determined by comparative nucleotide 
sequencing.
The flaviviruses as a family share a number of homologies both as 
antigens and at the nucleotide level. A number of flaviviruses, other than YF 
virus, represent major human pathogens, for which there are no candidate 
vaccines for their control at the present time. Thus, it was decided to 
investigate whether or not attenuation following six HeLa cell passages was 
unique to YF virus or common to other members of the Flaviviridae.
Previous studies involving YF virus used primates to demonstrate 
attenuation of virulence. In attempting to assay the effects of HeLa cell passage 
on other members of the Flaviviridae an alternative animal model was required 
for determining the virulence of a particular virus. Therefore, prior to beginning 
the study, two individual parameters had to be satisfied; choice of virus and 
animal model. In the following study. West Nile (WN) virus was passaged in 
HeLa cells and its resulting virulence assayed in an outbred strain of mouse.
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5.2 West Mie viruses
WN viruses are widely distributed throughout the world and in general 
cause self-limiting febrile illnesses in contrast to the viscerotropic disease 
characterised by the yellow fever viruses (see Chapter 1). Like YF virus, 
WN viruses are usually mosquito borne but because of their wide geographical 
distribution they use a number of mosquito vectors (primarily Culex sp. as 
opposed to Aedes sp.). WN viruses exhibit variation in virulence for mice 
depending on the geographical isolation of the virus (Hammam, 1965). The 
three isolates of WN virus used in this study differed in geographical origin 
(Figure 5.1) and pathogenicity for TO outbred mice as determined from 
previous studies conducted in our laboratory. WN strain Sarawak, from 
Malaysia, was found to be an isolate of enhanced virulence in comparison to 
WN virus strains Egypt 101 and Smithburn.
5.3 TO outbred mice
Mice have been used extensively to study the pathogenicity of flaviviruses. 
Whilst not reflecting, in many cases, disease syndromes associated with higher 
primates, they offer a susceptible animal model with which to assay virus 
virulence. The study made use of the TO outbred strain of white mouse (Olac, 
UK) which were female and 3-4 weeks of age.
The use of outbred animals has limitations when the inunune system is 
suspected to play a major role in susceptibility to infection but as neither
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Figure 5.1
A map of the world to illustrate the geographical location 
of the three West Nile virus isolates used in this study.
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the major histocompatibility system (\or cell mediated immunity of the animals 
was being studied, this point was noted but not investigated ftirther.
5.4 Experimental work
The WN viruses were plaque purified and passaged six times in HeLa 
cells. The HeLa and non-HeLa passaged viruses were analysed in a number 
of quantitative assays (determination of infectivity titres) and biological assays 
(reactivity with monoclonal antibodies and virulence in mice). A number of 
studies were performed to link alterations in virus virulence with the presence 
or absence of phenotypic markers.
5.5 Passage o f virus through HeLa cells
Virus was harvested when cpe was evident or on day 3 post infection, 
which ever was earlier. Virus infectivity was determined by plaque assay on 
LLC-MK2 cells and a TCID5 0  assay on HeLa cells, as HeLa cell plaque assays 
were generally unreliable. The results of passage in HeLa cells are shown in 
Table 5.1.
The WN virus strain Sarawak (hereafter called WNV-Sarawak) did not 
show cpe in HeLa cells until passage 4 (see Table 5.1). The lack of cpe was 
accompanied by an inability to detect virus by LLC-MK2 plaque assay from 
passages 1-4. However, low levels of virus could be detected at each passage
163
Table 5.1 Passage of WN viruses in HeLa cells
HeLa cell passage
Virus* 0 1 2 3 4 5 6
Smithburn
cpe + + + + + + +
log pfu/ml 
10 7.0 <1.0 <1.0 <1.0 <1.0 <1.0 <1.0
logj^TCID /^M 7.0 40 3.0 3.0 3.0 20 20
Egypt 101
cpe + + + + + + +
logjQ pfu/ml 7.0 <1.0 <1.0 <1.0 <1.0 <1.0 <1.0
log^^TCID /^M 7.0 4.0 20 20 20 3.0 3.0
Sarawak
cpe + — — — + + +
log pfu/ml 
10 33
<1.0 <1.0 <1.0 4.6 6.0 6.0
log^ T^CID^ Anl 3.0 1.0 20 20 4.0 6.0 6.0
* Plaque assays were performed on LLC-MK2 and TCID^ on 
HeLa cell monolayers.
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by a TCID5 0  test on HeLa cells. The appearance of cpe following 4 HeLa cell 
passages of WNV-Sarawak coincided with the detection of high levels of virus 
by the LLC-MK2 plaque assay. WN virus strains Egypt 101 and Smithburn 
(WNV-ElOl and WNV-Smithburn) gave cpe in HeLa cells throughout the six 
HeLa passages (Table 5.1). In most cases the monolayer was destroyed before 
3 days and often by 18 hours post-infection.
After six HeLa cell passages WNV-Egypt 101 and WNV-Smithburn had 
lost their ability to infect the LLC-MK2 cells, as determined by plaque assay. 
Attempts to plaque the virus at the intermediate passage levels were also 
unsuccessful, plaques being detectable only with the non-HeLa passaged parent 
viruses. Each passage was then tested by plaque assay on Vero cells, another 
monkey kidney cell line often used to plaque flaviviruses, but without success. 
Assays of virus using HeLa cells in a TCID5 0 test showed the presence of virus 
to a reasonable titre (10* TCIDg /^ml) at the lower passage levels, but dropping 
towards passage 6  (lOP TCID^q/ml). It was observed that there was a significant 
reduction in titre following a single HeLa cell passage (Table 5.1).
5.6 Virulence o f WNV for mice following i.n. or Lp. inoculation
Groups of eight mice were inoculated either i.n. or i.p. with virus and 
observed over a period of 21 days. The results show a variation in virulence 
between the virus strains and also between parent and HeLa p6  viruses (Table
5.2 and 5.3). Six sequential HeLa cell passages of WNV-Sarawak resulted in 
significant attenuation of the virus. The pfti/LDjo ratio of non-HeLa passaged
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Table 5.2 Lethality of WNV-Sarawak before and after 
passage in HeLa cells following i.p. or i.n. challenge
Passage Route
AST^
(days) Iog_^fu/LD^
0 i.h. 8.0+0.2 0.7
i.p. 85+0.9 0.8
4 i.n. ND# ND
i.p. 9.6+0.2 1.6
5 i.n. ND ND
i.p. 83+0.6 23
6 i.n. 8.7+0.7 33
i.p. 8.7+0.8 4.4
6* i.p. 9.0+0.4 4.9
^  AST, Average survival time (+ SEM)
* HeLa passage 6 virus given one additional 
passage in adult mouse brain
#  ND, Not done
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virus was 10°  ^ for i.p. and 10”'^  for i.n. inoculation.After six HeLa cell 
passages the pfii/LDjo ratio was 1 0 ** following i.p. inoculation and 1 0 ^^  
following i.n. inoculation. Thus, the HeLa p6  virus was attenuated 
approximately 4000-fold.
Passage of WNV-ElOl and Smithburn in HeLa cells gave similar effects 
to each other but distinct from that of WNV-Sarawak. The infectivity titre of 
viruses present after six HeLa passages was relatively low (Table 5.1). 
Following either i.p. or i.e. inoculation of adult mice the viruses proved to 
be totally avirulent (i.e. no mice died). However, the i.e. inoculated mice were 
hyperactive before they showed clinical signs of sickness between days 4 and 
7 post-inoculation, after which they recovered and survived the test period. In 
contrast, mice died following i.e. inoculation of 10^  pfti of non-HeLa passaged 
WNV-ElOl or Smithburn.
WNV-Sarawak HeLa p4 and p5 were also inoculated into mice to 
determine their lethality. WNV-Sarawak HeLa p4 appeared to be as virulent 
as the parent with no significant alteration in the ptu/LD^o of the virus (Table 
5.2). Following the fifth HeLa passage the virus exhibited a moderate degree 
of attenuation, but was still significantly more virulent than the HeLa p6  virus. 
However, the average survival time of mice inoculated with either the parent 
or HeLa passage 4, 5 or 6  viruses remained unchanged (approximately 8.2 
days). It was considered possible that the HeLa p6  virus was not homogeneous 
and may have consisted of a population of viruses of differing virulence, with 
the more virulent viruses being implicated with the disease seen in mice. To 
test this hypothesis adult mice were inoculated i.p. with WN-Sarawak HeLa p6  
virus and monitored until they became sick, at which time the animals were
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sacrificed and their brains removed. The brains were homogenized and their 
infectivity was titrated by plaque assay. All four brains examined contained 
large quantities of virus ( 1 0 ® pfii/ml), with a plaque morphology the same as 
with the HeLa p6  viruses. The brain-derived viruses were reinoculated i.p. into 
adult mice and the average survival time and pfu/LD^o ratio calculated. Table
5.2 shows that there was no significant difference in the average survival time 
and LD5 0  between the brain derived virus and the HeLa p6  virus used to 
inoculate the mice.
5.7 Pathogenicity o f WN virus strains Egypt 101 and Smithburn fo r newborn
mice
Following the demonstration of the avirulence of HeLa passaged WNV 
ElOl and Smithburn for 28 day old mice, approximately 100 pfii of each virus 
was inoculated i.e. into 1  day old suckling mice, this being the most sensitive 
animal model available for the detection of infectious virus. The infected mice 
became sick between days 4 and 16 post-infection, with a significant lack of 
movement and response to touch in comparison to the PBS mock-infected 
controls. No infectious virus, detectable by plaque assay, was found in brains 
of mice sampled on day 8  post infection. In comparison, newborn mice that 
were inoculated i.e. with 100 pfu of non-HeLa passaged WNV-Smithburn or 
WNV-ElOl died with AST’s of 3.7 and 4.1 respectively (Table 5.3). By day 
2 1  post-infection the control mock-infected mice had grown and were developing 
with no apparent effects from the inoculation, whereas the virus infected mice
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were significantly runted and visually appeared sick, although the animals moved 
freely. WNV-ElOl infected mice were approximately 43% lighter and the 
WNV-Smithburn infected mice 28% lighter than the mock-infected control mice 
(Table 5.3).
5.8 Monoclonal antibody (Mab) reactivity
Mabs were used to determine changes in epitopes on the envelope protein 
of both parent and HeLa p6  viruses. Mab C ll (prepared against Japanese 
encephalitis virus; Cao et al., unpublished observations), was found to be 
particularly interesting with respect to WNV-Sarawak virus because it was very 
effective in neutralising the parent virus (> 5  logjo reduction in virus 
infectivity), but not the virus that had received six HeLa cell passages (Table
5.4). Examination of WNV-Sarawak HeLa p4 and p5 with Mab C ll showed 
that at HeLa p4 the virus was effectively neutralised by Mab C ll,  whereas at 
HeLa p5 the virus was no longer neutralised by the Mab (Table 5.4). The 
brain derived WN-Sarawak HeLa p6  virus remained non-reactive for Mab C ll,  
as did the non-brain passaged HeLa p6  virus (Table 5.4). Interestingly, despite 
the loss of neutralising activity after five passages in HeLa cells, Mab C ll still 
recognised an epitope in IIP tests with WNV-Sarawak HeLa p5 and p6  (Table
5.4).
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Table 5.4 Reactivity of Mab C ll in PRNT 
and IIP tests with HeLa and non-HeLa passaged 
WNV-Sarawak
Virus
HeLa
passage
Mab C ll 
PRNT HP
WNV-Sarawak pO >5.0*
p4 >4.6 +
P5 0 . 0 +
p6 0 . 0 +
mb p6 # 0 . 0 +
* Neutralisation is expressed as the log jq reduction in virus 
infectivity in the presence of Mab C ll
IIP is indirect immunofluorescence: + = positive, -=  negative
#  HeLap6 virus was passaged once in adult mouse brain
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5.9 Temperature sensitivity (ts) o f HeLa and non-HeLa passaged virus
The temperature sensitivity (ts) of both HeLa and non-HeLa passaged 
virus was examined by efficiency of plaquing at 31, 35, 37, and 39.5°C. Due 
to the inability of HeLa passaged WNV-ElOl and Smithburn to form plaques 
on LLC-MK2 cells, the study concentrated on WNV-Sarawak.
Although WNV-Sarawak pO plaqued throughout the temperature range, 
WNV-Sarawak HeLa p6  was sensitive at the superoptimal temperature of 39.5°C 
(Table 5.5). In comparison to the parent virus, the HeLa p6  virus showed a 
4 logio reduction in infectivity titre (e.o.p.= 0.00015), as determined by LLC- 
MK2 plaque assay. In order to confirm the differences observed, the efficiency 
of plating (e.o.p.) was calculated (Table 5.5) and in contrast to WNV-Sarawak 
HeLa p6 , the HeLa p4 and p5 viruses were found not to be ts.
5.10 Haemagglutination by HeLa and non-HeLa passaged WN viruses
Most flaviviruses effectively agglutinate goose red blood cells. 
Haemagglutination (HA) is mediated by the haemagglutinin present on the 
envelope protein of the virus which is active over a narrow pH range, this 
range being dependent upon the particular flavivirus.
Non-HeLa passaged WNV strains Sarawak, Smithburn and Egypt 101 
effectively agglutinate goose red blood cells at their optimum pH of 5.7 (Table 
5.6). Following six passages in HeLa cells none of the viruses agglutinated 
goose red blood cells between the ranges of pH 5.7-7.2. Furthermore, in the
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case of WNV-Sarawak HeLa p6 , calculation of the pfu/HA ratio (^ 4 .4 )  
indicated that sufficient antigen was available for the resulting loss of HA 
activity to be significant (Table 5.6). Unfortunately, the titres for both WNV- 
Smithburn and ElOl (determined by HeLa cell TCID5 0) were too low for the 
HA negative result to be meaningful (pfii/HA values of ^ 0 .4  and ^1.4  
respectively) (Table 5.6).
Therefore, following HeLa cell passage the epitope(s) of the envelope 
protein which elicits HA appears to have been altered for WNV-Sarawak thus 
rendering it incapable of agglutinating goose red blood cells. HA was absent 
for all three WN viruses after a single HeLa cell passage and the pfu/HA 
ratios were duly calculated to determine the significance of the finding. The 
values in Table 5.6 implied that loss of HA activity following a single HeLa 
cell passage may not be attributable to changes in the haemagglutinin of the 
virus, but rather a lack of antigen in the 50p\ test system.
As flaviviruses are enveloped, it was reasonable to assume that following 
replication and release from the HeLa cell, the virus envelope would contain 
lipids and other host cell derived material. Therefore, whilst being unable to 
agglutinate goose red blood cell, the HeLa passaged viruses may be able to 
agglutinate red blood cells of human origin. Table 5.6 shows that neither the 
parent or HeLa passaged WN viruses agglutinated the human red blood cells. 
As a control, influenza type A virus was used which readily agglutinated the 
human red blood cells when incubated at 4°C (Table 5.6).
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Table 5.5 Temperature sensitivity of HeLa passaged WN viruses
HeLa Temperature ('“C)
Virus passage 31 35 37 39.5 e.o.p.*
WNV-Sarawak pO 7.8# 7.9 8.2 8.1 0.81
p4 4.4 4.6 4.6 45 0.60
P5 7.0 7.6 7.4 7.4 033
p6 7.0 7.7 7.9 4.0 0.00015
* e.o.p., efficiency of plating 39.5/37 C
#  log^^fu/ml determined by LLC-MK2 plaque assay
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Table 5.6 Effects of HeLa passage on the HA activity of WN viruses
HeLa Infectivity HA units ^ pfu/HA
Virus passage titre# goose human ratio
WNV-Sarawak pO 7.6 512 C2 3.6
pi 1.0* <2 <2 <0.6
p6 6.0 <:2 C2 ^  4.4
WNV-Smithburn pO 7.0 256 <:2 33
pi 4.0* <2 < 2 >24
p6 2.0* <2 <2 >0.4
WNV-Egypt 101 pO 7.0 512 <$2 3.0
pi 4.0* C2 ^ 2 >2.4
p6 3.0* < 2 <2 <1.4
Influenza type A - NA >1024 >1024 NA
* Determined by TCID^ on HeLa cells
#  log^^pfu/ml
^  per 50ul test volume 
NA Not available
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5.11 Passage o f WNV-Sarawak HeLa p6  through SW13, LLC-MK2 or Vero
cells and their ability to agglutinate goose red blood cells
Following the discovery that passaging of WNV-Sarawak in HeLa cells 
renders the virus incapable of agglutinating goose red blood cells experiments 
were undertaken to determine whether the loss of HA activity was permanent 
following HeLa cell passage or merely host cell dependent in origin.
WNV-Sarawak HeLa p6  (HA negative) was passaged three times in
SW13, LLC-MK2 or Vero cells, at an m.o.i. of between 0.1 and 1 before
assay of HA activity was undertaken with goose and human red blood cells. 
Virus that had been passaged in SW13 cells or LLC-MK2 cells were found 
to be HA positive whilst virus passaged in Vero cells remained HA negative 
(Table 5.7). It was interesting to note that passage of WNV-Sarawak HeLa p6  
in Vero cells produced rapid cpe characteristic of passage in HeLa cells, 
whereas passaging of virus in SW13 or LLC-MK2 cells was associated with 
a delay of upto 48 hours before cpe was evident. Infectivity titres of WNV- 
Sarawak HeLa p6 , (determined by plaque assay on LLC-MK2 cells), showed 
that large quantities of infectious virus were obtained from each of the three 
cell lines infected (Table 5.7).
Regaining of HA was evident following three passages in SW13 or LLC- 
MK2 cells which implied that selection of HA positive sub-populations of virus 
had occurred. To answer this question, WNV-Sarawak HeLa p6  was plaqued 
on HeLa cells and plaque picks were made. The plaque purified virus was then 
twice amplified in HeLa cells to produce a stock virus for subsequent tests. 
The plaque purified virus was tested in HA assays to confirm that it was HA
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Table 5.7 Effects of passaging WNV-Sarawak HeLa p6 virus in SW13, 
LLC-MK2 and Vero cells on HA activity for goose and human red 
blood cells
HeLa cell 
Virus passage
Infectivity
titre#
HA units ^  
goose human
pfu/HA
ratio
WNV-Sarawak pO 7.6 512 <2 3.6
p6 6.0 C2 C2 >4.4
p6 + 3xSW13 7.2 128 <2 33
p6 + 3xLLC-MK2 7.0 512 ^2 3.0
p6 + 3x Vero 8.0 <2 C2 >6.4
pp p6 + 3xSW13 6.2 64 <2 3.1
pp p6 + 3x LLC-MK2 6.2 512 <2 22
pp p6 + 3x Vero 6.0 <2 <2 >4.4
Influenza A NA >1024 >1024 NA
#  log^^pfu/ml determined by LLC-MK2 plaque assay
per 50ul test volume 
pp plaque picked virus
NA Not available
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negative before proceeding. HA negative virus was passaged three times in 
SW13, LLC-MK2 or Vero cells as before. The results in Table 5.7 reveal that 
passage through SW13 or LLC-MK2 cells returns HA activity to the virus after 
three passages and not before. Vero passaged virus, however, remained negative 
in comparison to the other two cell lines.
5.12 Lethality o f WNV-Sarawak p 6  HA positive and HA negative viruses
The lethality of WNV-Sarawak HeLa p6  (HA negative SW13 pi and 
Vero p3; HA positive SW13 p3) was tested by i.p. inoculation of adult female 
TO mice. The average survival time (AST) of the mice and pfu/LDjo of the 
viruses were then calculated where appropriate.
The results (Table 5.8) show there was no significant change in the AST 
of the mice or virulence (pfu/LDjo) of either SW13 or Vero passaged WNV- 
Sarawak HeLa p6 . Thus, WNV-Sarawak HeLa p6  retained its avirulent 
phenotype following passage in the different cell lines examined.
5.13 Phenotype o f HA positive and HA negative WNV-Sarawak HeLa p6
Passage of WNV-Sarawak HeLa p6  in two of the three vertebrate cell 
types mentioned above altered the HA capacity of the virus but had no 
apparent effect on lethality for adult mice (see 5.12). Earlier studies in this 
Chapter revealed the presence of a ts marker and escape of neutralisation with
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Table 5.8 Virulence of WNV-Sarawak HeLa p6 HA+ and HA- for adult TO mice
Cell
Virus passage
Route of 
inoculation HA#
AST 
(± SEM) logiopfu/LD^
WNV-Sarawak pO i.p. + 85+0.2 0.8
p6 i.p. 8.7+0.8 4.4
mb p6 i.p. 9.0+0.4 4.9
pp p6 + Ix SW13 i.p. - 8.9+0.4 4.0
pp p6 + 3xSW13 i.p. + 8.0+0.2 4.0
pp p6 + 3x Vero i.p. - 8.7+0.2 4.0
i.p. intraperitoneal inoculation
#  HA activity for for goose red blood cells: + haemagglutination
_ no haemagglutination
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Table 5.9 Phenotypic characteristics of WNV-Sarawak HeLa p6 
following passage in SW13, LLC-MK2 and Vero cells.
CbU
Virus passage HA* ts^
Mab C ll 
neut^ UP#
WNV-Sarawak pO + 0.81 + +
p6 - 0.00015 - +
mb p6 - 0.0001 - +
pp p6 + 3xSW13 + 0.0005 NA +
pp p6 + 3x LLC-MK2 + 0.0001 NA +
pp p6 + 3x Vero
— 0.0001 NA +
mb: mouse brain derived virus 
pp: plaque purified virus
#: indirect immunofluorescence, + = positive reaction 
* data from Table 5.7: + = positive HA activity
- = no detectable HA activity
NA: not available
^ : neutralising capacity of Mab C ll  
1 : efficiency of plating 39.5/37 C
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Mab C ll by HeLa passaged virus. Following a single mouse brain passage 
there was no change in phenotypic character. Therefore, it was important to 
examine the phenotype of WNV-Sarawak HeLa p6  that had received passage in 
either SW13, LLC-MK2 or Vero cells.
Experiments to determine the ts characteristics of SW13, LLC-MK2 and 
Vero cell passaged WNV-Sarawak HeLa p6  revealed the presence of a ts 
marker when LLC-MK2 plaque assays were incubated at the superoptimal 
temperature of 39.5°C. The results in Table 5.9 show that the ts phenotype 
remains approximately equal to that of the parent WNV-Sarawak HeLa p6  virus 
used to infect the different cell lines. Unfortunately, Mab C ll was not available 
to determine whether the epitope recognised by Mab C ll had regained 
neutralising activity after passage of the HeLa p6  parent virus in SW13, LLC- 
MK2 or Vero cells.
5.14 Discussion
Three strains of WNV, Sarawak, Egypt 101, and Smithburn were passaged 
6  times in HeLa cells to determine whether, like wild-type YF virus, they 
became significantly attenuated. WNV-Sarawak became attenuated for mice after 
5 HeLa cell passages and highly attenuated (4000 fold) following 6  passages. 
The two other strains of WN virus also became attenuated on passage in HeLa 
cells, but their higher pfti/LDgo ratio and lower levels of infectivity made a 
quantitative analysis more difficult.
An interesting point was that, although the virus at HeLa p6  was
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attenuated by such a degree, the average survival time of the mice remained 
unchanged. It would therefore appear likely that there has been little or no 
alteration in the neuroinvasiveness of the HeLa and non-HeLa passaged virus 
as determined by average survival time. However, further studies would be 
necessary to substantiate this possibility.
WNV strains Egypt 101 and Smithburn were shown to be avirulent for 
both adult and suckling mice even following i.e. inoculation. However, the 
viruses did infect suckling mice and apparently caused defects in their growth, 
with the mice being recorded as runted. Presumably the differences seen 
between WNV strains Sarawak, Egypt 101 and Smithburn on passage in HeLa 
cells relate to the different origins of the isolates. Moreover, WNV-Sarawak has 
an enhanced virulence for adult mice compared to the other two strains. 
Another possible reason for variation in the pathogenicity results may be the 
generation of defective interfering particles after passage at a high multiplicity 
of infection (Barrett and Dimmock, 1986). However, whereas defective 
interfering particles can be readily produced by passage of virus at a high moi 
in most cell lines, generation of such particles in HeLa cells is particularly 
difficult (Stark and Kennedy, 1978). It was possible that the virus population 
at HeLa passage 6  is not homogeneous and that virulent virus exists in the 
population. This was examined in two ways. Firstly, the viruses were plaque 
purified by plaque picking and considered to represent a homogeneous 
population of virions before passage in HeLa cells. Secondly, studies of WNV- 
Sarawak HeLa p6  after mouse brain passage showed that the virus had 
maintained it attenuated state when reintroduced into mice. We can therefore 
conclude that the HeLa p6  population does not contain a major virulent
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subpopulation and the changes confering attenuation at the genome level appear 
to be stable for at least one mouse brain passage or three passages in SW13, 
LLC-MK2 or Vero cells.
Attenuation following passage in HeLa cells was accompanied by an 
antigenic change(s) on the envelope protein of the virus as determined by Mab 
Cl l .  Very little overall change was observed between parent and HeLa 
passaged viruses as determined by Mabs in indirect immunofluorescence and 
neutralisation assays (Table 5.4). However, from the data with Mab Cl l ,  
antigenic changes in the envelope protein do occur on HeLa passage. Despite 
the loss of neutralising capabilities of Mab C ll with WNV-Sarawak HeLa p6 , 
the epitope recognised by Mab C ll was still present as determined by indirect 
immunofluorescence. This would imply that there may be a conformational 
change in the envelope protein of the virus.
In addition to the antigenic analysis with envelope protein reactive Mabs 
WNV-Sarawak was assayed for temperature sensitivity by incubation at sub- 
and superoptimal temperatures. The parent virus was permissive at all 
temperatures, yet after six HeLa cell passages the virus was ts at 39.5°C. The 
virus titre was reduced by 4 log,o units at 39.5°C, which is suggestive of a 
single nucleotide change at the genome level conferring temperature sensitivity. 
By analysis of intermediate passage levels similar to that undertaken with Mab 
Cl l ,  the temperature sensitivity marker was found to occur between the fifth 
and sixth HeLa passages. Loss of HA after HeLa cell passage was observed 
for wild-type YF virus in Chapter 3. Likewise, HA activity for goose red 
blood cells was lost for three isolates of WNV following passage in HeLa 
cells. Unfortunately, the only result deemed significant upon calculation of
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pfu/HA ratios was that for WNV-Sarawak. Loss of HA , however, was not 
permanent because passage of HA negative HeLa p6  virus in either SW13 or 
LLC-MK2 cells returned HA activity to the virus. This implies that loss or 
gain of HA ability in this situation is due to a conformational change dependant 
upon the host cell used for replication. Virulence tests with HA positive WNV- 
Sarawak HeLa p6  suggest that HA has little influence on attenuation of 
virulence as evidenced by virus remaining avirulent for adult mice. However, 
the ts phenotype is still present after passage of the HeLa p6  virus in SW13, 
LLC-MK2 or Vero cells. As only six HeLa cell passages have been made it 
seems likely that either alteration of an envelope protein epitope, or a 
combination of both, may be responsible for the attenuation observed. 
Alternatively, it is possible that neither of these biological markers is involved 
and that their presence is merely coincidental. To test this hypothesis both 
WNV-Sarawak HeLa p4 and p5 were tested for pathogenicity in mice. A 
number of interesting conclusions can be drawn from the results in Table 5.10. 
Firstly, that the parent and HeLa p4 viruses are both virulent for mice, both 
are fully neutralised by Mab C ll and neither exhibits temperature sensitive 
characteristics. Following five HeLa passages the neutralising capacity of Mab 
C ll is lost, but the virus still replicates at all temperatures tested. The loss 
of Mab C ll reactivity is accompanied by an approximately 33-fold attenuation 
of the virus in comparison to the parent virus. After six HeLa passages the 
virus is again not neutralised by Mab Cl l ,  is HA negative but is also 
temperature sensitive. A 4000 fold attenuation of the virus is seen when 
compared to the parent virus and a 125 fold difference over that of the HeLa 
p5 virus. It is therefore possible that both loss of neutralisation by Mab C ll
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Table 5.10 Summary of biological properties of WNV-Sarawak following passage in 
HeLa cells and subsequently in SW13 and Vero cells
Virus
passage
AST(± SEM) 
(days)# pfu/LDjo
ts
(e.o.p.)*
Mab C ll 
neut  ^ HP 2 HA
HeLa pO 8.9+0.9 6 0.81 >5.0 + +
p4 9.6+0.2 40 0.60 >4.6 + —
P5 8.8+0.6 200 033 0.0 + —
p6 8.7±0.8 25000 0.00015 0.0 + —
mb p6 9.0+0.4 79000 0.0001 0.0 + —
pp p6 + 3xSW13 8.0+0.6 10000 0.0005 NA NA +
pp p6 + 3x Vero 8.7+0.2 10000 0.0001 NA NA —
mb, mouse brain derived virus
#  Average survival time (+SEM)
* Efficiency of plating 39.5/37 ° C 
 ^ logio reduction in infectivity titre 
2 Indirect immunofluorescence
pp, plaque picked WNV-Sarawak HeLa p6
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and the presence of temperature sensitivity have an effect on virus virulence, 
with their contribution towards attenuation differing. The temperature sensitive 
phenotype coincides with the greater attenuation and may be important to the 
attenuation of virulence seen after six HeLa passages of WNV-Sarawak. We do 
not know the number or location of nucleotide and amino acid changes between 
non-HeLa and HeLa passaged WN-virus, but with only six HeLa passages few 
changes would be anticipated. If this is true, results with Mab C ll indicate that 
there has been a change(s) on the envelope protein. It is of note that a 
proportion of the experimental dengue virus vaccines exhibit temperature 
sensitivity along with a small plaque morphology (Eckels et al., 1976); hence 
further characterisation of this marker would be useful in determining its role 
in attenuation. In order to carry this out it will be necessary to obtain 
temperature sensitive revertants and/or Mab C ll escape mutants and examine 
their role in the pathogenicity of WN virus for mice. Unfortunately, attempts 
to generate such variants has proved unsuccessful.
"TW W -vs Vyxs rev/lev.:^
a « i  W  W .  ^  ^  R 5 o \
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Chapter 6. Passage of tick-borne flaviviruses through HeLa cells.
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6.1 Introduction
Tick-bome flaviviruses represent the largest complex in the Flaviviridae 
(Calisher et al., 1989). The viruses are responsible for diseases in many species 
of animal and are transmitted primarily by Ixodes species of tick. The particular 
type of Ixodes appears to vary according to geographic location. Susceptible 
hosts which are usually implicated in the transmission and replication cycle of 
ticks include numerous species of rodents and forest birds (Chamberlain, 1980). 
Tick-borne viruses have a wide distribution throughout Central and Eastern 
Europe, and parts of Asia with many of the viruses causing severe disease in 
man (see Chapter 1). The morphology, chemical and antigenic composition of 
tick-borne encephalitis (TBE) viruses is similar to those of other flaviviruses 
(Heinz and Kunz, 1977 and Heinz et al., 1981). Members of the TBE group 
differ however in their resistance to acidic pH; TBE viruses are more tolerant 
than other members of the Flaviviridae. Control of Central European TBE is 
by administration of an inactivated virus preparation. The vaccine is highly 
efficacious when challenged with the homologous virus but is less successful 
against unrelated strains of TBE virus. Live attenuated TBE viruses which are 
suitable for human vaccine trials have been difficult to obtain. At present, the 
most promising candidate virus is a Czechoslovakian isolate (Skalica). This virus 
was isolated from a bank vole and is non-pathogenic for mice (Gresikova and 
Sekeyova, 1980). TBE viruses appear as a distinct group when compared to 
mosquito borne flaviviruses and possess a number of unique characteristics. This 
Chapter analyses the effects of HeLa cell passage on two geographically distinct 
tick-borne viruses with respect to their antigenicity and pathogenicity.
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6.2 Viruses
a) Louping-ill
Louping-ill (LI) virus was first isolated in Scotland in 1929 and 
recognised as an agent causing neurological disease (Pool et al., 1930). Figure
6.1 details the known distribution of LI virus.
LI is predominantly a disease of sheep which, when infected, exhibit a 
biphasic illness with a prolonged viraemia which progresses in later stages to 
paralysis and tremors in the host (Reid and Doherty, 1971). Human infection 
with LI virus has been documented with the first case being described in a 
laboratory worker (Rivers and Schwentker, 1934). The majority of human cases 
remain attributed to laboratory workers.
The virus is transmitted by Ixodes ricims species of tick with both the 
sheep and grouse being utilised in the life cycle. LI has been controlled in 
sheep by the administration of a formalin inactivated, methanol precipitated 
vaccine (Brotherston and Boyce, 1970), but this is no longer produced.
b) Langat strain TP2I
Langat (LGT) virus was originally isolated from ground rats in the Langat 
forest region of Malaysia (Gordon-Smith, 1956) and since on numerous 
occasions from Ixodes granulatus ticks from that region (Berge, 1975). Figure
6.2 details the origin of LGT virus. Little is known of the host-virus 
relationships of LGT virus. LGT TP21 virus is highly pathogenic for mice even 
when inoculated by the intraperitoneal route (Gordon-Smith, 1956). Human
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Figure 6.1
Map of the world showing the geographical origins of 
the tick-borne virus isolates used in this study
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infection is very rare and there is no natural disease recognised. LGT virus 
has therefore been used as a candidate virus for numerous live tick-borne virus 
vaccine programmes but unfortunately with little success (Il’enko et al., 1968; 
Thind and Price, 1966).
6.3 Experimental work
Plaque purified LI (strain ADRI/3 from Oban, Scotland) and LGT (strain 
TP21) viruses were amplified in Vero cells to yield stock viruses. Virus was 
then passaged in HeLa cells as described in Materials and Methods prior to 
biological characterisation. Pathogenicity studies were performed in outbred adult 
female TO mice (four weeks old) with virus being inoculated by the i.p. route.
6.4 Passage o f LI and LGT viruses through HeLa cells
As with previous assays, virus was inoculated onto HeLa cell monolayers 
at an m.o.i. between 1 and 5 and virus harvested on or before day 3 post­
infection, depending on the degree of cpe exhibited by the viruses. Virus titres 
were measured by plaque assay on LLC-MK2 cells and TCID5 0  on HeLa cells. 
The results are shown in Table 6.1.
Following passage in HeLa cells, LGT virus exhibited the characteristic 
rapid appearance of cpe (approximately 24 hrs), high titres of virus and large 
plaque morphology associated with HeLa cell passage. This was in contrast to
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Table 6.1. Passage of LI and LGT viruses through HeLa cells
HeLa cell passage
Virus 0 1 2 3 4 5 6
Louping-ill
CPE + + + + + + +
Log^^pfu/ml 93 5.4 5.4 4.6 5.2 43 33
Log^^TCm^Anl 8.0 5.0 5.0 4.0 4.0 4.0 3.0
Langat TP21
CPE + + + + + + +
Log 10 pfu/ml 6.2 4.2 5.7 8.0 8.0 7.4 7.2
ND* ND ND ND ND ND ND
Plaque assays were performed on LLC-MK2 and TCID^ assays on 
HeLa cell monolayers.
*ND. Not done.
+: indicates positive cpe on propagation of the virus in cell culture.
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the non-HeLa passaged parent virus which exhibited small plaque morphology. 
Interestingly, LI virus infection of HeLa cell monolayers was accompanied by 
a slow onset (approximately 48-60 hrs) of cpe in comparison to LGT virus and 
retained a small plaque morphology on LLC-MK2 cells after six passages in 
HeLa cells. A very marked reduction in virus titre was noted for LI virus over 
the six HeLa cell passages, the reduction being particularly marked following 
the first HeLa cell passage (Table 6.1).
6.5 Pathogenicity o f the tick-borne viruses U  and LGT
HeLa and non-HeLa passaged LI and LGT viruses were inoculated i.p. 
into adult mice to determine their relative lethality. The results in Table 6.2 
show that both LI and LGT viruses remained as virulent for mice after six 
HeLa cell passages as the respective parent virus. In addition no difference in 
average survival time was observed between the parent or HeLa p6  viruses 
(Table 6.2).
6 . 6  Monoclonal antibody reactivity
Monoclonal antibodies (Mabs) were used to analyse the surface epitopes 
on the envelope protein of HeLa and non-HeLa passaged LI and LGT viruses 
in indirect immunofluorescence (IIP) tests and plaque reduction neutralisation 
tests (PRNT’s). IIP and PRNT tests revealed little apparent change to the
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epitopes of the envelope protein of HeLa and non-HeLa passaged LI virus 
(Table 6.3). LGT virus proved to be of greater interest, as this virus was 
recognised by Mab C ll which proved of significance in differentiating between 
HeLa and non-HeLa passaged WNV strain Sarawak (see Chapter 4). IIP tests 
with Mab C ll demonstrated the presence of an epitope before and after HeLa 
passage in a similar fashion to WNV-Sarawak (Table 5.4). In PRNT tests, non- 
HeLa passaged LGT virus was neutralised to a high degree (3.2 log,o reduction 
in infectivity) and following six passages in HeLa cells LGT virus was still 
effectively neutralised by Mab C ll,  but to a lesser degree (2.1 log,o reduction 
in infectivity). The results are shown in Table 6.3.
6.7 Temperature sensitivity of HeLa and non-HeLa passaged LI and LGT viruses
Temperature sensitivity (ts) was assessed by plaque assay on LLC-MK2 
cells by incubation at a number of different temperatures as described in 
Materials and Methods (see Chapter 2). Table 6.4 presents the data for both 
HeLa and non-HeLa passaged LI and LGT viruses. All viruses were permissive 
throughout the temperature range and consequently non-ts in phenotype. 
Calculation of the efficiency of plating (eop) substantiates the observations.
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Table 6.2. Lethality of tick-borne viruses for mice after passage
in HeLa cells#
Virus Passage
AST*
(days) Logjo pfu/LDjo
Louping-ill 0 8.1+0.8 3.2
6 8.8+0.7 2 5
Langat TP21 0 11.0±0.6 21
6 123±0.5 1.8
#  Injected i.p. into mice.
* AST, Average survival time + SEM
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Table 6.3 Reactivity in indirect immunofluorescence (IIP) and 
neutralisation (Neut) tests of LI and LGT viruses with 
monoclonal antibodies
Louping-ill Langat TP21
IIP
pO
Neut
p6
IIP Neut HP
pO
Neut np
p6
Neut
Mab
C9 + - + - + - + -
C l l - - — — + 3.2 + 21
C13 + - + + - + -
C23 + - + + - + -
C26 + - + + - + -
+
Negative IIP result or neutralisation <0.5 log^^reduction 
in infectivity.
Positive IIP result
Log reduction in virus infectivity
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Table 6.4 Temperature sensitivity of HeLa passaged LI and LGT viruses
Virus 31
Temperature °  C 
35 37 39.5 e.o.p.#
Louping-ill pO 8.6* 8.6 8.7 8.7 1.00
p6 3.0 3.5 3.2 3.2 1.00
Langat TP21 pO 6.4 6.5 6.4 6.0 0.33
p6 6.9 7.0 7.3 6.4 0.15
#  e.o.p. Efficiency of plating 39.5/37 °G
Log 10 pfu/ml
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6 . 8  Haemagglutination o f goose red blood cells by HeLa and non-HeLa 
passaged LI and LGT viruses
When wild-type LI and LGT viruses were incubated with a standardised 
solution of goose red blood cells at room temperature and optimum pH, 
haemagglutination (HA) of the red blood cells was observed. When the test was 
repeated with LI HeLa p6  or LGT HeLa p6  viruses at a number of different 
pH values, the viruses were incapable of agglutinating the red cells (Table 6.5). 
The pfii/HA ratio was determined for each virus to show that loss of HA 
activity was due to changes in the biological activity of the virus and not 
reductions in virus titre. Non-HeLa passaged LGT virus which readily 
agglutinated goose red cells had a log,opfu/HA ratio of 2.3. Following six 
passages in HeLa cells LGT virus no longer agglutinated the red cells and 
yielded a logiopfii/HA ratio of >5.0 . The result demonstrated that there was 
sufficient antigen present at HeLa p6  to elicit HA if such a reaction was to 
occur. A similar calculation of log,opfu/HA ratio was made for LI HeLa p6  
virus which was also HA negative following HeLa cell passage in comparison 
to the respective parent virus. Unfortunately, the results were not conclusive for 
the following reason. Non-HeLa passaged LI virus possessed a log,opfu/HA ratio 
of 5.0 whereas LI HeLa p6  virus had a ratio of >0 .2 . The ratio obtained 
represented the fact that LI HeLa p6  virus replicated to a low infectivity titre 
and therefore from comparison of the calculated ratios there was insufficient 
antigen present to elicit HA.
In a similar manner to previous tests, both LI and LGT HeLa pi viruses 
were assayed for HA. In each case there was no HA observed following
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incubation at a number of different pH levels. Calculation of the logjopfu/HA 
ratios was undertaken to determine whether the negative results were significant. 
LGT HeLa pi virus possessed a log,opfu/HA ratio of >1 .3  which was below 
the figure obtained for the HA positive parent virus (ratio of 2.3). The result 
is therefore inconclusive because of the lack of antigen in the preparation. A 
similar scenario was observed for LI HeLa pi virus which had a ratio of 
>2.0 . This was well below the figure obtained for the HA positive parent 
virus (ratio of 5.0) and hence the result was probably not genuine.
The HA assays were repeated with human type O red blood cells 
incorporating influenza type A as a positive control virus. None of the 
flaviviruses gave a positive HA results with the human red cells whilst 
influenza virus yielded a titre of >1024 for both human and goose red cells 
(Table 6.5).
6.9 Passage o f LGT HeLa p6  virus through LLC-MK2, SW13, and Vero cells.
Passaging of HeLa p6  viruses through different vertebrate cell lines was 
restricted to LGT HeLa p6  virus. HA negative LGT HeLa p6  virus was 
passaged three times in either LLC-MK2 cells, SW13 cells, or Vero cells at 
an m.o.i between 0.1-1.0 before reassessment of HA activity was made. LGT 
HeLa p6  virus replicated rapidly in Vero cells to a high titre with cpe being 
evident 24 hours post-infection. In comparison, following inoculation of the 
above virus onto LLC-MK2 or SW13 cells resulted in a delayed appearance of 
cpe which occurred approximately 36-48 hours post infection. HA tests were
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Table 6.5 Effects of cell passage on the HA ability of LI and
LGT viruses
Passage Log pfu/ml
HAunits/50ul 
goose human#
pfu/HA
ratio
LI pO 93 256 <2 5.2
LI pi 5.4 <2 <2 >20
I I  p6 33 <2 <2 >0.2
LGT pO 6.2 256 <2 23
pi 4.2 <2 <2 13
p3 8.0 < 2 <2 >6.4
p6 7.2 <2 <2 >5.0
Influenza type A NT >1024 <1024
-
#  Human type O red blood cells. 
NT. Not tested.
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Table 6.6 Haemagglutination activity of LGT HeLa p6 virus following passage in 
SW13, LLC-MK2 or Vero cells
Cell Infectivity HA units ^  pfu/HA
Virus passage titre# goose human ratio*
LGT pO 6.2 256 <2 23
p6 7.2 <2 <2 >3.3
p6 + 3xSW13 8.0 256 <2 4.2
p6 + 3x LLC-MK2 8.0 512 <2 3.9
p6 + 3x Vero 8.0 <2 <2 >53
pp p6 + 3xSW13 7.6 128 <2 3.2
pp p6 + 3x LLC-MK2 8.0 256 <2 4.2
pp p6 + 3x Vero 7.8 <2 <2 >5.2
#  Infectivity titre determined by LLC-MK2 plaque assay and expressed as lo^^ pfu/ml. 
^  HA units per 50ul test volume.
* pfu/HA ratio expressed as log^ ^
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then performed on the viruses using standardised goose or human red blood 
cells. The results in Table 6 . 6  show that following three passages in 
LLC-MK2 or SW13 cells restored HA activity to LGT HeLa p6  virus. In 
comparison, passaging of virus in Vero cells did not restore HA activity. The 
amount of virus produced from the three cell lines were of a comparable titre 
and calculation of the log,opfu/HA ratios confirmed that lack of HA for Vero 
cell grown virus was not merely due to insufficient virus (Table 6 .6 ). To 
safeguard against selection and propagation of minor sub-populations of HA 
positive virus from the LGT HeLa p6  population, a plaque picked virus was 
taken. The LGT HeLa p6  plaque pick was twice amplified in HeLa cells and 
confirmed to be HA negative prior to passage as before in the different 
vertebrate cell lines. The results obtained were very similar to those for the 
whole population with the return of HA activity for virus that had received 
LLC-MK2 or SW13 passage but not for virus passaged in Vero cells.
6.10 Discussion
Tick-borne flaviviruses represent an important number of highly pathogenic 
viruses which are responsible for severe outbreaks of disease. Control of tick- 
borne flaviviruses in man involves the use of an inactivated virus vaccine which 
affords satisfactory protection. Attempts to produce live attenuated tick-borne 
vaccines has been undertaken by several workers but with little success.
Previous studies in this thesis have demonstrated that six HeLa cell 
passages of the mosquito borne flaviviruses YFV and WNV leads to a high
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degree of attenuation of these viruses (see Chapters 3 and 4). The attenuated 
variants derived will be of use in determining the mechanism of attenuation 
of these viruses and hopefully in the design of future vaccines. Therefore, two 
tick-borne viruses were passaged in HeLa cells to determine whether or not 
these viruses could be attenuated in a similar manner.
Passaging of LI and LGT viruses in HeLa cells revealed differences 
between the two viruses with respect to their apparent replicative abilities. 
When inoculated onto HeLa cell monolayers, both viruses exhibited cpe but 
the onset of cpe and resulting titre of virus obtained by passaging LI virus 
was greatly reduced in comparison to HeLa passage of LGT virus. Moreover, 
a very high reduction in virus titre was noted for LI virus after just a single 
HeLa passage (reduction of 3.9 log,o pfu/ml). In contrast, LGT virus displayed 
the characteristics that appear to be associated with HeLa passaged viruses: 
rapid appearance of cpe accompanied by high virus titre and large plaque 
morphology. The tick-borne viruses as a group show greater homology at the 
amino acid level than most other groups of the Flaviviridae and one would not 
expect perhaps such a difference in replicative abilities between viruses for a 
single cell line. One reason for the apparent inability for LI virus to replicate 
efficiently in HeLa cells may be due to the obtaining of a variant virus during 
the initial plaque picking of the virus. This is an inherent problem of plaque 
picking in that the virus may represent a minor variant from the population. 
Undoubtedly, the HeLa cells are exerting a high degree of selective pressure 
on the virus which may enhance further the generation of variants.
In contrast to the attenuation of the mosquito borne YF and WN viruses, 
the two tick-borne viruses LI and LGT remained as virulent as the parent
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viruses for adult mice after six HeLa cell passages. The difference in reaction 
to HeLa passage suggests that there may be fundamental differences between 
mosquito and tick-borne viruses that governs cell/virus interactions. Alternatively, 
tick-bome viruses may require a greater number of HeLa cell passages before 
attenuation for mice is observed. Excess passaging of the virus, however, is 
equivalent to an empirical derivation of an attenuated vims which, when 
analysed at the molecular level would yield a confusing array of nucleotide 
changes, any number of which may play a role in attenuation of vimlence. 
Passaging of LI and LGT vimses in HeLa cells was performed in an attempt 
to generate attenuated vimses after very few passages, thus limiting the number 
of nucleotide changes which would be implicated in the attenuation process. 
Previous workers have attenuated LGT TP21 vims for mice by multiple 
passages (empirical derivation) of the vims in chick embryo tissue (Thind and 
Price, 1966). The attenuated variant (LGT E5 vims) possessed low levels of 
neurovimlence for mice when inoculated peripherally and interestingly a slow 
rate of growth in HeLa cells. LGT HeLa p6  vims exhibited neither of the 
above characteristics.
Information obtained using the small panel of envelope protein reactive 
Mabs suggested that there was little change to the surface epitopes of the 
vimses following six passages in HeLa cells. This observation is unique to LI 
and LGT vimses as previous work presented in this thesis demonstrates 
significant changes to epitopes on YF and WN vimses following very few 
passages in HeLa cells (see Chapters 3 and 4). Use of a larger panel of 
envelope reactive Mabs would greatly facilitate the antigenic analysis of both 
HeLa and non-HeLa passaged LI and LGT vimses. A small change was
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observed for LGT HeLa p6  virus with respect to the neutralising capabilities 
of Mab C ll. A reduction of 1 log,o in virus neutralisation was observed for 
LGT HeLa p6  virus, however, the virus was still effectively neutralised by Mab 
C ll and the virus remained highly neuropathogenic for adult mice. The 
importance of the epitope recognised by Mab C ll in relation to virus virulence 
may be intrinsic. To test the hypothesis it would be necessary to obtain LGT- 
C ll escape variants. This has been undertaken (Alan Jennings- unpublished 
observations) recently but in each case, the variants were unable to replicate in 
the cell lines used. Virus had entered the cells as evidenced by positive 
reactions with selected envelope protein reactive Mabs. Moreover, the virus 
epitopes being expressed on the cell membrane were non-reactive with Mab C ll 
confirming that the escape variants lacked the epitope recognised by Mab C ll;  
this in contrast to native virus. Therefore, loss the epitope in question appeared 
to limit the replicative ability of the virus. It was interesting to consider why 
HeLa passaged viruses which exhibited a reduced level of reactivity with Mab 
C ll in comparison to their respective parent viruses did not exhibit reduced 
replication? The solution probably lies with the method by which the C ll 
variants were obtained. Obtaining Mab escape mutants by exposing the virus 
population to a particular antibody selects for minor sub-populations which are 
likely to lack the epitope completely. Minor variants such as these occur 
spontaneously during replication and are considered ’dead-end mutants’ in that 
they are usually defective in critical areas of virus replication. The epitope 
recognised by Mab C ll may represent a critical epitope. Selection of C ll  
escape variants by passage in HeLa cells appeared to alter the neutralising site 
on the epitope but not destroy the site completely because Mab C ll still
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recognised an epitope in IIP tests. To determine the role of the epitope 
recognised by C ll in virus virulence, further passaging of LGT HeLa p6  virus 
in HeLa cells may remove C ll reactivity in a similar manner to WNV-Sarawak 
(Chapter 4). If this were the case, assay of LGT HeLa-Cll escape variants in 
virulence studies may corroborate the findings for WNV-Sarawak HeLa p6  virus 
in which loss of C ll reactivity played a role in attenuation of virulence. 
Passage of LI and LGT viruses in HeLa cells removed the HA activity of the 
virus for goose red blood cells. As with previous assays, HA was not detected 
after a single HeLa cell passage suggesting alteration of HA activity after the 
first passage. Unfortunately, calculation of pfu/HA ratios, which determine 
whether sufficient antigen is present, gave conflicting results. Passage of HA 
positive LI virus in HeLa cells reduced the infectivity titre of the virus to low 
levels. The reduction in titre was so great that the pfu/HA ratio determined that 
there was insufficient antigen present to perform the HA test and hence the 
loss of HA on HeLa passage was not conclusive for this virus. In comparison, 
LGT virus replicated to high titres in HeLa cells and calculation of pfu/HA 
ratios revealed the presence of antigen to significant levels thus the HA negative 
result was regarded as authentic. Similar to LI HeLa pi virus, LGT virus was 
also HA negative after the first passage. However, the virus was of too low 
concentration to elicit HA when the pfu/HA ratio was calculated. Therefore, 
loss of HA occurred during the passage series but the point at which this took 
place was dependant on the titre of the virus in order to satisfy the pfii/HA 
ratio. LGT HeLa p3 had a high infectivity titre which allowed confirmation that 
the virus was HA negative. Loss of HA has been documented for ECHO virus 
after passage in a number of human continuous cell lines including HeLa cells
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(Cova and Aymard, 1980). After seven passages in HeLa cells ECHO virus 
type 11 had irreversibly lost HA activity without any alteration in pathogenicity. 
A similar scenario is observed for LI and LOT HeLa p6  viruses, loss of HA 
without change in virulence of the virus or overall stability as suggested by 
thermal stability of the virus at various temperatures. An interesting difference 
between the two sets of data is the reversibility of the HA reaction for 
flaviviruses when HeLa passaged viruses are passaged in other vertebrate cell 
lines. Therefore, in contrast to the situation documented for ECHO virus, which 
implies that a genomic change was responsible for loss of HA activity, a 
conformational change is more likely to be responsible for the loss of HA in 
the flaviviruses.
The results of this Chapter suggest that six passages in HeLa cells does 
not effect the virulence of tick-borne flaviviruses. Therefore, significant 
differences may exist between mosquito and tick-borne flaviviruses governing the 
process of virus/cell interactions. Although this is not apparently due to the 
neurotropic potential of the viruses as YF, WN, LI and LOT viruses are all 
neurotropic in mice.
208
Chapter 7. Virulence of dengue virus infections in mice following treatment 
with sodium aurothiomalate: A model for dengue virus studies.
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7.1 Introduction
Dengue (Den) virus poses as great a threat today as at any time in past 
history. Den virus is an expanding health problem in many tropical regions 
of the world and threatens both residents of endemic areas and its visitors. 
Despite the prevalence of the disease, which is thought to be about 100 million 
cases per year (Sangkawibha et al., 1984), the most effective control of the
virus, and thus disease, is by eradication of the Aedes aegypti mosquito vector.
In tropical regions of Asia, which has the highest dengue endemicity, 
dengue fever is of a more severe nature. In these areas the virus causes a 
rapidly fatal disease, particularly in children, which is known as dengue 
haemorrhagic fever (DHF) or in its most severe form dengue shock syndrome 
(DSS) (Halstead, 1988). Den virus therefore represents a global health problem
and an obvious candidate for production of a vaccine.
Den virus exists as four distinct serotypes (Den 1-4) which can be 
differentiated by plaque reduction neutralisation tests using Den virus specific 
antisera (Russell et al., 1967). The viruses grow in a number of cell lines, 
predominantly those of monkey kidney origin.
A number of live attenuated vaccine candidates have been produced over 
recent years. The first was a vaccine against Den-1 virus which was produced 
by passage of an Hawaiian isolate in mouse brain tissue (Sabin and Schlesinger, 
1945). The vaccine produced little in the way of neutralising antibody but did 
however give protection to volunteers. Recently, vaccine trials in humans has 
involved a derivative (SI) of a Puerto Rican Den-2 isolate (strain PR-159) 
which was isolated from a patient with Den fever. The virus was sequentially
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passaged in primary green monkey kidney cells before a stable clone (Den-2 
PR159/S1) was obtained. The candidate vaccine virus (PR-159/S 1) was 
temperature sensitive, produced uniformally small plaques in cell culture and 
exhibited reduced neurovirulence for mice and monkeys (Eckels et al., 1976; 
Harrison et al., 1977; Eckels et al., 1980). Trials in humans revealed few 
vaccine associated problems but, interestingly, in flavivirus non-immune 
recipients seroconversion rates were low at 61%. If, however, volunteers had 
received YF vaccine previously seroconversion rates of 90% were recorded 
(Scott et al., 1983). The most promising candidate vaccine to date has been 
produced by a group in Thailand (Bhamarapravati, 1987). The virus (Den-2 
16681-PDK53) possesses similar phenotypic characteristics to the SI candidate 
vaccine and has protected human volunteers without side-effects.
Despite the development of vaccine candidates, there is currently too little 
information known concerning the effects of immunisation to a single Den 
serotype with, presumably, incomplete protection sensitising recipients to 
DHF/DSS. As described above, the use of empirical methods has lead to the 
production of live attenuated Den vaccine candidates. Nonetheless, cheaper and 
safer methods of vaccine production will have to be found.
The outstanding problem associated with design of Den vaccines is the 
lack of an effective animal model with which to assay virus virulence. Mice 
have been used in previous investigations but the only data for virus virulence 
was obtained with highly mouse adapted (> 8 0  mouse brain passages) virus 
introduced i.e. into the animal. Multiple passaged virus becomes rapidly adapted 
to cell culture and non-representative of the field isolate and therefore likely to 
be biologically very different to the parent virus. The use of non-laboratory
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adapted virus in conjunction with a sensitive animal model is desired.
7.2 Enhancement o f virus disease by administration o f sodium aurothiomalate
Gold salts have been increasingly used in the treatment of numerous 
arthritic conditions in man. When given either orally or injected, they reduce 
significantly the inflammation associated with such conditions.
CHjCOONa
AuSCHCOONa Sodium aurothiomalate
The compounds appear to impair the function of monocytes and 
macrophages, in particular, phagocytosis is greatly reduced following exposure 
to moderate levels of the salt (Vernon-Roberts, 1979). Treatment of mice with 
large doses of sodium aurothiomalate (SATM) increased their susceptibility to 
infection with a usually avirulent strain of Semliki Forest virus. Increased 
virulence was attributed to an impairment of phagocytosis and degradation of 
the virus by macrophages (Oaten et ah, 1980). Since the work described above 
the use of SATM in enhancing virus infection has been observed for the 
flaviviruses WN and LOT (Mehta and Webb, 1987) and for Coxsackievirus B3 
(Kabiri et al., 1978). Den virus uses the macrophage type cells as its primary 
replication site in many animals (Scott et al., 1980). The lack of susceptibility 
of certain animal models to Den infection may lie in the efficient removal of 
virus by the macrophage. If macrophage function was compromised, thus 
rendering its enzymatic/degradative systems inactive, virus may replicate to high
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titres and manifest disease. In this chapter, the virulence of two Den-2 virus 
isolates was assayed in mice which had received either virus alone or in 
conjunction with SATM.
7.3 Dengue viruses
Two Den-2 virus isolates were used in this study: the prototype virus 
from Papua New Guinea (Den-2 New Guinea C [NGC]) and an isolate from 
Jamaica, strain 1409, (Den-2 Jam). The two viruses represent distinct topotypes 
(geographical serotypes) as determined by T1 oligonucleotide mapping (Trent et 
al., 1983). Figure 7.1 displays the origins of the two virus isolates.
Den-2 NGC virus had been passaged previously in mouse brain tissue and 
was known to be neuroadapted for mice. This isolate was included as a 
reference virus for the titration study in mice. Den-2 Jam virus had received 
few laboratory passages and was likely to be biologically similar to the original 
isolate.
7.4 Experimental work
Both Den-2 NGC and Den-2 Jam viruses were amplified in LLC-MK2 
cells to provide stock viruses for the pathogenicity study. Den virus 
pathogenicity tests were performed in two strains of adult mice for comparison: 
strain TO mice which were of an outbred genotype and strain Balb/C mice
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Figure 7.1
Map of the world showing the geographical origins 
of the dengue viruses used in the study
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which were of an inbred genotype. Mice were inoculated either i.e. or i.p. 
with virus which had been diluted in PBS. The effects of administration of 
SATM on virus virulence was also studied with mice receiving lOO/zl of a 
lOOmg/ml solution of SATM 3hrs prior to virus inoculation. In each case the 
average survival time and pfu/LD^ were calculated and statistical analysis 
performed where possible.
7.5 Pathogenicity o f Den-2 NGC and Den-2 Jam viruses for mice inoculated i.e. 
with or without the presence o f SATM
A comparison was made of the virulence of two Den-2 virus isolates 
following inoculation into adult female TO (outbred genotype) mice in the 
presence or absence of the gold salt SATM. Figures 7.2a and 7.2b display the 
effects of inoculating 10^  pfu of Den-2 NGC virus by the i.e. route. Mice that 
had been treated with SATM three hours prior to virus challenge exhibited a 
more raid onset of disease than non-SATM treated mice. Although all mice in 
both groups died following inoculation, the average survival times were 
statistically different (Table 7.1). Those animals receiving Den-2 NGC virus 
alone died with an AST of 7.54:0.9 days while those animals that were pre­
treated with SATM died with an AST of 5.0+.0.9 days (P< 0.001).
The experiment was repeated with Den-2 Jam virus by inoculation of 10^  
pfu of virus i.e. Figures 7.3a and 7.3b detail the response of the mice to 
inoculation. In a similar manner to the results observed for Den-2 NGC virus, 
adult TO mice inoculated i.e. with Den-2 Jam virus succumbed to a lethal
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Figure 7.2a
Progression of disease in adult TO strain mice following
3
i.e. inoculation with 10 pfu of Den-2 NGC virus.
Each point represents a single mouse.
Figure 7.2b
Progression of disease in SATM treated adult TO strain 
mice following i.e. inoculation with l(f pfu of Den-2 NGC 
virus. Each point represents a single mouse.
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Figure 7.3a
Progression of disease in adult TO strain mice following
3
i.e. inoculation with 10 pfu of Den-2 Jam virus.
Each point represents a single mouse.
Figure 7.3b
Progression of disease in SATM treated adult TO strain 
mice following i.e. inoculation with 10^ pfu of Den-2 Jam 
virus. Each point represents a single mouse.
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infection. Mice that received virus alone died with an AST of 7.0+.1.4 days 
whilst SATM treated mice became sick much earlier and died with an AST of 
5.0Ji0.5 days (p< 0.001) (Table 7.1).
7.6 Pathogenicity o f Den-2 NGC and Den-2 Jam viruses fo r mice inoculated i.p. 
with or without the presence o f SATM
Adult female TO mice (outbred genotype) were inoculated i.p. with W  
pfu of either Den-2 NGC or Den-2 Jam virus and their relative virulence 
compared in mice that had received virus alone or virus plus SATM. A 
comparison of Figure 7.4a and 7.4b reveals that pre-treatment of mice with 
SATM augments infection with Den-2 NGC virus. Mice that were inoculated 
with virus alone died with an AST of 9.6+.0.5 days whereas those mice that 
received virus plus SATM died with an AST of 9.2j+0.4 days, a difference 
that was not significant (P<0.1) (Table 7.1). In comparison to the preceding 
section (section 7.5) in which mice were inoculated i.e. (see Figures 7.2a/b), 
the onset of disease was less marked and appeared more insidious.
Den-2 Jam virus highlighted the effects of pre-treatment of mice with 
SATM (see Figures 7.5a and 7.5b). Animals inoculated i.p. with virus alone 
survived challenge with no mice exhibiting signs of disease or ill-health. SATM 
treated mice inoculated in a similar way became sick and a number of fatalities 
were recorded (3/5 or 60%) (Table 7.1). Statistically, the result obtained 
following treatment of mice with SATM prior to virus challenge was significant 
in a small sample t-test (P < 0.001) (Table 7.1).
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Figure 7.4a
Progression of disease in adult TO strain mice following
4
i.p. inoculation with 10 pfu of Den-2 NGC virus.
Each point represents a single mouse.
Figure 7.4b
Progression of disease in SATM treated adult TO strain 
mice following i.p. inoculation with l(f pfu of Den-2 NGC 
virus. Each point represents a single mouse.
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Figure 7.5a
Progression of disease in adult TO strain mice following
4
i.p. inoculation with 10 pfu of Den-2 Jam virus.
Each point represents a single mouse.
Figure 7.5b
Progression of disease in SATM treated adult TO strain 
mice following i.p. inoculation with 10'* pfu of Den-2 Jam 
virus. Each point represents a single mouse.
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7.7 Effects o f i.e. inoculation o f Balb/C mice with Den-2 NGC with or without 
the presence o f SATM
Adult male Balb/C mice (inbred genotype) were inoculated i.e. with 10^  
pfu of Den-2 NGC virus with or without treatment of mice three hours prior 
to virus infection with SATM. Figures 7.6a and 7.6b display the outcome of 
infection with Den-2 NGC virus. SATM treated animals, as in previous 
experiments, displayed a rapid appearence of disease when compared to mice 
inoculated with virus alone. None of the mice survived i.e. challenge with Den- 
2 NGC virus. Table 7.2 shows a significant difference in the AST of the study 
groups; non-SATM mice possessing an AST of 9.1+.0.9 days and SATM 
treated mice a figure of 5.3+.0.7 days (P < 0.001).
7.8 Effects o f i.p. inoculation o f Balb/C mice with Den-2 NGC virus with or 
without the presence o f SATM
The majority of the mice (adult male Balb/C) inoculated i.p. with Den- 
2 NGC virus alone survived infection (40% mortality) (Table 7.2). However, 
when mice had been inoculated with SATM before introduction of virus i.p., 
all mice in the study group succumbed to disease (Figures 7.7a and 7.7b). The 
data in Table 7.2 shows a greatly reduced AST (10.14:0.7 days) that is 
attributable to the administration of SATM. The mortality rate (100%) associated 
with the i.p. inoculation of SATM treated mice with Den-2 NGC virus was 
significant with p <  0.001 (Table 7.2).
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Figure 7.6a
Progression of disease in adult Balb/C strain mice following
3
i.e. inoculation with 10 pfu of Den-2 NGC virus.
Each point represents a single mouse.
Figure 7.6b
Progression of disease in SATM treated adult Balb/C strain 
mice following i.e. inoculation with 10  ^pfu of Den-2 NGC 
virus. Each point represents a single mouse.
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Figure 7.7a
Progression of disease in adult Balb/C strain mice following
4
i.p. inoculation with 10 pfu of Den-2 NGC virus.
Each point represents a single mouse.
Figure 7.7b
Progression of disease in SATM treated adult Balb/C strain 
mice following i.p. inoculation with lO'* pfu of Den-2 NGC 
virus. Each point represents a single mouse.
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7.9 The effects o f SATM on control mice
For each group of experiments the appropriate controls were set up. This 
involved the inoculation of mice i.p. with SATM alone followed by either i.e. 
or i.p. inoculation of PBS. SATM was observed to have an effect on the 
appearance of the mice as early as day 3 post-inoculation. The effects were 
manifested by lethargy of the mouse accompanied by a characteristic ruffling 
of the fur and diminished peritoneal cavity. At no time were there any deaths 
or paralysis attributed to inoculation of SATM (Tables 7.1 and 7.2).
7.10 Determination o f the pfu/LDso o f Den-2 NGC and Den-2 Jam viruses for  
TO mice in the presence or absence o f SATM
Previous work in this Chapter has demonstrated that outbred TO mice 
were susceptible to disease when inoculated with Den-2 virus. The outbred 
strain of mouse exhibited greater susceptibility to disease than did the inbred 
Balb/C mice. Therefore, the strain of choice for determining virulence was the 
outbred strain TO mouse. The outbred TO mice used in the study were 
younger adults than those used in earlier experiments ( 2 1  days old as opposed 
to 35-40 days old). Mice inoculated with Den-2 Jam virus were pre-treated with 
SATM prior to virus challenge because virus inoculated alone i.p. was avirulent 
(Table 7.1). The results showed a marked difference in the pfu/LDgo between 
the viruses (Table 7.3). Den-2 NGC inoculated i.p. into non-SATM treated 
young adult TO mice killed the animals with an AST of 9.2+.0.4 days.
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Table 7.3 Lethality of Den-2 NGC and Den-2 Jam viruses for adult 
TO mice
Virus
Route of 
inoculation
+/-
SATM AST* Log,„pf“/LD5û
Den-2 NGC i.p. _ 9.2+0.4 4.8
i.p. + 8.9+0.7 4.2
Den-2 Jam i.p. — No deaths ^7.0
i.p. + 15.6+0.7 6.1
* AST Average survival time + SEM 
NA Not applicable
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Calculation of the pfu/LDgq revealed the virus to be significantly virulent by 
the i.p. route with a logiopfu/LDjo of 4.8. Animals that had been treated with 
SATM had a lower AST than non-SATM treated mice producing a figure of 
8.9+.0.7 days. The logiopfu/LDjo of 4.2 was not much lower than the figure 
obtained for inoculation of non-SATM treated mice. In comparison, Den-2 Jam 
virus was of a lower virulence when inoculated i.p. as determined by the 
pfu/LDjo. Following inoculation of 10'* pfti of virus alone i.p. into young adult 
mice, there was no clinical sign of infection. Mice that were treated with 
SATM, however, gave results which confirmed earlier work (see Section 7.6). 
The AST obtained of 14.8±.0.7 days was comparable to the figure of 15.6+.0.7 
for older TO mice. The log,opfu/LDjo of 6.1 suggested the virus possessed 
relatively low virulence for mice when inoculated by the i.p. route.
7.11 Discussion
Den viruses are a major cause of morbidity and mortality in many parts 
of the world (Halstead, 1988). To date there is no commercially available 
vaccine with which to control the disease. Development of Den vaccines is 
fraught with problems, a number of which may be overcome if there was an 
effective animal model available to study virus pathogenesis.
The data presented in this Chapter indicates that the mouse can provide 
a model for the assay of Den virus virulence without prior adaptation of the 
virus by multiple passages in the laboratory.
Two isolates of Den-2 virus were analysed, namely the prototype strain
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New Guinea C, and strain 1409 from Jamaica. Den-2 NGC virus was a mouse 
adapted isolate whereas Den-2 Jam virus had received few laboratory passages 
and was thought more likely to represent the original isolate. Inbred and 
outbred mice were used as previous work has demonstrated that resistance to 
flavivirus disease can be mediated by a single allele (Webster, 1933; Sab in, 
1952; Brinton, 1973).
Adult mice inoculated i.e. with either virus died rapidly with AST’s of 
approximately 7 days. However, when Den-2 NGC was introduced by the same 
route in adult Balb/C mice, an AST of 9 days was recorded. Den-2 Jam was 
not inoculated into Balb/C mice in this study. Inoculation of virus by the i.p. 
route resulted in a number of different outcomes depending on the virus and 
species of mouse. Inoculation of W  pfu of Den-2 NGC virus i.p. into adult 
TO mice showed the virus to be virulent with 80% of mice succumbing to a 
lethal infection. The same virus when inoculated into adult Balb/C mice 
however resulted in two sporadic deaths which were not statistically significant. 
The differences in susceptibility of the two strains of mice is interesting. The 
inbred Balb/C strain, in which there is a defined genotype, exhibited a marked 
degree of resistance to virus challenge in comparison to the outbred TO strain 
(mixed genotype). Whether the difference is due to resistance genes in the 
Balb/C genome is unknown but recent data with JE virus suggests that if such 
genes- are present they may play an important role (Miura et al., 1990). 
Inoculation of 10'* pfu of Den-2 Jam virus i.p. into mice resulted in sickness 
before recovery and 1 0 0 % survival of the mice, the virus therefore appearing 
to cause infection but non-lethal. The above result is in standing with 
observations made with other Den-2 viruses (Boonpucknavig et al., 1981). These
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workers were unable to demonstrate disease symptoms in Swiss outbred mice 
which were inoculated i.p. with Den-2 NGC. The reason for the differences 
observed with the results for the Den-2 NGC virus in this study certainly 
represents prior adaptation of Den-2 NGC virus for mice. Importantly, even 
though the virus isolates may be of different passage levels, numerous sub- 
types of Den-2 NGC are known to exist. However, the most plausible reason 
revolves around the type of mouse used in the study. This Chapter describes 
the first use of outbred TO mice for the study of Den virus virulence, a 
species of mouse which AST data has suggested has a greater susceptibility to 
Den virus infection.
Enhancement of virus disease has been shown for a number of viruses 
following pre-treatment of mice with the gold salt SATM (Mehta and Webb, 
1987). SATM is believed to alter the normal functions of the macrophage type 
cells thus allowing virus replication and dissemination. Experiments were 
therefore devised to determine the effects of pre-treatment of mice with SATM 
to subsequent challenge with Den-2 NGC and Den-2 Jam viruses.
Previous pathogenicity experiments were repeated with the mice being 
challenged with SATM three hours before either i.e. or i.p. inoculation of 
virus. Pre-treatment of mice with the gold salt had dramatic effects on virus 
virulence. Mice which were inoculated i.e. with 10^  pfii of either Den-2 NGC 
or Den-2 Jam viruses died much faster than had been previously observed, in 
most cases between two to three days earlier. Importantly, however,was the 
effects of SATM treatment on virus inoculated by the i.p. route. Balb/C mice 
which were resistant to 10" pfu of Den-2 NGC in earlier experiments died 
following challenge with a similar dose of virus (AST of 10 days). Outbred
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TO strain mice inoculated with SATM prior to i.p. challenge with 10" pfu of 
Den-2 Jam virus also died in contrast to non-SATM treated mice (AST of 15 
days). Treatment of mice with SATM had rendered a usually avirulent Den 
infection virulent with virus replication obviously being enhanced and 
manifesting itself in paralysis and death of the animals. Statistical analyses 
revealed a high degree of significance attributed to the results P <  0.001. 
Pre-treatment of mice with SATM did not apparently debilitate the control mice 
in any way.
Titration of the viruses to determine their lethality was undertaken with 
mice being inoculated by the i.p. route. Challenge of mice by the i.p. route 
was undertaken because Den virus produces a disease which is classically 
associated with peripheral/non-neurotropic infection. Moreover, studies in this 
Chapter have shown that both Den-2 NGC and Den-2 Jam viruses are highly 
virulent when inoculated directly into the brain, hence data obtained by i.e. 
inoculation could be misleading, this being particularly so for the mouse adapted 
Den-2 NGC strain. Den-2 NGC virus showed a high peripheral pathogenicity 
when inoculated by the i.p. route with a logiopfu/LDjo of 4.8. Mice became 
sick shortly after inoculation with disease progression illustrated by neurological 
involvement; the appearence of hind limb paralysis prior to total paralysis and 
death with an AST of 9.2 days. SATM did not enhance appreciably the 
virulence of Den-2 NGC virus (log,(,pfu/LDjo of 4.2) following i.p. inoculation. 
Den-2 Jam virus showed low peripheral virulence for mice when inoculated by 
the i.p. route with all mice in the study group surviving challenge with 1 0 " pfu 
of virus. Treated mice that received Den-2 Jam i.p. exhibited a slow 
progression of disease with an AST of 14.8 days. A low level of virulence
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was recorded for the virus (logiopfii/LDjo of 6 . 1 ) in comparison to mouse 
adapted Den-2 NGC virus (logiopfu/LD^ of 4.2). It was interesting to note 
that the pfu/LDjo value for Den-2 Jam was only obtained if mice had been 
treated with SATM thus impairing the mouse immune system. The results 
provided a number of unique observations. First, there are large differences in 
the virulence of the Den-2 isolates when compared in mice. This may reflect 
fondamental differences in pathogenicity that exist between topotypes of Den 
virus although Den-2 NGC virus was known to be neurovirulent for mice. Den- 
2 NGC virus is highly virulent for adult TO mice when inoculated either i.e. 
or i.p. Den-2 Jam virus in comparison has high virulence i.e. but low 
peripheral virulence with mice only succumbing to disease i.p. if the mouse 
immune system had been compromised. Second, the AST data shows that both 
Den-2 NGC and Den-2 Jam viruses have a neurotropic disease pattern in TO 
mice, animals have a greatly reduced AST when inoculated by the i.e. route. 
Treatment with SATM enhanced the rapidity at which symptoms occurred or 
in the case of Den-2 Jam virus inoculated i.p., produced the first symptoms of 
disease which progressed in a paralytic fashion.
The mechanism by which SATM enhances the virulence of certain viruses 
is not folly understood. Allner et al. (1974) and Oaten et al. (1980) suggested 
that the inhibition of lysosomal enzyme action by SATM in peritoneal 
macrophages may play an important role. Inhibition of macrophage fonction 
could be particularly pertinent for the increase in Den virus virulence following 
SATM treatment of mice as macrophages and macrophage like cells are known 
to be important in the virus replication cycle (Boonpucknavig et al., 1976). 
This point is highlighted by the enhancement of infection of adult Balb/C mice
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inoculated i.p. with Den-2 NGC virus. Inbred adult Balb/C mice seem to 
possess a greater resistance to infection with Den virus than does the adult 
outbred TO strain of mouse used in this study as evidenced by the AST data. 
Darnell and Koprowski (1974), discovered that macrophages from resistant mice 
do not support flavivirus infection and replication as well as macrophages from 
a susceptible mouse strain. Reversal of the i.p. inoculation of Balb/C mice with 
Den-2 NGC virus from avirulent to virulent may suggest that even macrophages 
from ’resistant’ strains of mice can support Den virus replication following 
inactivation of macrophage degradative pathways. This point requires further 
investigation
SATM when used in a therapeutic manner in humans reduces the 
immunoglobulin (Ig) output by B-cells which in certain circumstances results in 
hypogammaglobulinaemia (So et al., 1984). Thus alteration of macrophage 
function may represent only a small part of the overall effect of SATM 
treatment. However, although SATM reduces the reaction of B-cells to mitogen 
stimulation in vitro in the mouse model, there is no detectable changes in the 
levels of antibody production (Alexander, 1984). Important to this study, it has 
been shown that virus enhanced infection using SATM is not associated with 
a reduction in circulating antibody levels in the mouse (Allner et al., 1974). 
Given this, antibody should be produced following challenge with Den virus and 
be available to react in the normal fashion despite the presence of SATM. This 
raises a number of very interesting questions, the most important of which 
concerns the Fc mediated entry of virus into Fc receptor bearing cells. 
Antibody/antigen complexes are often removed from circulation by the binding 
of the Fc portion of the antibody to a receptor present on certain cell types.
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Macrophages possess such a receptor and once the complex has been 
internalised, degradation of the complex usually takes place. Fc mediated entry 
into macrophages has been suggested to be responsible for the severe DHF/DSS 
observed in some Den infections (Halstead, 1988). In this study, it would be 
expected therefore, that following challenge of mice with Den virus a normal 
antibody response would be mounted. Entry of virus into the preferred site of 
replication, the macrophage, would be by a combination of virus/cell interaction 
and Fc mediated entry. If the mouse has been treated with SATM the normal 
macrophage function will be negated thus allowing the replication of Den virus 
to high titres. Further work will be required to confirm the findings, including 
a detailed analyses of sites of replication of virus and the titres of virus in 
circulation and major organs to determine the probable mode of disease.
The data presented in this Chapter is unique in that titration of Den virus 
has been achieved by i.p. inoculation of adult TO strain mice. The value of 
SATM treatment of mice in initiating infection has been instrumental to the 
work. One of the most pressing of problems in Den virus research is to 
determine the process of DHF/DSS. It may be possible given the earlier 
arguments to treat primates with SATM prior to challenge experiments with the 
hope of initiating a disease pattern similar to that in human cases. The use of 
such a chemical though, will undoubtedly have far reaching effects for the 
study of viruses which are major pathogens of man but to which there is no 
animal model to study pathogenesis. Hopefully, this study will provide a simple 
and convenient method for the study of Den virus pathogenesis and Den virus 
vaccine candidates.
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Chapter 8. Passage of Dengue virus strain New Guinea C through HeLa cells.
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8.0 Introduction
Control of dengue (Den) fever is limited, at the present time, to 
supportive therapy of infected individuals because no effective prophylactic 
measures are available. Prevention of Den epidemics relies largely on the 
eradication of Aedes aegypti (the principal mosquito vector) breeding sites by 
the use of insecticides (Halstead, 1988). Testing of putative Den virus vaccines 
has most often involved human subjects because there are no effective animal 
models available for vaccine trials (Innis et al., 1988). Cloned vaccine 
candidates are sometimes assayed in primates for viraemia and central nervous 
system infiltration and subsequent lesion score; any virus exhibiting 
neurovirulence is considered a failure. Selection of candidate Den virus vaccines 
is a complex process. Phenotypic markers thought to be associated with 
attenuation of Den virus included small plaque morphology, temperature 
sensitivity and low peripheral virulence in monkeys (Bhamarapravati et al., 
1987). A number of putative vaccines possessing the above characteristics have 
been tested in man with some success (Stephenson, 1988). However, the use 
of temperature sensitivity and small plaque morphology as markers of attenuation 
has not proven reliable (Innis et al., 1988; Marchette et al., 1990). Empirical 
derivation of vaccines which has been used to date is not an ideal method 
because of possible over-attenuation of the virus, selection of mutants with a 
high reversion frequency not to mention the time consuming process of cloning 
and amplification that is required. Therefore, Den-2 NGC virus was passaged 
in HeLa cells in an attempt to attenuate the virus. In the previous Chapter, an 
animal model was developed to assay the virulence of adapted and non-adapted
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Den virus. This Chapter describes the effects of six HeLa cell passages on the 
phenotype and virulence of neuroadapted Den-2 NGC virus for mice.
8.2 Virus
The prototype Den-2 virus strain New Guinea C (Den-2 NGC) was used 
in this study. As shown in Chapter 7, the virus possesses a high degree of 
neurovirulence as determined by differences in the AST for virus inoculated i.e. 
and i.p. (7.0 days and 9.6 days respectively). Den-2 NGC lethality was 
calculated for virus inoculated i.p. in adult female TO mice (log,opfu/LD^ of 
4.8). The virulence of Den-2 NGC virus was greater than that for Den-2 Jam 
virus and would hopefully highlight small changes in virulence more effectively.
8.3 Experimental work
Den-2 NGC virus (identical stock to the virus use in Chapter 7) was 
passaged six times in HeLa cells at an m.o.i. between one and five. The 
passage characteristics of the virus were noted for each passage and virus 
infectivity determined by plaque assay on LLC-MK2 cells and TCID5 0  on HeLa 
cell monolayers. Virus was then assayed for phenotypic characteristics in a 
similar manner to earlier Chapters and virus virulence calculated using the Den 
virus mouse model described in Chapter 7.
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8.4 Passage o f Den-2 NGC virus in HeLa cells
Plaque purified Den-2 NGC virus was amplified in LLC-MK2 cells 
subsequent to six passages in HeLa cells. Virus was inoculated onto 
subconfluent HeLa cell monolayers at an m.o.i. of between one and five and 
virus harvested on or before day three post-infection depending on the degree 
of cpe.
Rapid appearence of cpe on HeLa cells was observed following two 
passages, the cell monolayer being completely destroyed in 24 hours. Table 8.1 
shows the passage characteristics of Den-2 NGC virus following passage in 
HeLa cells. Cpe was observed at each passage with virus infectivity titre 
increasing after each subsequent passage as determined by plaque assay on LLC- 
MK2 cells. The parent non-HeLa passaged virus displayed a small plaque 
morphology on LLC-MK2 cells with plaques becoming visible after five to six 
days incubation at 37°C. In comparison, Den-2 NGC HeLa p6  virus displayed 
a large plaque morphology with plaques appearing after 24 hours incubation at 
37°C. Moreover, the large plaque virus was predominant after a single HeLa 
cell passage and represented 100% of the population after two HeLa cell 
passages. When parent non-HeLa passaged virus was titrated simultaneously on 
HeLa and LLC-MK2 cell monolayers, there was a 0.9 log,o reduction in 
infectivity titre on HeLa cells which represents a near 90% loss of plaquing 
efficiency and/or virus infectivity for that cell line in comparison to LLC-MK2 
cells (Table 8.2). The experiment was repeated with Den-2 NGC HeLa p6  virus 
but there was no difi e^rence in infectivity titre of the virus whether grown in 
HeLa or LLC-MK2 cells (Table 8.2).
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Table 8.1 Effects of HeLa cell passage on Den-2 NGC virus
HeLa cell passage
Virus 0 1 2 3 4 5 6
Den-2 NGC 
CPE" + + + + + + +
Plaque morphology * SP SP/LP LP LP LP LP LP
Log^^pfu/ml# 5.0 43 7.1 8 . 0 8 . 0 & 1 8 . 0
LogJCID^M # 5.0 5.0 7.0 8 . 0 8 . 0 8 . 0 8 . 0
Positive cpe : + Negative cpe -
* Plaque morphology: SP- small plaque, LP- large plaque
#  Plaque assays were performed on LLC-MK2 and TCID  ^on HeLa cell 
monolayers.
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Table 8.2 Differences in infectivity titre of Den-2 NGC virus when 
assayed in HeLa and LLC-MK2 cells
Virus Cell line CPE
Plaque
morphology#
Infectivity
titre*
Den-2 NGC pO LLC-MK2 + SP 5.2
HeLa + SP/LP 43
Den-2 NGC p6 LLC-MK2 + LP 8 . 1
HeLa + LP 8 . 1
#  Plaque morphology: SP- small plaque, LP- large plaque
* Infectivity titre expressed as log^ p^fu/ml
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8.5 Virulence o f Den-2 NGC for adult TO mice following passage in HeLa cells
The results described in this section analyse the virulence of HeLa and 
non-HeLa passaged Den-2 NGC virus for adult TO mice in the presence of 
SATM. Both HeLa and non-HeLa passaged viruses were diluted in PBS prior 
to inoculation of mice i.p. which had received SATM three hours previously. 
The mice were observed for 21 days after which time the AST and pfu/LDgo 
were calculated.
Parent non-HeLa passaged Den-2 NGC virus had been shown to be 
virulent for TO mice following i.p. inoculation with an AST of 9.4 days and 
a logio pfu/LDgo of 4.8 (see Table 7.3). When the experiment was repeated with 
SATM treated animals, the AST and log,o pfti/LDjo remained largely unchanged 
with figures of 9.2 days and 4.2 respectively (Table 8.3). Therefore, SATM 
had not appreciably altered pathogenicity of Den-2 NGC virus inoculated i.p. 
Inoculation of adult TO mice to determine the virulence of Den-2 NGC HeLa 
p6  virus involved SATM treated mice alone. Inoculation of non-SATM treated 
mice with only one dose of HeLa passaged Den-2 NGC virus allowed 
calculation of the AST alone (Table 8.3). Non-SATM treated mice died 
following i.p. inoculation of 10" pfu of Den-2 NGC HeLa p6  virus with an 
AST of 8.0 days. This figure was lower than had previously been recorded for 
Den-2 NGC inoculated animals and suggested the virus to be of enhanced 
virulence (Table 8.3). However, the mice were slightly younger than in the 
previous Chapter at 21 days old in comparison to 35-40 days old. SATM 
treated mice inoculated i.p. died rapidly with paralytic manifestations. Figures 
8.1a and 8.1b show the differences in disease pattern for SATM and
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Figure 8.1a
Progression of disease in adult TO strain mice following
4
inoculation i.p. with 10 pfu of Den-2 NGC HeLa p6  virus. 
Each point represents a single mouse.
Figure 8.1b
Progression of disease in SATM treated adult TO strain mice 
following inoculation i.p. with lO"^  pfu of Den-2 NGC HeLa p6  virus. 
Each point represents a single mouse.
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non-SATM treated mice receiving HeLa passaged Den-2 NGC virus at a 
concentration of 10" pfu. Calculation of the pfu/LD^q for HeLa passaged virus 
revealed a figure of 3.8 which was nearly equivalent to the non-HeLa passaged 
virus, the virus remaining as lethal as the parent virus after six passages in 
HeLa cells.
8 . 6  Haemagglutination (HA) o f goose red blood cells by HeLa and non-HeLa 
passaged Den-2 NGC virus
Non-HeLa passaged Den-2 NGC virus agglutinated a standardised solution 
of goose red blood cells at pH 6.4 and room temperature. The assay was 
performed with LLC-MK2 derived virus at an infectivity titre of 10^  pfu/ml 
which yielded a HA titre 2560 HA units per/ml (128 HAU for a 50/d test 
volume) (Table 8.4). In comparison, Den-2 NGC HeLa p6  virus was unable to 
agglutinate the standardised goose red blood cells. The HA test was performed 
at a variety of pH values with virus possessing an infectivity titre of 10* 
pfu/ml as determined by LLC-MK2 plaque assay; therefore loss of HA activity 
did not appear to be due to the presence of too little antigen. Log,opfti/HA 
ratios of 1.8 and >5.3  for non-HeLa and HeLa passaged Den-2 NGC viruses 
respectively confirmed that loss of HA activity following HeLa cell passage 
was genuine. The intermediate HeLa passages were also assayed for HA at a 
number of different pH values with standardised goose red blood cells. HA was 
not observed after the first HeLa cell passage, however, the pfti/HA ratio 
implied that there was insufficient antigen present in the preparation to validate
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Table 8.4 Effects of HeLa cell passage on the HA activity of
Den-2 NGC virus
Virus
HeLa
passage
Infectivity
titre#
HAunits "  
goose human
pfu/HA
ratio*
Den-2 NGC pO 5.0 128 C2 1.8
pi 43 >2 <2 ^0.8
p2 7.1 <2 <2 M 3
P3 8.0 <2 <2 >53
P4 8.0 <2 C2 >53
P5 8.0 <2 <2 >53
p6 8.0 <2 < 2 >53
Influenza A — nt >1024 >1024 —
#  Infectivity titre determined by LLC-MK2 plaque assay and expressed 
as log^^fu/ml.
"  HA units per 50ul test volume.
#  pfu/HA ratio expressed as log^  ^
nt: not tested
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the observation (log,opfu/HA ratio of > 0 . 8  which is below the figure of 1 . 8  
obtained for the HA positive parent virus) (Table 8.4). Human red blood cells 
were also used in the study to examine whether a change in specificity for red 
cell type had taken place during passage in HeLa cells. Influenza type A virus 
was included as a positive control virus for the assay which agglutinated the 
human red blood cells with a titre of >1024 at 4°C. At no time was 
agglutination of human red blood cells noted for HeLa or non-HeLa passaged 
Den-2 NGC virus.
8.7 Effects on HA ability o f Den-2 NGC HeLa p6  virus following passage in 
SW13, LLC-MK2 or Vero cells
HA negative Den-2 NGC HeLa p6  virus was passaged three times in 
SW13, LLC-MK2 or Vero cell monolayers to discover whether or not passage 
would reverse the HA activity of the virus. Previous Chapters have 
demonstrated that following passage of HA negative HeLa cell passaged virus 
in SW13 and LLC-MK2 cells restored HA activity to the virus. Den-2 NGC 
HeLa p6  virus was passaged in the different vertebrate cell lines at an m.o.i. 
of between 0.1 and 1.0 for three consecutive passages before HA tests and 
infectivity titres of the viruses were determined. Passage of the HeLa p6  virus 
was accompanied with the appearence of cpe in all three cell lines, however, 
the rapidity at which cpe occurred was found to vary. Den-2 NGC HeLa p6  
virus grown in Vero cells, led to total destruction of the monolayer 24 hours 
post-infection which was similar to passaging virus in HeLa cells. A similar
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virus preparation which was grown in SW13 or LLC-MK2 cells gave a delayed 
cpe which appeared between 36 and 48 hours post-infection. The infectivity 
titres of the viruses were equivalent at approximately 1 0 * pfu/ml and all 
possessed large plaque morphologies. Virus passaged three times in SW13 or 
LLC-MK2 cells was positive in HA tests with goose red blood cells (HA titres 
of 128 per/50/il each) whilst Vero cell grown virus remained negative (Table
8.5). Estimation of the pfu/HA ratio for Vero cell passaged Den-2 NGC HeLa 
p6  virus revealed that ample virus was present to make the test viable (Table
8.5). Plaque purified Den-2 NGC HeLa p6  virus was also passaged in the three 
different vertebrate cell lines as a precaution against selection of HA positive 
variants from the HeLa p6  population. Plaque purified and HeLa cell amplified 
virus gave comparable results to the HeLa p6  whole population after passage 
in the three vertebrate cell lines. HA activity was restored to virus that had 
been passaged in SW13 and LLC-MK2 cells (HA titres of 128 and 64 per/50jitl 
respectively) but not for Vero cell passaged virus which remained negative 
(Table 8.5).
8 . 8  Temperature sensitivity (ts) o f HeLa and non-HeLa cell passaged Den-2 NGC 
virus
Temperature sensitivity (ts) has often been used as a phenotypic marker 
for Den virus attenuation. HeLa and non-HeLa passaged viruses were assayed 
for ts by incubating virus on LLC-MK2 plaque assays plates at 31, 35, 37 and 
39.5°C. Parent non-HeLa passaged Den-2 NGC virus was not ts as evidenced
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Table 8.5 Haemagglutination activity of Den-2 NGC HeLa p6 virus following 
passage in SW13, LLC-MK2 or Vero cells
cell
Virus passage
Infectivity
titre#
HA units "  
goose human
pfu/HA
ratio*
Den-2 NGC pO 5.0 128 <2 1.8
p6 8.0 <2 C2 >53
p6 + 3xSW13 7.8 128 <2 43
p6 + 3x LLC-MK2 8.0 128 <2 4.2
p6 + 3x Vero 8.0 <2 <2 >53
pp p6 + 3xSW13 7.1 128 <2 3.5
pp p6 + 3x LLC-MK2 73 64 <2 3.3
pp p6 + 3x Vero 7.1 <2 <2 >4.4
#  Infectivity titre determined by LLC-MK2 plaque assay and expressed as log pfu/ml.
"  HA units per 50ul test volume. 
* pfu/HA ratio expressed as log
10
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Table 8.6 Temperature sensitivity (ts) of Den-2 NGC virus following passage in 
HeLa cells
Temperature (°C)
Virus 31 35 37 39.5 e.o.p.#
Den-2 NGC pO 4.8* 5.0 5.0 4.7 0.50
pi 3.9 4.4 4.4 4.0 0..40
p2 7.0 7.0 7.0 5.9 0.08
p3 7.4 8.0 8.1 <1.0 >10'^
p4 8.0 8.0 83 <1.0 >10'^
P5 8.1 7.8 8.0 <1.0 >10'^
p6 8.0 8.4 8.1 <1.0 >10’^
* LogjQ pfu/ml as determined by LLC-MK2 plaque assay
#  Efficiency of plating 39.5/37 °C
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by the ability of the virus to replicate throughout the temperature range (Table
8 .6 ). The efficiency of plating (e.o.p.) was calculated and confirmed the 
observed result. Den-2 NGC HeLa p6  virus replicated efficiently at the lower 
temperatures but was found to be completely restricted at 39.5°C with no 
plaques detectable after eight days incubation (Table 8 .6 ). Intermediate HeLa cell 
passages of Den-2 NGC virus were tested for restricted growth in a similar 
manner with the result that ts occurred between HeLa cell passages two and 
three (Table 8 .6 ).
8.9 Discussion
Dengue virus (Den) will continue to cause major epidemics worldwide 
until a safe and efficacious vaccine becomes available to control the disease. 
Testing of numerous candidate vaccines has been undertaken with some success, 
however, the vaccines are not for use commercially. A number of problems 
have arisen during the process of obtaining putative attenuated Den virus 
vaccines one of which appears to be the reliance of researchers to look for 
phenotypic markers of attenuation. The use of virus exhibiting ts and small 
plaque morphology have often been used (Eckels et al., 1976; Halstead et al., 
1984; Innis et al., 1988). Unfortunately, recent evidence has highlighted the 
unreliability of these markers with a number of reversions taking place during 
vaccine trials despite the virus still maintaining the markers (Innis et al., 1988). 
Derivation of the vaccines by traditional empirical methods has often led to 
high genetic instability of the virus and because of cloning minor populations
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there is an absence of gradual changes in biological markers that are 
characterised in uncloned viruses at different passage levels. Further studies 
concerning the derivation of attenuated Den viruses would be of great use, 
moreover the use of novel methods for assaying virus attenuation and virulence. 
Therefore, Den virus was passaged six times in HeLa cells with the hope of 
producing an attenuated variant that possessed phenotypic markers for attenuation 
combined with some degree of virus stability.
Following six passages in HeLa cells, the neuroadapted prototype Den-2 
virus, strain New Guinea C (Den-2 NGC), exhibited the characteristics of a 
HeLa cell adapted virus; including enhanced replicative ability (shorter 
replication time and increased infectivity titres) and large plaque morphology. 
The appearence of large plaques after HeLa cell passage was in contrast to the 
small plaque morphology of the parent non-HeLa passaged virus. Eckels et al., 
(1976) noted a failure to consistently isolate large plaque clones from the Den- 
2 vaccine candidate PR159/S1. They suggested that this was due to a high 
frequency mutation from large plaque to a mixture of small and medium 
plaques and that a lower frequency of mutation occurred from small plaque to 
large plaque reversion. The large plaque virus obtained after HeLa cell passage 
appeared relatively stable as the large plaque morphology prevailed after 
passaging in other vertebrate SW13, LLC-MK2 and Vero cell lines. Assay of 
HeLa passaged virus for phenotypic markers that have been previously used for 
Den vaccine trials revealed that the virus at HeLa p6  was restricted for growth 
at 39.5°C. Replication of the virus was completely ’shut-off at the super- 
optimal temperature which was similar to an observation made for a Den-3 
vaccine candidate (Den-3 CH53489 clone 24/28) (Innis et al., 1988). It was
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surprising to discover that six passages in HeLa cells Den-2 NGC virus 
possessed one of the ’attenuating’ biological markers used by many researchers. 
Initiation of virulence studies in mice was conducted in an optimistic manner 
with the sensitive TO strain of mouse being used to assay virus infectivity. 
Unfortunately, the virus remained as virulent as the parent virus following six 
passages in HeLa cells. There was a reduced AST observed for SATM treated 
mice inoculated i.p. with the HeLa passaged virus (6 . 8  days) in comparison to 
the parent non-HeLa passaged virus inoculated by the same route (8.9 days). 
The HeLa passaged virus therefore exhibited an enhanced neurotropism which 
could not be attributable solely to the presence of SATM because there was no 
observed enhancement of infection with the parent virus. Therefore, similar to 
the data of Innis et al., (1988), a Den virus which exhibited ts had proved to 
be virulent and thus use of such a biological marker of attenuation must be in 
doubt. Alternatively, ts and neurotropism may be separate biological phenotypes 
coded for by different nucleotide sequence(s).It is not known whether the virus 
present in the mouse brain had maintained the ts marker and it will be 
necessary to assay this virus to determine whether a reversion to wild type has 
taken place via host cell adaptation. It appears likely that the stability of such 
changes must be low considering that only six passages in HeLa cells have 
generated the mutant. Whether the mutant arose by genetic change or mere 
selection from the parent population is open to discussion. Passaging the parent 
Den-2 NGC virus once in HeLa cells led to a near 90% reduction in 
infectivity which high selection procedure. Thereafter, consecutive passages has 
lead to the amplification of the mutant with apparent accruing of ts by HeLa 
passage three. The gradual reduction in e.o.p. points to selection and
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amplification of a specific mutant which has enhanced replicative abilities and 
forms large stable plaques. It may be that Den vaccine failures may have been 
attributable to the presence of large plaque revertants in small plaque virus 
vaccine preparations. Indeed, it has been documented that revertants isolated 
from human blood exhibited large plaque morphology (Eckels et al., 1976).
Loss of HA activity for goose red cells was noted following passage in 
HeLa cells. Loss of HA probably occurred after a single HeLa cell passage but 
because the pfu/HA ratio was low this cannot be assumed with any certainty. 
HA was definitely absent after three passages in HeLa cells and was absent 
at HeLa passage six. Therefore, in a similar manner to previous Chapters, 
HeLa cell passage removes HA activity but not permanently as evidenced by 
regaining the biological activity if virus is passaged in SW13 or LLC-MK2 
cells. The loss of HA by HeLa cell passage therefore probably represents a 
conformational change in the envelope protein and not a genetic modification 
which was observed for HeLa cell passaged Echovirus (Cova and Aymard, 
1980). The reason for differences in host cell modification of this activity is 
unknown at present but may lie in the processing of virus by the cell and 
more importantly the host cell modifications that take place.
Analysis of the envelope protein of HeLa and non-HeLa passaged Den- 
2 NGC virus by Mabs was not undertaken due to the lack of Den reactive 
antibodies. HeLa cell passage of flaviviruses has been shown to be accompanied 
by changes at the epitope level some of which may play a role in loss of 
virulence. It is open to speculation as to whether changes will have taken place 
following HeLa cell passage of Den-2 NGC virus but because the virus has 
remained virulent a study would be purely academic.
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The results presented here concerned a single isolate of Den virus and 
in no way represents the reactivities of Den viruses as a group. Den viruses 
represent a very diverse group within the Flaviviridae with four distinct 
serotypes existing. It would be interesting to assay the effects of HeLa cell 
passage on other isolates of Den virus which differ from each other in 
topotype, serotype and pathogenicity. Den-2 Jam virus which had demonstrable 
pathogenicity for adult TO mice (see Chapter 7) would be an obvious starting 
candidate. However, its relatively low virulence i.p. would make for a detailed 
and costly virulence assay to be sure of accurate and representative results.
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Chapter 9. Studies on the ability of wild-type and attenuated yellow
mooKcy
fever viruses to bind to'^  liver cell receptors
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9.1 Introduction
When viruses exhibit a predilection for specific receptors on the surface 
of a cell, a degree of tropism exists. The nature, number and distribution of 
the host cell receptors is therefore a major determinant of not only the host 
cell range of the virus but also the tissue tropism of the virus (Lentz, 1990). 
Classic studies performed with influenza virus demonstrated that the
haemagglutinin portion of the influenza virus bound to the sialic acid receptor 
on the host cells. When the cells of the nasal cavity of a mouse were 
subsequently treated with neuraminidase, thus removing the receptor, a large 
degree of protection against intranasal challenge of mice with influenza virus 
was seen (Stone, 1948). The focusing of infection and damage caused to certain
cell types that bear a specific virus receptor can often account for the pathology
and the disease (Mimms, 1989). This is possibly the case for YF virus
infection of the liver. Although the specific cell receptor for YF virus has yet 
to be identified, it is known that liver hepatocytes, and more importantly the 
Kupffer cells of the liver, are the primary sites of YF virus infection and 
replication. Further evidence of wild-type YF viruses predilection for the liver 
of primates comes from the knowledge that following intracerebral inoculation 
of virus into monkeys, although the animals succumb to death earlier than 
animals that received peripheral challenge, the cause of death was still chronic 
liver failure (Theiler, 1951).
In comparison to the attenuated YF vaccine viruses do not cause 
viscerotropic disease in man and monkeys but do to varying degrees possess 
a neurotropic potential. It is therefore postulated that attenuation of YF virus
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coincides with the loss of viscerotropism of the virus. In order to examine this 
hypothesis, both wild-type YF viruses and YF vaccine viruses were studied for 
their ability to bind to monkey liver cell receptor preparations. The membranes 
were derived by homogenisation and purification of a membrane receptor 
preparation obtained from the liver of a Cynomolgas monkey. Also included 
in the study were the newborn mice attenuated Asibi- LP Hela p6  and FVV 
HeLa p6  viruses, the former virus which had already been demonstrated to 
possess a lowered viscerotropism for monkeys (Barrett et al., 1990). It was 
therefore hoped to demonstrate that attenuation of wild-type YF viruses for 
man, monkeys and newborn mice coincides with the loss of virus 
viscerotropism.
9.2 Experimental work
a) Viruses
Wild-type YF virus strains Asibi- LP and FVV together with their HeLa 
p6  derivatives (Asibi- LP HeLa p6  and FVV HeLa p6 ) were used in the study. 
YF 17D-204 U.K. and YF FNV-IP represented the YF live attenuated vaccine 
viruses which were also used in the following study. The control virus for the 
experiment was a JE virus isolate (strain 782219) from India which does not 
cause viscerotropic disease but does possess a highly neurotropic characteristic.
b) Liver receptor binding assays
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Dilutions of the viruses and liver receptor preparations were mixed and 
incubated as described in section 2.21. Plaque assays for determining residual 
virus infectivity following incubation were performed on LLC-MK2 cell 
monolayers and plaques were visualised by staining with neutral red after the 
requisite number of days incubation.
9.3 Reduction in virus infectivity following incubation with liver cell receptor 
preparations
Following incubation of virus with the liver cell receptor preparations 
(LCRP), residual virus infectivity was determined by centrifuging of the LCRP 
from the tube and compared to control virus samples that had not been exposed 
to the receptor preparations. Table 9.1 details the results obtained.
Both wild-type YF viruses, Asibi- LP and FVV, bound to the liver cell 
receptors as evidenced by the reduction in virus infectivity titre when compared 
to the control wild-type virus plaque assays (Table 9.1). Reductions in virus 
infectivity titre of 1.0 log,o and 1.1 log,o for Asibi- LP and FVV viruses 
respectively being obtained. Therefore, wild-type YF viruses which exhibit 
viscerotropism, shows a binding of 90% of infectivity to the LCRP thus 
representing binding of the virus to the membranes. Asibi- LP HeLa p6  and 
FVV HeLa p6  viruses, which were significantly attenuated for newborn mice 
after six passages in HeLa cells, were also examined for their potential to bind 
to liver cell receptors. The results in Table 9.1 show that FVV HeLa p6  virus
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Table 9.1 The ability of YF viruses to bind to monkey liver cell 
receptors
Virus
Cell
passage
Control
titre*
Receptor
titre# Reduction
YF Asibi-LP pO 63 53 1.0
p6 6.5 5.6 0.9
p6 + 3xSW13 6.6 55 1.1
Y F F W pO 5.8 4.7 1.1
p6 6.6 6.4 0.2
p6 + 3xSW13 6.6 63 03
YF17D-204 pO 7 5 6.9 0.6
(U.K.)
YF FNV-IP po 7.8 7.6 0.2
JE (782219)^ pO 5.9 5.7 0.2
* Control virus titre as measured by plaque assay on LLC-MK2 ceils and expressed as log pfu/ml
#  Residual infectivity titre of virus following exposure to liver cell receptor preparation. Titre 
expressed as log^^pfij^i].
^Reduction in virus infectivity titre following exposure to liver cell receptor preparations.
1, Control virus which does not possess viscerotropic characteristics.
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no longer binds to the liver cell receptors as determined by the 0 . 2  log,o 
reduction in virus infectivity titre in comparison to the control FVV HeLa p6  
virus. This latter result is in contrast to that obtained for Asibi- LP HeLa p6  
virus (Table 9.1). Whilst Asibi- LP HeLa p6  virus is highly attenuated for 
newborn mice and has been demonstrated to possess low monkey virulence 
(Barrett et al., 1990) a degree of virus binding to liver cell receptors 
comparable to the parent Asibi- LP virus was observed (0.9 log,o reduction in 
infectivity titre for Asibi- LP HeLa p6  virus). In a similar manner to previous 
experiments in this thesis, YF HeLa p6  viruses that had been passaged in 
different vertebrate cell lines (Chapter 3) were also examined for their ability 
to bind to liver cell receptor preparations. The reason for this was to 
determine whether or not attenuation/loss of viscerotropism following six 
passages in HeLa cells was host cell specific. Therefore, Asibi- LP HeLa p6  
and FVV HeLa p6  viruses that had been passaged three times in SW13 cells 
were examined in the receptor binding assay. Comparable results were obtained 
to the results for Asibi- LP and FVV HeLa p6  viruses (Table 9.1). FVV HeLa 
p6  which had received passage in SW13 cells did not bind significantly to the 
liver cell receptors as evidenced by the 0 . 2  logio reduction in virus infectivity 
titre when compared to the control virus (Table 9.1). However, Asibi- LP 
HeLa p6  virus which had received passage in SW13 cells bound to the receptor 
preparation to a similar degree as the HeLa p6  virus and also the wild-type 
parent virus (1.1 log,o reduction in virus infectivity titre) (Table 9.1).
Both of the YF vaccine viruses (YF 17D-204 U.K. and YF FNV-IP) do 
not exhibit viscerotropic disease but according to classical experiments possess 
a neurotropic potential. This was largely confirmed in the liver cell receptor
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binding assays, although in standing with the earlier results in this Chapter, a 
higher degree of receptor binding was noted for YF 17D-204 U.K. virus. YF 
vaccine virus 17D-204 U.K. had a reduction in virus infectivity titre of 
0.6 logio (equivalent to 75% loss of infectivity due to binding to the LCRP) 
in comparison to the control virus, thus suggesting that some binding of virus 
had taken place (Table 9.1). YF vaccine virus FNV-IP, in comparison, showed 
no evidence of binding to the liver cell receptor preparation with 0.3 log,o 
reduction in virus titre when compared to the control virus (Table 9.1).
The neurotropic control virus (JE virus strain 782219) did not bind to the 
liver cell receptor preparation (Table 9.1).
9.4 Discussion
The predilection of viruses for certain host cells confers a degree of 
tropism to the virus. If the receptors are present on only a limited number of 
cell types, the corresponding tropism can be highly specific; for example 
polioviruses affinity for the anterior horn cell of the central nervous system 
(Mimms, 1989). Alteration of virus tropism may be responsible for the 
attenuation of virus disease, or at least modification of the disease pathology. 
Wild-type YF viruses classically produce disease of the liver which is the 
primary site of YF virus replication (Monath, 1989). Death in primates is 
usually attributable to gross changes in liver function as a result of virus 
replication in the organ of question, with infiltration of other sites in the body 
being a terminal event and of little consequence to the overall pathology of the
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disease (Monath, 1989). It was noted that the YF vaccine viruses had lost their 
viscerotropic characteristic for primates following peripheral challenge. However, 
after intracerebral inoculation the viruses had a greatly enhanced neurotropic 
characteristic, this being particularly so for the FNV type vaccines which were 
attenuated by multiple passages in mouse brains.
Changes in the tropism of a virus presumably arises following changes to 
surface epitopes of the virus which are critical for the binding of virus to cell 
surface receptors. Hahn et al. (1987) discovered that following 243 passages of 
wild-type YF strain Asibi in chick embryo tissue to produce the attenuated 
17D-204 U.S.A. vaccine, there were 15 nucleotide and 12 deduced amino acid 
changes occurring on the YF envelope protein. The authors concluded that one, 
or a combination of the amino acid changes could be responsible for the loss 
of viscerotropism displayed by the YF vaccine virus. Because of the number 
of passages that have been made to derive the YF 17D-204 U.S.A. vaccine 
virus, the actual site that may be important in the alteration of virus tropism 
remains uncertain. However, by examining the tropism of wild-type YF viruses 
that have been attenuated following six passages in HeLa cells, it should be 
possible to determine whether or not attenuation of virus virulence and loss of 
viscerotropism coincide with each other.
In order to examine the possible link between attenuation of virus 
virulence and changes in virus tropism, a set of experiments were performed 
which assayed the ability of YF virus to bind to monkey liver cell receptor 
preparations. The hypothesis at the beginning of the study supposed that wild- 
type YF virus should bind to the liver cell receptors following incubation and 
would be detectable by a reduction in residual virus infectivity. In comparison.
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attenuated viruses would not bind to the liver cell receptor preparations, 
indicating that a change(s) had occurred to an epitope(s) thus rendering virus 
binding to the receptor unlikely.
The results of the experiment largely confirmed the hypothesis in that 
wild-type YF viruses bound to the liver ce ll. receptor preparation, whereas 
viruses that exhibited attenuation for either monkeys or newborn mice did not 
bind. However, the situation was not that straight forward upon closer 
examination of the results. Wild-type YF virus FVV bound to the receptor 
preparation with a resulting loss in virus infectivity of 1 . 1  log,o in comparison 
to the control FVV virus which had not been exposed to the receptor 
preparation. FVV HeLa p6  and FVV HeLa p6  virus that had been passaged 
in SW13 cells did not bind to the receptor preparation at all. Both of these 
viruses are highly attenuated for newborn mice. Therefore, six passages in HeLa 
cells has radically altered the reactivity of the virus with the receptors present 
on the monkey liver to which the wild-type virus actively binds. Likewise, the 
FNV-IP YF vaccine virus which had received over 200 passages in mouse 
brains did not bind to the liver cell receptor preparation. The latter result is 
probably not too surprising because earlier studies have shown the rapidity at 
which YF virus tropism can change following passage in mouse brain (Theiler, 
1930).
Wild-type YF strain Asibi- LP effectively binds to the receptors present 
on the liver cells as evidenced by a 1 . 0  log,o reduction in virus infectivity titre. 
Surprisingly, the newborn mouse attenuated Asibi- LP HeLa p6  and Asibi- LP 
HeLa p6  SW13 passaged viruses also bound to the liver membrane receptor 
preparation at approximately the same degree as the wild-type parent virus (0.9
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and 1.1 logio reductions in virus infectivity titre respectively). Moreover, the 
YF 17D-204 U.K. vaccine virus also bound to the receptor preparation to a 
certain degree with 0.6 log,o reduction in virus infectivity titre being recorded. 
These results produce a confusing set of information which on further 
consideration allows some meaningful data to be gleaned. Liprandi (1981) 
showed that the YF 17D-204 vaccine viruses to consist of a heterogeneous 
population of virions which varied in plaque size and also pathogenicity (adult 
mice). It is possible that the reduction in infectivity titre for the membrane 
treated 17D-204 preparation relates to the binding of viscerotropic subpopulations 
of virion within the vaccine population. Further work involving the isolation of 
plaque purified variants from the vaccine population would aid in exploring this 
point further. With respect to the apparent ability of the HeLa passaged Asibi- 
LP viruses to bind to liver cell receptors, a number of factors may be 
important. It seems likely that attenuation of virulence and thus alteration of 
virus tropism may not be intrinsically linked. However, what is not presently 
known is whether HeLa passaged Asibi- LP virus, or for that matter 17D-204 
U.K. vaccines can replicate once bound to the liver cells. It is possible that 
following binding of virus to the liver cell receptor that an abortive infection 
is initiated. This cannot be stated with any conviction at the present time but 
will require further investigation. What is apparent is that significant differences 
exist between the YF viruses Asibi- LP and FVV and their HeLa cell 
attenuated derivatives. Both Asibi- LP and FVV viruses are atypical YF viruses 
and are likely to react in a different manner to other virulent wild-type strains 
of YF virus. It may be that the Asibi strain of YF virus is more virulent than 
the FVV isolate thus accounting for the persistence of viscerotropism detected
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by the liver binding experiments. In Chapter 3, it was noted that attenuation 
of FVV virus occurred more rapidly than for Asibi- LP virus following passage 
in HeLa cells suggesting an enhanced susceptibility of FVV virus to change.
The control virus for the study, an isolate of JE virus which is a 
neurotropic flavivirus, did not bind at all to the liver cell receptor preparation 
thus showing that a fixed tropism precludes binding to cells that do not possess 
specific receptors.
The results suggest that following attenuation of virulence of YF virus by 
passage in HeLa cells or empirical vaccine virus derivation, changes in virus 
tropism do occur. The degree to which this happens varies, and the factors the 
factors governing this are multifactorial. To examine this point further, the 
intermediate HeLa cell passages of YF virus FVV must be tested with the liver 
receptor preparation to determine whether loss or gain of vaccine/wild-type YF 
epitopes has any bearing on loss of virus tropism. The way forward will be 
to obtain Mab resistant escape variants of YF virus that are attenuated for mice 
and/or monkeys and to assay their binding affinities for liver cells.
v*s\.W iaV '.cÎK  Vc> a . r \ o ^ ^ j e .  W o njv . ,t u >cS .
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Chapter 10. General discussion
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The attenuation of wild-type YF virus strain Asibi following six passages 
in HeLa cells was demonstrated by Hardy (1963) and later by Hearn et al., 
(1966). More recently, the original experiments have been repeated by Barrett 
et al. (1990) who attenuated wild-type YF virus strain Asibi for monkeys and 
newborn mice. Attenuation of viruses following passage in HeLa cells has also 
been achieved for VEE virus (Murphy et al., 1955) although 65 passages were 
required before the virus was significantly attenuated for mice.
This thesis examined whether or not attenuation of virus virulence 
following six passages in HeLa cells was unique to wild-type YF strain Asibi, 
or whether other members of the Flaviviridae could be similarly attenuated.
The study firstly revealed that attenuation after very few passages in HeLa 
cells was not unique to wild-type YF virus strain Asibi. Another wild-type YF 
virus (strain FVV), was significantly attenuated for newborn mice after six 
passages in HeLa cells. Following on from this work, three strains of WN 
virus became attenuated for adult mice after passage in a similar manner. Both 
the wild-type YF and WN viruses are primarily mosquito borne and it was 
therefore postulated that perhaps attenuation of flavi virus virulence was specific 
for mosquito borne flaviviruses. In order to examine this hypothesis, two tick- 
borne viruses were passaged six times in HeLa cells and the virulence of HeLa 
and non-HeLa passaged viruses determined in adult mice. The two HeLa cell 
passaged tick-borne viruses remained as virulent for adult mice as the non-HeLa 
cell passaged parent viruses, thus suggesting that vector preference may have 
a bearing in the process of attenuation following passage in HeLa cells. It was 
noted that the tick-borne flaviviruses may simply be refractive to attenuation by 
passage in HeLa cells when compared to mosquito borne flaviviruses, and
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therefore require additional passages in order to derive an attenuated variant. 
However, the link between vector preference and attenuation in HeLa cells was 
rather tenuous, even more so when it was remembered that VEE virus (a 
mosquito borne alphavirus) should require such a large number of HeLa 
passages before attenuation was observed.
A further mosquito borne flavivirus was examined for the effects of six 
passages in HeLa cells on virus virulence. Den-2 virus was passaged in HeLa 
cells and its virulence determined for outbred adult mice. Because no reliable 
animal model for Den virus virulence existed prior to this study, a novel 
method of examining virus virulence in mice was developed which involved the 
enhancement of virus infection by treating mice with the gold salt SATM. It 
was surprising to discover that Den-2 virus remained virulent for mice after six 
passages in HeLa cells thus suggesting that it was perhaps not vector preference 
alone that governed the outcome of virus virulence after passage. Interestingly, 
the Den-2 virus used in this study was a mouse neuroadapted strain of virus 
and did not represent the usual tropism of Den viruses. It was becoming 
apparent that virus tropism was likely to have an influence in the process of 
attenuation after passage of virus in HeLa cells. Wild-type YF and WN viruses 
exhibit a viscerotropic and a febrile type illness respectively in comparison to 
the neurotropic disease manifested by the tick-borne viruses, Den-2 virus and 
significantly VEE virus.
In order to answer the question of whether neurotropic flaviviruses were 
refractive to attenuation of virulence after few passages in HeLa cells, two YF 
vaccine viruses (which exhibit varying degrees of neurovirulence) were passaged 
in HeLa cells and their resulting virulence determined for newborn mice. The
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experiment was particularly important because the viscerotropic wild-type 
progenitors to the YF vaccine viruses were highly attenuated after a similar 
passage series. The results showed that following six passages in HeLa cells 
the YF 17D-204 vaccine virus was apathogenic for newborn mice in comparison 
to YF FNV-IP vaccine virus which remained pathogenic. YF FNV-IP vaccine 
virus possesses a significant degree of neuroinvasiveness which probably reflects 
derivation after prolonged passage in mouse brain tissue. In comparison, YF 
17D vaccine viruses possess a low degree of neuroinvasiveness and may be a 
function of derivation in non-neurotropic chick tissue. Therefore, there was 
increasing evidence to suggest that flaviviruses that possess a fixed neurotropic 
response require significantly more than six passages in HeLa cells before an 
attenuated variant is obtained. In order to dispel the possibility that vector 
preference is important to the attenuation process it would be necessary to 
passage tick-borne viruses that exhibited viscerotropic/haemorrhagic tropism in 
HeLa cells. Unfortunately, although such viruses exist, their pathogenicities are 
too great to allow safe handling in this laboratory.
Attenuation of YF and WN viruses was accompanied by biological changes 
to virus envelope epitopes as determined in IIF tests with a panel of Mabs. 
HeLa cell attenuation of wild-type Asibi- LP and FVV viruses coincided with 
the loss of wild-type specific virus epitopes and the acquisition of epitopes 
associated with YF vaccine viruses. Interestingly, a YF 17D/17DD vaccine 
specific Mab, which detected an epitope on the HeLa attenuated Asibi- LP virus 
did not recognise a similar epitope on the HeLa attenuated FVV virus. This 
suggests that an attenuation site unique to Asibi virus and its derivatives exists. 
The appearance of YF vaccine associated epitopes on the HeLa cell passaged
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viruses occurred after very few passages in HeLa cells and was correlated with 
a significant degree of attenuation of virus virulence for newborn mice. 
Therefore, although a replica YF 17D or FNV vaccine virus has not been 
created, it is possible to confer that the attenuation of virulence of wild-type 
YF viruses and the appearance of YF vaccine virus epitopes may be of 
importance in the attenuation of YF virus. Moreover, loss of a wild-type 
specific neutralising epitope recognised by Mab S18 was found to occur for 
both HeLa cell passaged YF viruses. The importance of the epitope recognised 
by Mab S18 to the attenuation of virulence of wild-type YF virus would have 
to be determined by generating Mab S18 escape variants, assaying virus 
virulence in newborn mice and to sequence the change(s) responsible for 
attenuation.
Changes to envelope protein epitopes following passage in HeLa cells 
was not unique to YF virus as evidenced by WNV-Sarawak escaping 
neutralisation by Mab C ll in contrast to the parent virus which was neutralised 
to a high level. Loss of reactivity with Mab C ll was accompanied by a degree 
of attenuation of virus for adult mice. Unfortunately, attempts to generate 
WNV-Sarawak C ll escape variants has failed so far hence conclusive evidence 
for the role of the epitope recognised by this Mab in the attenuation process 
is uncertain.
Modifications to virus function other than at the epitope level also 
occurred after passage in HeLa cells with notably the presence of ts phenotypes 
for certain viruses. The appearance of ts after six passages in HeLa cells of 
WNV-Sarawak corresponded with a significant degree of attenuation of virus 
virulence for newborn mice. However, a ts phenotype was also found to exist
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for the HeLa cell passaged Den-2 virus which remained virulent for mice after 
passage in HeLa cells. The presence of ts and the failure of Den-2 virus to 
show any degree of attenuation gives cause for concern that the use of such 
a phenotypic marker exists for putative Den virus vaccines.
Loss of haemagglutination (HA) ability for goose red blood cell was 
observed for all viruses following six passages in HeLa cells. The inability of 
virus to elicit HA did not have an apparent relationship with attenuation of 
virus virulence because of the virulent nature of HeLa cell passaged tick-borne 
and Den viruses. More importantly, regaining of HA ability by HeLa cell 
attenuated viruses following passage in SW13 or LLC-MK2 cells did not revert 
the attenuated viruses to virulence. The theory therefore exists that HA ability 
in flaviviruses does not influence virus virulence and is a phenomenon due to 
passage of virus in HeLa cells. Because HA activity was returned to HA 
negative viruses after passage in different cell lines, it suggests that the changes 
conferring loss of HA are conformational as opposed to genetic which was 
found to be responsible for the irreversible loss of HA activity for Echovirus 
type 11 after eight passages in HeLa cells (Cova and Aymard, 1980).
Evidence suggests that six passages in HeLa cells attenuates flaviviruses 
that do not possess a pronounced neurotropism and that furthermore, loss of 
virus virulence after passage in HeLa cells is accompanied by antigenic and 
phenotypic changes in virus character. Since only six passages in HeLa cells 
have been made, there should be correspondingly few nucleotide changes 
conferring attenuation. Nucleotide sequencing of the envelope protein should 
allow the elucidation of these attenuating sites. In order to confirm the 
importance of such changes, it will be necessary to obtain Mab escape variants
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and sequence such mutants and compare their sequences with HeLa cell 
attenuated and vaccine viruses, the study being limited at the present time to 
YF viruses. The use of YF virus infectious clones (Rice et al., 1989) to 
examine the role of precise changes on the genome will be the ultimate goal 
in deducing attenuating mutations. One important area of research that will 
exploit the technology will be to determine which amino acid(s) or nucleotide(s) 
govern YF virus tropism.
Wild-type YF viruses exhibit viscerotropic disease in comparison to the 
YF vaccine viruses which, like the HeLa attenuated YF variants, have lost 
their ability to cause viscerotropic disease. Whether or not loss of 
viscerotropism is responsible for attenuation of YF virulence is unknown at 
the present time. However, studies performed in this thesis imply that this 
may not be the case. Whilst wild-type YF viruses bound to monkey liver cell 
receptors, it was noted that the HeLa cell attenuated YF viruses did not. 
Unfortunately, whilst the YF FNV-IP vaccine also did not bind to the liver 
receptors, the YF 17D-204 vaccine virus did to a significant degree. It may be 
possible that residual viscerotropic response of the vaccine virus is required in 
order to elicit protective immunity, what is certain however, is that the YF 
17D vaccine virus is probably the most successful live virus vaccine available. 
To determine whether or not viscerotropism has an intrinsic function in YF 
virus virulence it will be necessary to obtain attenuated Mab resistant escape 
variants and to examine their ability to bind to liver cell receptors. By 
sequencing the envelope protein of the mutants and combining the information 
gained from HeLa cell. attenuated YF viruses, it is hoped to determine the 
molecular basis of attenuation of YF viruses.
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Overall, passage of flaviviruses in HeLa cells provides an excellent model 
system to investigate the molecular basis of attenuation of particular flaviviruses 
because few passages are required to generate attenuated variants. Clearly, this 
system may be applicable to examine dengue virus virulence and further studies 
are required to investigate SATM enhancement of various strains of dengue 
viruses for mice and the effects on virulence following passage in HeLa cells. 
Finally, it has been observed that the attenuated phenotype of HeLa passaged 
viruses is maintained on passage into other cell lines. This gives rise to the 
possibility of developing live attenuated flavivirus vaccines by passage of HeLa 
cell viruses into WHO approved cell lines.
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